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CHAPTER 1 
1 DRUG DELIVERY AND POLY(2-OXAZOLINE)S 
 
ABSTRACT The work described in this PhD thesis comprises the experiments and efforts on 
the synthesis, optimization and upscaling of defined high molecular weight poly(2-oxazoline)s in 
combination with their use in oral drug formulations. Although the work is highly interdisciplinary, 
it is written to obtain the degree of Doctor of Philosophy in Chemistry. The first chapter is meant 
to give a complete background on the work that has been performed over the four years of my 
PhD. 
 In the first section, the importance of drug delivery will be explained as well as the use of 
polymers in this growing field of drug development.  
 In the second section the focus will be put on oral drug formulations, as the main 
application within this PhD. Here a description is given about the type of formulations that exist, 
how to prepare them, how to characterize them and the state-of-the-art polymers used 
nowadays in oral drug delivery.  
In the third part, poly(2-oxazoline)s are proposed as a suitable alternative to serve as an 
excipient in oral drug formulations. A short overview of 50 years of poly(2-oxazoline) work is 
described first with the focus on their monomer synthesis and an in-depth discussion on the 
cationic ring-opening polymerization mechanism towards poly(2-oxazoline)s. Furthermore, the 
different type of poly(2-oxazoline) homopolymers that are suitable for the application in drug 
delivery will be described, together with their thermal and solution properties. Finally, a short 
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1.1  HOW DRUG DELIVERY AND POLYMERS MEET 
Development, formulation and delivery of drugs, medicines or active pharmaceutical 
ingredients (APIs) are omnipresent in our daily life. Enormous efforts are being done by 
companies, from big pharmaceutical multinationals to smaller drug development and 
formulation companies, to provide therapies for treatment of a broad scope of diseases. In this 
aspect a few steps are key, such as drug delivery and the corresponding formulations, and it is 
well-known that drug discovery and development takes a long time, i.e. approximately 15 years 
from discovery up to drug approval (Figure 1).1,2 In this long-term development process, over 
10,000 compounds can be screened in discovery to end up only with 1 approved drug after 15 
years of work. With respect to retain more of these valuable drugs, and thereby increasing the 
ratio of approved drugs to screened compounds, a more detailed description of the 
development process (Figure 2) shows the importance of finding the right drug formulation. 
Inherently, the right drug formulation for a specific API should provide a good drug delivery and 
bioavailability of that API.3–7  
According to the encyclopedia of medical concepts, the definition of drug delivery 
(systems) includes ´Systems for the delivery of drugs to target sites of pharmacological actions 
combined with the technologies employed to achieve this delivery, such as drug preparation or 
formulation, route of administration, site targeting, metabolism and toxicity.´ In this thesis we will 
mostly focus on improving oral drug formulations of highly water-soluble or poorly water-soluble 
model APIs, in order to optimize their drug delivery. Other important topics such as targeting, 








Figure 1. Drug discovery and development timeline over a period of approximately 15 years, starting from 10,000 lead 
compounds to one approved drug entering the market.8  
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Figure 2. Detailed description of the drug development time line starting from research, via approval up to 
commercialization.9 
A drug formulation generally consists of an API and aiding substances, or so-called 
pharmaceutical excipients or matrices. These excipients are pharmacologically not active, i.e. 
inert, and it can be seen as a generic name for every additive in a drug formulation, except for 
the API.2,10,11  
In the case of small molecule drug delivery, the drug consists of relatively low molecular 
mass molecules (< 500 g/mol; analogous to the Lipinski rule12 of five explaining the drug alikeness) 
which are regarded as ´active´ pharmaceutical ingredients. In contradiction to drugs, polymers 
or macromolecules are defined, as stated by IUPAC, as ´A molecule of high relative molecular 
mass, the structure of which essentially comprises the multiple repetition of units derived, actually 
or conceptually, from molecules of low relative molecular mass´ i, and can be regarded as an 
example of an excipient (Figure 3). 
The conceptually different drug molecule and a polymer or macromolecule, are often 
united when drug delivery is regarded. The fact that a polymer is relatively high in molecular 
mass compared to an API, gives it properties like a glass transition, semi-crystalline behavior and 
tunable hydrophilicity making it an interesting carrier material for APIs or drugs. Within this field, 
in the last 10-20 years, the amount of scientific publications and reviews published on polymers 
                                                                
i ´In many cases, especially for synthetic polymers, a molecule can be regarded as having a high relative molecular mass if the 
addition or removal of one or a few of the units has a negligible effect on the molecular properties. This statement fails in the 
case of certain macromolecules for which the properties may be critically dependent on fine details of the molecular structure´ 
Source: PAC, 1996, 68, 2287 (Glossary of basic terms in polymer science (IUPAC Recommendations 1996)) on page 2289. 
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related to drug release increased exponentially (Figure 4).13–15  According to IUPAC, a polymer 
drug is a ´polymer that contains either chemically-bound drug molecules or pharmacologically 
active moieties.´ Furthermore, polymers can also have a strong impact in physical mixtures with 
drugs. Here supramolecular interactions take place between the drug and the polymer, such as 
ionic interactions, hydrogen bonding interactions, etc. These interactions can play an important 
role in controlling the release of a certain API. There is also an increasing interest in oral drug 
formulations containing polymer carriers as excipient or aiding substance, for the APIs delivery, 















Figure 4. Visualization of the exponential increase of literature publications on polymer therapeutics, over the last 50 
years, according to Scifinder.  
 Even though the fact that polymers and drug delivery go hand in hand, the following 
introduction and overview will be divided in two different parts, including a first part on oral drug 
formulations and a second part on the poly(2-oxazoline) polymer family. In the first part, the aim, 
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the advantages and the different types of oral drug formulations will be explained. In addition, 
a last section in this part will be devoted to the state-of-the-art polymers that are nowadays used 
as matrix excipient for oral drug formulations, combined with their current advantages, 
drawbacks and challenges. In a second part the poly(2-oxazoline)s will be introduced, starting 
from their monomers, polymerization mechanism and insights towards their interesting properties 
that have led to their application being strongly focused on the biomedical field.  
1.2  ORAL DRUG FORMULATIONS 
Drug formulation and delivery is essential to create efficient therapy for the treatment of 
diseases, vide supra. If one considers all different types of drug administration routes, including 
e.g. intravenous injections and transdermal, oral drug delivery is by far the most convenient and 
used method of administration, due to its high patient compliance, cost-effectiveness and ease 
of production, as explained in a review by Baghel et al. and many others (Figure 5).16–21 In an 
article by Savjani et al., it was reported that more than 85 % of the most sold drugs in the USA 
and Europe are orally administered drug formulations,17,22 to name a specific literature example 
that supports the importance of oral drug formulations. Another review by Agrawal et al.23 reports 












Figure 5. Overview of the different routes of administration for active pharmaceutical ingredients or drugs. 24 
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The main challenge that is addressed by all these (oral) drug formulations is to increase 
the overall oral bioavailability, i.e. the amount of drug that reaches the blood stream 
(intravenous bioavailability is 100 %),17,24,25 of the active pharmaceutical ingredient (API) or drug. 
For (oral) drug delivery, bioavailabilityii is mostly related to two important aspects, i.e. the water-
solubility and the permeability of the API, which is also how it was categorized in the 1990s, by 
Gordon Amidon and co-workers, as the biopharmaceutics classification system (BCS, Figure 
6).26,27 The development classification system (DCS), is an extension of the BCS based on more 
bio relevant media, such as fasted state simulated intestinal fluid (FaSSIF), to assess solubility and 
in vivo correlation. In the DCS, class II APIs are divided into class IIa, i.e. the dissolution rate limited 
APIs, and class IIb, i.e. the solubility limited APIs.  In general, four different classes of drugs or APIs 
are classified, starting with class I that includes the highly water-soluble and highly permeable 
drugs are located, up to class IV that covers the poorly water-soluble APIs with low permeability 
through the membranes. In Figure 6 (right graph), the boundaries of the different classes are 
defined, based on rather empirical calculations resulting from different in vivo studies.28  If we 
consider this graph, an API is highly water-soluble if ´the highest dose strength of the drug which 
is administered, is soluble in less than 250 mL of water, over a pH range of 1-7.5.´ Furthermore, a 
drug is highly permeable when over 90 % of the drug is absorbed by the intestines in in vivo 
studies, i.e. possesses > 90 % bioavailability. 
Figure 6. Biopharmaceuticals classification system20,28, two different representations stating either the chances for using 
non-oral dosage forms along the different classes of drugs ( left) or the ´boundaries´ between the different classes 
(Right).20 
 Important for all drug delivery systems is to keep the drug levels within the 
therapeutic window. The borders of this therapeutic window exist in the minimum effective level, 
i.e. resembling the minimum desired drug concentration in the plasma in order to have a 
therapeutic effect, and the maximum tolerating level or toxic level, i.e. above these 
                                                                
ii Bioavailability is defined as a measure of the rate and the extent to which a drug reaches the systematic circulation. 
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concentrations the drug concentration exceeds the desired levels in the blood and can cause 
side effects. In Figure 7, the desired controlled release level is indicated and most often drug 
concentrations vary in an alternating fashion around this profile upon drug administration. For 
very good water-soluble APIs drug concentration levels can increase very fast above the toxic 
level, but decrease very fast under the minimum effective level. If sustained release formulations 
are applied, burst release can be suppressed and drug levels can stay more continuous over 
time.29 For poorly water-soluble APIs it is challenging to get to drug plasma concentrations that 










Figure 7. Schematic representation of the drug concentration in the blood versus time, with indication of the minimum 
effective concentration (MEC low) and the maximum safe concentration (MSC, i.e. toxic level). In between these 
levels, the therapeutic window is located to have desirable controlled release. Reprinted from29 
Depending on the class of the API, different formulation strategies are necessary to 
increase the overall bioavailability of those drugs. It is a fact that the importance and chances 
for oral drug formulations decreases alongside the classes, with APIs from class IV bearing the 
highest chances of being administrated by non-oral dosage forms. Therefore, in the following 
explanation of enhancing drug bioavailability through oral drug delivery formulations, only the 
strategies for APIs of class I to III will be elaborated. 
 For the highly water-soluble APIs of class I, extended or sustained release formulations 
(SRF, vide section 1.2.2) are preferred to prolong their retention time in the gastrointestinal (GI) 
tract up to maximum 24 hours.30 These SRF mainly consist of porous or swelling (cross-linked 
hydrophilic) matrices, which control or extend the release of the API, and protect the API from 
burst release in the different pH environments of the GI tract, upon administration of the tablets. 
In research studies comprising the investigation of these SRF, metoprolol tartrate (MPT), which is 
highly water-soluble and possesses a low melting temperature (Tm), is regarded as ´the´ model 
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compound to challenge release matrices for SRF as a function of drug load, in vitro and in vivo 
release studies, etc.31–35 
 If class III APIs that are highly water-solubility with poor permeability, are considered, 
also strategies concerning SRF are applicable (vide class I APIs). The poor permeability problems 
are often solved by combination of prolonged residence times in the GI tract and/or the use of 
permeation enhancing excipients, such as the use of prodrugs or tight junction openers. 
Metformin (MTF) hydrochloride can be regarded as one of the model APIs used to study the 
formulation effect of this class of APIs into further detail.36–38 
Finally, the class II APIs (and in a certain extend also class IV) includes poorly water-soluble drugs 
with high permeability through the membranes, which resemble the majority of drugs developed 
in target and drug identification studies. The fact that this is the largest class of APIs in the BCS, is 
not remarkable, considering that the chemical composition of most drugs consist of highly 
(complex) structures with many hydrophobic units, e.g. aromatic moieties, rigid structures, etc., 
and possess high tendencies to maintain complex crystalline structures; affecting and inducing 
most of the times poor water-solubility. Multiple strategies are found in literature to improve the 
water-solubility rate, and thus, overall bio-availability of class II APIs, such as solid dispersions (SD, 
vide section 1.2.1), liquid dispersions, nano-milling or suspensions and cyclodextrin inclusion 
complexes. Since class II APIs are highly interesting for formulations, multiple model APIs, including 
e.g. fenofibrate, itraconazole and griseofulvin, have been studied over the years in order to 
challenge different types of excipients for the formulation of poorly water-soluble drugs. In the 
following sections only the solid dispersion strategy will be further elaborated, as it is most relevant 
for the application of poly(2-oxazoline)s (PAOx) as matrix excipient in different types of 
formulations with model APIs of class II. 
 In the following, section 1.2.1 will explain in more detail the use of extended or SRF with 
some highly water-soluble model APIs from class I and class III. Furthermore, in section 1.2.2 the 
solid dispersions for improving bioavailability of poorly water-soluble APIs from class II, will be 
explained. Regardless of the nature of the APIs, generalized methods for the preparation of those 
drug formulations exist, which are briefly discussed in section 1.2.3. Finally, in section 1.2.4 
currently marketed polymer excipients are described. 
1.2.1  Sustained and/or control led release formulatio ns 
If one considers controlled, sustained or extended release formulations, mostly polymer 
drug conjugates in which the drug molecules are covalently bound to the polymer are 
considered to tune the release of the drug upon an external trigger, e.g. pH, inside the human 
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body, if one considers extended release/circulation times upon intravenous injection.24,39–44 Other 
types of carriers rely on the fact that the drug is encapsulated in a hydrogel, cross-linked network 
or hydrophobic polymer matrix, via supramolecular interactions between the drug and the 
carrier, in order to sustain the drug release.45–47 In that way the release can be triggered upon 
external stimuli, by swelling of the matrix or by passive diffusion (Figure 8). In both covalent and 
non-covalent types of carrier systems, the interaction with the polymer is required for the 
controlled release of the drug as the bare drug possesses fast release kinetics in the body, which 
can induce too high drug levels in a short period of time. Apart from the swelling matrices or 
porous matrices, erosion based tablets also slow down the release of a water-soluble drug. 
Additionally, enteric coatings can prevent dissolution of a water-soluble drug depending on the 
pH, e.g. release is triggered by the higher pH upon entering the intestines and the drug is 
protected against the pH of the stomach. Most often, in contrast to the further mentioned SD, 
the highly water-soluble API is preferably present in the crystalline state. If the API would be 
present in the amorphous phase, the solubility rate would be even faster, which is unwanted in 
SRF.48–51 
 
Figure 8. Illustration of the three most important sustained release formulation mechanisms, including swelling, erosion 
and diffusion (out of a hydrophobic matrix).52 
1.2.2  Sol id dispersions 
The majority of new drugs in development (70 – 90 %) are being qualified under Class II 
and Class IV and are characterized by low aqueous solubility.53,54 This number illustrates the 
importance to address these solubility issues and the fact that the pharmaceutical industry is 
continuously searching for new pharmaceutical excipients that can enhance dissolution rates 
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rate for (newly) developed APIs, including APIs that are not yet formulated or not used because 
their further development is stopped due to above mentioned reasons. Over the last decade a 
number of strategies have been developed in order to enhance the bioavailability of poorly 
water-soluble drugs, including the use of surfactants,55,56 cyclodextrin inclusion 
complexation,17,57,58 emulsification processes,56,59,60 co-solvency,61 salt formation powder milling62–
65 and nanocrystals.66–68 All of these techniques have been challenged with inherent problems 
concerning efficacy, product stability and versatility of the excipients and, therefore, only have 
specific uses. Moreover, to obtain more versatile/compatible and stable drug formulations, an 
increased amount of excipients must be added to the formulation in order to solubilize 
hydrophobic APIs, which increases the risk of side effects caused by the excipients, resulting in 
low patient compliance.69,70 
Initially solid dispersions were introduced in 1960s by Sekiguchi and Obi. In recent years, the 
formulation of APIs in stable solid dispersions and solid solutions has received major interest to 
enhance bioavailability of poorly water-soluble drugs.20, 56, 65,71–77 Improved bioavailability of drugs 
formulated in solid solutions or solid dispersions is generally based on the following two principles:  
• Dispersion of amorphous API clusters in a binary demixed 2-phase system (amorphous 
solid dispersion), dissolving the API in in a crystalline (solid solution) or amorphous (glass solution) 
polymer matrix that enhances the availability of the API by keeping it in a higher energy state 





Figure 9. overview of the different drug forms in a polymer excipient, carrier or matrix: crystalline solid d ispersions or 
sustained release formulations (Left), amorphous solid dispersions (Middle) and solid solutions (Right).78 
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• The polymer excipient should also interact with the API after release to stabilize a 
supersaturated solution state and prevent crystallization, which is also referred to as the spring-
parachute principle (Figure 10). 
Hence, the main task of solid dispersions and solid solutions is to prevent macroscopic 
crystallization of the API at all times, that is before and after release as well as during storage. 
The physical stabilization of the amorphous drug in solid dispersions results from strong polymer-
drug interactions leading to an increased Tg of the polymer-drug mixture, compared to the Tg of 
the pure drug. As a result, the mobility of the drug is lowered, which inhibits nucleation and, thus, 
crystallization of the drug. Nucleation is also inhibited by the distance between separate drug 
molecules, (Figure 9, 2-phase versus 1-phase systems) especially in solid solutions, which is closely 
related to drug-polymer miscibility and drug content in the formulation. The success of SD and 
solid solutions is often related to the specific interactions between the drug and the polymeric 
carrier. 
In general, solid dispersions can be prepared by precipitating from a solution of drug and carrier 
or by rapid cooling of a melt, referred to as the solvent method and melting (or fusion) method 
(vide section 1.2.3-1.2.4) for which spray drying and hot-melt extrusion/injection moulding 







Figure 10. Drug concentration as a function of time for a crystalline drug and amorphous drug which is in a higher 
energy state (spring concept) and kept at a supersaturated state (spring + parachute concept). 20 
1.2.3  Methods of preparation 
Solvent methods 
In order to prepare SRF or SD, a solvent method can be applied. All solvent methods 
are based on the dissolution of both the API and the excipient in a common, preferably organic, 
Spring + parachute 
Spring  
Amorphous drug  
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solvent, such as dichloromethane, chloroform, methanol, etc. In a second stage a drying step is 
applied, to get the oral drug formulation with the excipient in a dry and stable state. Examples 
of processes that use this basic technique of co-solubilizing the API with the excipient are solvent 
casting, spray drying and electrospinning. Even though solvent casting is the most basic 
technique, the slow evaporation of the solvent limits the formulation process as it provides more 
time and mobility for API crystallization. Often, this technique is used as a fast screening method 
for the preparation of SD, since this non-optimal drying technique can reveal insides about the 
ability of the excipient to keep the API in its amorphous form under worst-case-scenario 
conditions. Besides this initial screening by solvent casting, other more advanced solvent 
techniques can be applied to ensure fast evaporation of solvent. In spray drying (Figure 11), 
which is considered as the most used technique in industry, very small droplets are formed 
through an atomizer, which enlarges the surface to volume area to ensure quicker drying of the 
particles. Depending on the type of atomizer, such as pneumatic or rotary atomizers, the 
average size of the droplets can vary between 5 and 350 µm and will consequently determine 
the powder properties. Furthermore, a drying gas, mostly an inert gas such as nitrogen or argon 
gas, is introduced in the drying chamber to facilitate the drying of the formed particles.81 Finally, 
the dried particles are collected and separated from the gas stream, most often by a cyclone, 
i.e. an accelerated flow which induces separation based on the density difference of the 
particles compared to the gas. In conclusion, spray drying can be performed from small to large 
scale and is dependent on a large variety of parameters, which makes it a complicated process, 
including the feed rate, inlet temperature, the flow of the gas particles, etc.; which can have an 
influence on the powder characteristics of the spray dried particles.31,51–54 The requirements for 
the polymer and API, include good co-solubility in an organic solvent, ´good´ viscosity (not too 
high) to ensure drying of the droplets. Furthermore, the Tg of the polymer should preferably be 
higher than 50 °C, so that the polymer-API mixture can form a stable non-sticky powder. There is 
limited restriction regarding heat-sensitive APIs or APIs with extremely high Tm´s.85 
Another solvent-based technique which can be used for drug formulation is 
electrospinning (Figure 11).63,64,86,87 This technique has quite some similarities with the spray drying 
process, e.g. the feed contains a solvent in which the polymer and drug are co-solubilized, but 
there are also some important differences. Within the electrospinning process, a high voltage is 
applied on the material feed, instead of a heated gas stream. The fluid that comes out of a 
capillary or syringe pump is put under a large potential difference with the counter electrode, 
which creates charges and repulsion on the surface of the particles resulting in a jet and the 
formation of a so-called Taylor cone. The resulting jet is most often accelerated downstream the 
collector, while volatile organic solvents are quickly evaporated during the process. The 
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obtained powder-like fibers range from micrometer down to 100´s of nanometer size, depending 
on the set parameters, including feed ratio, concentration of the feed and applied voltage. 
Solvent methods often give a powder formulation, meaning that a milling or 
granulation step is not necessary for downstream processing. Nevertheless, most often the 
powder has poor flowability and bulk density. After collection or compaction of the powder, a 







Figure 11. Schematic representation of a spray drying set-up78 (Left) and lab scale set-up of the electrospinning process 
(Right).88  
Melting methods 
In contrast to the described solvent methods, the melting methods include formulation 
of the API and the polymer in absence of any (organic) solvent, under elevated processing 
temperatures and/or with the application of high pressures. The most important melting methods 
include HME, IM and melt granulation. Originally, HME was first introduced in the 1700s, for the 
processing of metal materials, whereas in the 1930s its use flourished with the increased 
production of polymeric bulk materials.89 Nowadays, HME is still responsible for more than half of 
the processing techniques used in industry. However, for the pharmaceutical industry, HME is a 
relatively new technique, originating from the 1970s, when it was first applied for the preparation 
of oral drug formulations, by Doelker et al.60, 85,90  
The HME process includes a feeding step, a conveying part including barrel and screw 
system for transport and mixing of the materials, a die and downstream processing equipment, 
such as grinders, millers and IM (Figure 12). In the feeding step the raw materials, including API 
and polymer, are added to the barrel. The screw system in the heated barrel, which can be 
single or twin-screws (co or counter-rotating), moves the heated material with a certain force or 
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torque towards the die. In order to melt-mix the polymer with the API efficiently, preferably twin-
screw extruders or compounders are applied. The dimensions of the barrel and the screw, i.e. 
determined by the length to diameter ratio (L/D), will be one of the important parameters to 
achieve complete mixing during the process. Additional parameters that can be varied are 
rotation speed of the screws and the temperature of the barrel, preferably below the 
degradation temperature of the API and above the Tg (or Tm) of the polymer.  
There are certain advantages of HME compared to spray drying. Firstly, the simplicity 
of manufacturing on an industrial scale makes it popular with pharmaceutical manufacturers. It 
has also been shown that more uniform (molecular) dispersions are formed with HME resulting in 
enhanced bioavailability.60 The absence of residual solvents in the produced formulations is 
preferable, although the different types of polymers that are suitable for HME are more limited 
compared to the ones that can be applied in spray drying. On the contrary, high processing 
temperatures and shear magnitudes, applied in HME, can be a drawback in terms of 
degradation of the polymer excipient and API. Another significant drawback using this 
technique is that HME often requires an additional processing step such as grinding, milling, 
calandering and cutting of extrudates for the production of, e.g. tablets, films, pellets or mini-
tablets. Nevertheless, these additional processing steps, e.g. in HME coupled to IM, permits 
manufacturing of very complex shapes and allows to accurately control the three-dimensional 







Figure 12. Schematic view of a hot-melt extruder including the feed of the API and polymer, twin-screw set-up and 
barrel with cylindrical die.85 
Besides milling and grinding of the extrudates, IM (Figure 13) is very often coupled as 
downstream process equipment to ´shape´ the extrudates in the preferred manner. In fact, the 
IM process closely resembles the HME process without the mixing and homogenization of the API 
and polymer mixture. Generally, an injection moulder consists of an axial screw in a barrel, a 
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plunger and a cavity or mould. The plunger shapes the extruded material in a predefined and 
closed mould under high pressure and certain temperature conditions. Upon processing the 
pressure and temperature will be changed from high to low, to end up with a cooled tablet that 
can be withdrawn from the mould as final dosage form. The different process temperatures and 
pressures can be varied according to the nature of the API and polymer melt, to optimize the 











Figure 13. Simplified representation of an injection moulder with plunger and tablet mould, that can be coupled to a 
hot-melt extruder.92,93 
In Table 1, an overview is given of the main advantages and disadvantages that are correlated 
to solvent and melting formulation methods.  
Table 1. Advantages and disadvantages of spray drying versus hot-melt extrusion for the preparation of SD or SRF; 
summarized from references.60, 74, 79,85 
Solvent Method (spray drying) Melting Method (HME) 
No problems regarding thermal degradation of API and/or 
polymer 
Thermal degradation can occur  
Large range of polymers applicable Limited range of polymers applicable  
(Organic) solvent needed 
Common solvent for API and excipient required 
No solvent 
Large scale applicable/ often batch process Continuous processing on large scale easy and 
straightforward 
Downstream processing: poor flowability/low bulk density Downstream processing can be challenging and needed: 
e.g. milling, IM 
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1.2.4  Characteri zation methods for oral  drug formulations  
Analysis and spectroscopy methods 
Characterization of the retrieved oral drug formulations can be done using several 
techniques including thermal characterization, powder analysis and microscopy. For thermal 
characterization of the formulations, thermogravimetric analysis (TGA) is often used to retrieve 
information concerning thermal degradation (prior to processing) and residual moisture content 
of the prepared formulations. Furthermore, differential scanning calorimetry (DSC) is used to 
gather knowledge about the glass transition temperature and melting temperature of the 
polymer, the API and their (physical) mixture (Figure 14). The Tg will be influenced by interaction 
of the API with the polymer matrix in a SD or SRF. If the API acts more like a filler, i.e. filling up 
empty spaces between the polymer chains, or strongly interacts with the polymer this will lead 
to an increase in the Tg. Poor interactions between the API and the polymer may result in a 
plasticizing effect, or even separate thermal transitions may be observed when phase 
separation occurs. A physical mixture (i.e. non-formulated) of the API and polymer will also show 
two distinctive Tg´s (the Tg of the drug is often below zero). Finally, the quantitative and qualitative 









Figure 14. Example of a differential scanning calorimetry (DSC) diagram, including the different Tg´s and melting peaks 
(Tm) for the pure API and polymer, a physical mixture of both and a solid dispersion or sustained release formulation.  
Alternatively, via powder X-ray diffraction (XRD, Figure 15), one can look at the 
crystalline fragments (indicated by sharp peaks in an the XRD spectrum) of the API compared 
to the amorphous fractions of the polymer (broad bands in XRD spectrum), to qualitatively 
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determine the interaction between the API and the polymer in a drug formulation. It is also 
possible to determine quantitatively the crystalline fraction, nevertheless it is not that 
straightforward if polymer-API mixtures are considered. 
Other characterization techniques to identify polymer-drug interactions include 
infrared (IR) and Raman spectroscopy or mapping.97 This type of spectroscopy, irradiates the 
sample with a laser while a scattering pattern is observed. Similar to XRD, smaller molecules or 
APIs are giving more defined scattering patterns compared to polymers, giving IR and Raman 
spectroscopy the ability to detect small fragments of crystalline drug in the amorphous drug 
formulations with high sensitivity (< 1 % mass of tablet). An excellent review from Palermo et al. 








Figure 15. Example of an X-ray diffraction diagram and proposed peak shapes for the pure drug, polymer, solid dispersion and 
a solid solution.  
Dissolution testing or kinetics 
An important part in the characterization of oral drug formulations comprises the 
release of the drug as a function of time in a dissolution medium, i.e. in vitro dissolution testing, 
performed for quality control purposes or to predict in vivo behaviour.54, 94,99,100 It should be noted 
that all of these test are standardized according the pharmacopeia and regulation agencies. 
The release kinetics of the drug from the (polymer) matrix are tested in in vitro dissolution media, 
being at first aqueous buffer media with pH ranges of 1.2-7.5. Secondly, biological relevant 
media should be introduced, combining buffer and enzymes in order to get better results 
according to in vitro-in vivo correlations, referred to as simulated gastric fluid (SIG, pH 1.2) and 
simulated intestinal fluid (SIF, pH 6.5). The temperature of the dissolution tests is most commonly 
set at human body temperature, 37.5 °C. In order to maintain poorly water-soluble drugs soluble 
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in the dissolution medium, most dissolution tests are performed in ´sink conditions´. Sink conditions 
are defined as ´the volume that exceeds at least three times the volume that is needed to 
achieve a saturated solution of the API´.99 Despite these sink conditions, there are still a number 
of drugs that have such poor solubility, that another medium such as, isopropanol or other 
aqueous alcoholic media, has to be used to carry out dissolution tests. The analysis of the 
released drug is most often performed by UV/VIS spectrophotometric analysis or high-
performance liquid chromatography (HPLC) methodologies.  
A final step could include the performance of bio-relevant tests in animals or humans 
(last stage), i.e. measuring plasma concentration in time after oral administration of the 
prepared oral drug formulations. Most often in vitro-in vivo correlations are not straightforward 
since predictions often fail due to the general complexness of in vivo studies. In conclusion, drug 
dissolution tests of the designed drug formulations will have to be performed in in vivo assays in 
order to finally reach the market. More details and discussion about in vivo dissolution tests and 
different important parameters can be found in a literature review by Newman et al.73 
 Shelf-life stability 
The stability of the drug formulations in time, mostly regarded to SD, has to be assessed. 
If for example a SD is characterized to possess only amorphous fractions of the API, thereby 
improving the bioavailability, the question will rise how long this dispersion is stable (remains 
amorphous) over a certain period of time. Mainly, these tests include the performance of (a few 
of the) aforementioned characterization techniques at different times after preparation of the 
specific drug formulations. On the one hand the characterization can take place after the 
formulations have been stored at the ideal storage conditions for a time period of e.g. 6-24 
months. On the other hand, standardized tests describe stability essays at elevated temperatures 
and humidity that simulates the long-term stabilization of the formulation, in order to drastically 
shorten the time for stability testing.101,102 
1.2.5  State-of-the-art polymers as matrix excipients: l imitations 
and chal lenges 
Various polymeric materials (Figure 16, Table 2), such as poly((methyl) methacrylate)s 
(P(M)MA) and amino copolymers thereof;103 poly(vinyl pyrrolidone)s (PVP) and copolymers with 
e.g. vinyl acetate;66,104–106 poly(ethylene glycol-co-vinyl acetate-co-vinyl caprolactam) graft co-
polymers (PEG-VA-CL)107, hydroxypropylmethylcellulose (HPMC),33, 64,80,81 thermoplastic 
polyurethanes (PU),48 etc. have been used for the production of solid dispersions and/or 
sustained release formulations.  
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Despite the increasing potential of the use of polymers as excipient in formulations, 
there is still a limited number of polymer-based formulations available on the market, today. This 
number accounts to approximately 24 formulations based on the solid dispersion principle which 
have been marketed over the last 30 years, which are clearly summarized in a recent review by 
Jermain et al.108  The main reason can be found in the current drawbacks associated with these 
marketed polymer excipients, such as the lack of physical and chemical stability, processability, 
solubilizing capability, long-term shelf-life stability and versatility (structurally). In addition, none 
of the aforementioned polymers could serve as a platform for the formulation of a wide range 
of APIs.56,68,69 Table 3, gives an overview of the current limitations and challenges for the 
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Table 2. Overview properties various (non-)marketed (co)polymers for solid dispersions or sustained release 
formulations.65 
 
Table 3. Overview of the main limitations, challenges and commercial availability of P(M)MA, PVP, PVP-VA, PEG-VA-CL 
and HMPC as matrix excipient for API formulations. 
Polymer excipient Main limitations and challenges 
P(M)MA 
 
 Degrades above 155 °C limiting applicability for HME 
 Has been shown to initiate decomposition of the API 
 Low Tg can limit physical stability (amino methacrylate polymer, Tg 56 °C) 
 No commercial formulations marketed; yet FDA approved 
PVP  Limited physical stability because of its hygroscopic nature 
 High Tg: need plasticizing API or plasticizer if processed by HME 
 Residual peroxides, Low thermal stability 
 Commercial formulations marketed 
PVP-VA copolymer  Relatively hydrophobic: limits formulation of poorly water-soluble APIs 
 HME possible for APIs with Tm above 150 °C 
 Commercial formulations marketed 
PEG-VA-CL  Limited physical stability due to potential hydrolysis of vinyl acetate 
groups 
 Low Tg can limit physical stability of solid dispersion 






Method of preparation Immediate (IR) or 
sustained release 
(SR) 
PVP Povidone® 168 Hot-melt extrusion/ spray drying IR 
PVP-VA Plasdone® 106 Hot-melt extrusion/spray drying IR 
HPMC Methocel® 170-180 Spray drying/ direct compression SR/IR 
PEG-VA-CL Soluplus® 70 Spray drying IR 
P(M)MA Eudragit® 130  Hot-melt extrusion/ spray drying IR/SR 
Amino PMA 
copolymers 
Eudragit® E 56 Hot-melt extrusion IR 
PVAc/PVAL Parteck® 40-80 Spray drying SR/IR 
PU Tecoflex® -26-10 (Tm 50-80) Hot-melt extrusion SR 
PLA Expansorb® 60 (Tm 130-180) Microcapsules SR 
HEC Natrosol® 120 Hot-melt extrusion/IM SR 
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HPMC  High Tg: not very suitable for HME 
 Used in spray drying and direct compression 
 Difficult to mill 
 Limited solubilizing capability (max 40 % in sustained release 
formulations) 
 Not relevant for thermally unstable APIs 
 Commercial formulations marketed 
In the context of these limitations of commercial polymer excipients, PAOx polymers 
are proposed as an alternative for the preparation of oral drug formulations. Apart from their 
proven biocompatibility, the use of PAOx can offer advantages considering tunability of the 
overall hydrophilicity and thermal properties, processability and high physical and chemically 
stability.109,110 The structure of PAOx is amphiphilic and contains a tertiary amide group in the 
repeating unit, which are proposed to be beneficial for its use as excipients. An overview of their 
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1.3  POLY(2-OXAZOLINE)S    
Numerous 2-oxazolines have been used in the cationic ring-opening polymerization 
(CROP) to obtain the corresponding poly(2-oxazoline)s (PAOx, also referred to as POx, POz).  
PAOx originate from 1966, when they were reported for the first time by four independent 
research groups.111–114 Besides their use as monomers, 2-oxazolines are also commonly used as 
ligands in asymmetric catalysis.115–117 In the last decade PAOx have received increasing interest, 
especially for biomedical applications. Several reviews on this topic have recently been 
published providing an excellent overview of the current state-of-the-art.109,118–123 Even though 
the application potential of PAOx is tremendous and has been the focus of many review articles, 
it is relatively difficult to get a complete overview of the different PAOx structures that have been 
reported as well as a systematic insight in the properties of these different PAOx.  
In section 1.3.1, first a brief description of the 2-oxazoline monomer synthesis is given. 
Furthermore, the CROP of 2-oxazolines will be described (1.3.2) including the most important side 
reactions (1.3.3). Finally, a comprehensive overview of PAOx homopolymer structures (1.3.4) and 
their thermal (1.3.5) and solution properties (1.3.6) will be elaborated. In section 1.3.7, PAOx and 
their most important biomedical applications are discussed. 
1.3.1  Synthesis of 2 -oxazol ine monomers  
2-Substituted 4,5–dihydrooxazoles, i.e. 2-substituted-2-oxazolines, referred to as 
2-oxazolines in the following paragraphs, are the most commonly used cyclic imino ether 
monomers in the cationic ring-opening polymerization (CROP). In addition some 4- and 5-
substituted 2-oxazolines have been polymerized by CROP.124–127  Typically, 2-oxazolines are 
synthesized via the direct synthesis from non-activated carboxylic acids,128 the Witte-Seeliger 
synthesis from nitriles129,130 or the Wenker method,131 i.e. a two-step synthesis via cyclization of β-
halo amides (see Figure 17). 
Other less common synthesis routes, e.g. αlpha-deprotonation of 2-methyl-2-oxazoline 
followed by alkylation towards more complex 2-oxazolines, are also reported.132,133 For a more 
detailed overview and description of the synthesis of 2-oxazolines one can refer to the recent 
review by Verbraeken et al.134  
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Figure 17. Overview of the synthesis of 2-oxazolines monomers. 1. Direct synthesis via non-activated carboxylic acids, 2. 
The Witte-Seeliger method starting from nitriles and 3. The (modified) Wenker method. For reaction 1 and 2, any zinc 
salt can serve as catalyst for the reaction. 
1.3.2  Cationic r ing-opening polymerization of 2 -oxazol ines 
The first CROP of 2-oxazolines was reported 50 years ago by four independent research 
groups, resulting in a new class of polymers, i.e. the PAOx.111–114 The CROP mechanism consists of 










Figure 18. The cationic ring-opening polymerization of 2-oxazolines under ideal conditions (no side-reactions included), 
three-step mechanism with initiation, propagation and termination step. Depending on the used initiator and counter 
ion, the ring-opened version of the oxazolinium species after initiation and during propagation are shown. 
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 Initiation 
In the first step of the CROP a nucleophilic attack of the nitrogen lone pair of the 2-
oxazoline monomer onto an electrophilic initiator forms an oxazolinium cation, initiating the 
polymerization reaction. Different initiator systems can be used including alkyl sulfonates such as 
methyl p-toluenesulfonate (MeOTs), which is most frequently found in literature, 
p-nitrobenzenesulfonates (nosylates) and trifluoromethanesulfonates (triflates), alkyl, benzyl and 
acetyl halides, oxazolinium salts (synthesis vide chapter 4) and lewis acids.135–143 It is important to 
note that the counter-ion of the initiator influences the equilibrium between the cationic 
oxazolinium species versus the ring-opened isomer or covalent species. It is reported that the 
ratio of cationic versus covalent species is greatly dependent on the leaving group properties 
of the counter-ion, and influences the propagation (vide infra).141,144 Moreover, the first monomer 
addition often leads to the covalent species while the cationic oxazolinium is formed upon 
further monomer addition, which is influenced by interactions with the carbonyl group of the 
neighboring penultimate ring-opened poly(2-oxazoline) unit. Also functional initiators can be 
used as long as they don’t bear any nucleophilic character that could interfere with the CROP. 
An overview of various functional initiators that have been reported can be found in a review 
by Lapinte et al.145  
 Propagation 
Subsequently, in the propagation step of the CROP the 2-oxazoline monomer attacks 
the cationic oxazolinium intermediate, forming the poly(2-oxazoline) backbone by ring-opening 
and the formation of an amide while retaining the living oxazolinium chain-end.146 Also here the 
equilibrium between cationic and covalent species plays an important role, as propagation 
proceeds much more rapidly on the cationic species ensures the propagation reaction. It has 
been reported that the initiator counter-ion and its ability to form more cationic species, e.g. 
with bromides, iodides, tosylates or triflates, leads to a faster propagation rate constant (kp) as 
polymerization proceeds nearly exclusively on the cationic species when both cationic and 
covalent propagating species are present.141,144 In an ideal polymerization no chain coupling, 
transfer or termination reactions occur resulting in the living CROP of 2-oxazolines. The livingness 
of the polymerization results in control over molecular weight and narrow molar mass distribution, 
i.e. dispersity (Đ), if the initiation is fast and quantitative. Therefore, often the propagation rate 
constant is taken as the overall polymerization rate constant for the living CROP of 2-oxazolines. 
In the absence of irreversible termination, the rate of propagation follows first order kinetics 
according to the following formula (1) which can be integrated as formula (2).147,148 
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Unfortunately chain transfer reactions, such as β-elimination, and coupling reactions 
have been reported to be inherent to the polymerization, which become especially important 
when aiming for high molar mass PAOx.149–153 A more detailed overview of the CROP mechanism 
and chain transfer mechanism can be found in a recent review by Verbraeken et al. and in 
section 1.3.3 of this chapter.154  It is important to note that, the synthesis of well-defined PAOx 
with a narrow molar mass distribution requires thorough purification of the initiator, monomer and 
solvent used for the polymerization, to avoid the presence of nucleophilic impurities, including 
traces of moisture, that induce chain transfer and termination reactions. A recent patent, by 
Monnery et al., shows the ability of synthesizing defined high molar mass poly(2-oxazoline)s by 
excluding these side reactions under carefully optimized reaction conditions, including 
specialized vacuum techniques and low temperature polymerization (vide chapter 4).155 
 Termination 
Finally, termination of the CROP of 2-oxazolines occurs via nucleophilic attack of an 
added termination agent on the living cationic chain-end. Most strong nucleophiles, such as 
methanolic potassium hydroxide, carboxylates and amines, can be used to terminate the living 
oxazolinium polymer chain end onto the 5-position of the activated 2-oxazoline ring (Figure 19). 
Termination on the 2-position – where the side-chain is located – has also been reported for 





Figure 19. Example of termination reaction respectively on the 2-position, e.g. with water, and on the 5-position of the 
oxazolinium chain-end. 
                                                                
iii  The symbols represent the initial monomer concentration [𝑀]0 , monomer concentration at certain time point [𝑀]𝑡 , the 
concentration of propagating species [𝑃+]  assumed to be equal to the initial initiator concentration [𝐼]0 for an ideal CROP, 
time and propagation rate constant 𝑘𝑝. 
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With the CROP being a living/controlled polymerization mechanism, functionalities can 
be easily introduced during initiation and termination with high end-group fidelity. Oxygen, 
nitrogen, sulfur and carbon centered nucleophiles, which exclusively terminate via reaction at 
the 5-position, can be used to introduce functional groups at the -chain-end. A near complete 
overview can be found in a recent review by Glassner and Vergaelen et al.158 
1.3.3  Insights in s ide reactions of the CROP of 2 -oxazol ines 
Most of the important findings on side reactions during the CROP of 2-oxazolines were 
done in the early years around 1960-80s, by the groups of Levy, Litt et al. and Greenhalghs et 
al.,149–151,159 who were the first in describing the chain transfer and coupling processes induced 
by impurities such as water and interfering polymerization solvents or nucleophilic side-chains. 
Follow-up research studies on this topic were again initialized in the years 2000 by Diab et al. and 
Park and Kataoka et al., 160–163 together with the revival of the use of PAOx polymers in all kinds 
of primarily biomedical applications.109, 118,164,165  
Most of the side reactions described in section 1.3.2 are induced by extrinsic 
contaminants, including water, ammonia and other nucleophiles, of which the reaction 
mechanisms have been described by Greenhalghs et al.159 and Monnery et al.153  In order to 
deal with these extrinsic impurities, stringent purification methods can be applied,166 following an 
in situ purification of the reaction mixture, via the sacrificial initiator method (vide chapter 4) and 
high vacuum techniques (analogous to anionic polymerization purification processes) as 
described by a patent to uniformly synthesize PAOx polymers, by Monnery and Hoogenboom.155  
Intrinsic side reactions  
The most difficult impurities to deal with are the intrinsic side reactions induced by 
components of the polymerization reaction mixture, including the monomer, solvent, initiator 
and temperature. Litt et al. already identified the chain transfer processes that are independent 
of the purification methods used, indicating that they are intrinsic side reactions for the CROP of 
2-oxazolines. In this regard, chain transfer to monomer can occur (Figure 20) without any impurity 
being present in the polymerization mixture. The origin of this chain transfer to monomer reaction 
can be found in the ability of the 2-oxazoline to act as a base instead of a nucleophilic monomer 
for the CROP of 2-oxazolines. Via this route, the 2-oxazoline base induces β-elimination, when a 
proton is abstracted from the living propagating oxazolinium species, resulting in a ´non-living´ 
enamine species. (Figure 20, top) Subsequently, the ´non-living´ enamine polymer can act as a 
nucleophile attacking another living oxazolinium polymer chain, described as chain coupling 
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(Figure 20, bottom). However, due to the lower reactivity of the enamine compared to the 2-
oxazoline monomer, chain coupling mostly occurs at higher monomer conversion. 
Analogous to this intrinsic chain transfer reaction mechanism, chain transfer to solvent 
and chain transfer induced by extrinsic impurities (vide supra) can occur inducing either chain 
coupling, branching or termination of living species in the polymerization mixtures. All of these 
side reactions attribute to broadening of the mass distribution and higher Ð, thus non-uniformity 
of the PAOx polymers synthesized. It has been reported that lowering the reaction temperature, 
around 42 °C, and aiming for lower monomer conversions helps decreasing the amount of chain 
transfer and coupling reactions. 160–163,167 In addition, it is found that chain transfer occurs less 
when the β-position is more substituted. It is however still unclear why chain coupling reactions 
also happen for e.g. 2-phenyl-2-oxazoline (PhOx), which does not have a β proton available to 
undergo elimination. Until today, it is not clear whether other side reactions may be occurring 











Figure 20. Schematic overview of the chain transfer to monomer, as in β-elimination, that occurs as an intrinsic side 
reaction during the propagation step of the CROP of 2-oxazolines. (Top) Chain coupling reaction resulting from the 
formation of the enamine non-living polymer; which can act as a nucleophile to propagate other living oxazolinium 
chain-ends. (Bottom) (Reformat from ref.153) 
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In the last years the group of Hoogenboom et al. reported the synthesis of defined PAOx 
polymers up to 200,000 g/mol indicating that over the years the tremendous efforts in 
understanding the mechanistic details of the side reactions for the CROP of 2-oxazolines 
enabled suppression of these intrinsic side reactions resulting in a reproducible process to 
synthesize defined PAOx polymers with a MW over 20,000 g/mol.168,169  This important pioneering 
work serves also as basis for this PhD project. 
1.3.4  Poly(2-oxazol ine) homopolymers  
In the last 50 years an enormous range (over 100) of PAOx with varying side-chain 
structures has been reported in the literature. In Table 4, the most important PAOx homopolymers 
for this PhD project were selected from the comprehensive review by Glassner, Vergaelen and 
Hoogenboom, which reports all 2-oxazoline monomers whose respective PAOx homopolymers 
have been prepared by CROP, so far.158  
Table 4. Condensed version of all the tables found in the comprehensive review of Glassner et al.;158 selection is made 
according to the homo PAOx polymers of possible interest for this thesis. 
Monomer Abbr. Ref. Monomer Abbr. Ref. 











































Poly(2-aryl-2-oxazoline)s      
 
PhOx 113, 128, 171, 
173,197–201 
   
The simplest and most widely studied PAOx, with regard to systematic investigations of 
the CROP, are those with linear or branched alkyl side-chains (references see Table 4). The 
propagation rate constants (kp) (overview in Table 5), assuming 100 % initiator efficiency for e.g. 
MeOTs, of 2-alkyl-2-oxazolines decrease generally with an increase of the inductive electron 
donating character of the 2-substituent on the side-chain that lowers the reactivity of the formed 
oxazolinium cation. Therefore, the kp decreases in the order MeOx > EtOx > nPrOx, if one 
considers the same solvent-initiator system for accurate comparisoniv. It is noteworthy that an 
increase of the side chain length for linear alkyl chains from ethyl to n-nonyl has a minimal 
influence on the kp.170 Amongst 2-oxazolines with a propyl side-chain the kp decreases in the 
order cPrOx > nPrOx > iPrOx.178 The CROP of 2-aryl-2-oxazolines is generally slower compared to 
2-alkyl-2-oxazolines due to conjugation of the phenyl ring and the 2-oxazoline. Electron 
withdrawing para-substituents such as Cl or NO2 slightly increase the kp of 2-phenyl-2-oxazoline 
derivatives which can be explained by an increased reactivity of the cationic propagating 
species.197 An exception to this general trend are ortho-fluoro substituted PhOx, whereby 2,6-
difluoro-2-phenyl-2-oxazoline (2,6-DFOx) is the fastest 2-oxazoline monomer in the living CROP 
                                                                
iv will be assumed if kp´s are further discussed in this section of the chapter 
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reported to date.202 This acceleration of the CROP of orthofluoro substituted PhOx is due to loss 
of the conjugation by out of plane twisting of the aryl substituent. For functional 2-oxazoline 
monomers, rate accelerations can also be observed such as e.g. in the work of Bouten et al., 
where methyl ester containing 2-oxazolines (MestOx) were found to polymerize faster than 
MeOx, EtOx and PrOx monomers.196 The acceleration was ascribed to the interactions of the 
oxazolinium chain-end with the neighboring MestOx units, thereby increasing the reactivity of 
the 5-position of the oxazolinium ring leading towards faster propagation. Furthermore, the 
MestOx units in the polymer stabilize the transition state for the additional of the next monomer. 
Not only the monomer and polymerization temperature influence the kp of the CROP 
of 2-oxazolines, but also the solvent nature determines the overall polymerization rate. 
Commonly, more polar solvents induce faster propagation through efficient solubilisation of the 
cationic chain-end species and in addition it ensures disruption of the ion paring. In contrast, the 
less polar solvents induce less chain transfer or side reactions (vide supra 1.3.3).144, 153, 166,203 Up to 
date no systematic investigation on the effect of solvents on the CROP of 2-oxazolines has been 
reported. Consequently, this will be an important part of this thesis work (vide chapter 2 and 3), 
and serve as a basis for the synthesis of defined high molecular weight PAOx polymers. 
Table 5. Overview of the propagation rate constants for the CROP of the most common 2-oxazolines (reformat from 
literature reference148). All polymerizations were carried out in acetonitrile at 140 °C with MeOTs as initiator (except for 
2,6-DFOx which is carried out in nitromethane). 
Monomer kp (in 10-3 L/mol.s) 
MeOx 146 ± 3 
EtOx 105 ± 1 
nPrOx 93 ± 2 
nButOx 139 ± 2 
nPentOx 120 ± 3 
nHeptOx 127 ± 3 
nNonOx 111 ± 5 
iPrOx 47.8 ± 7 
cPrOx 257 ± 10 
C2MestOx 171 ± 4 
C3MestOx 193 ± 4 
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An important feature of the PAOx family is versatility, i.e. the fact that polymer 
properties can be controlled by variation of the side-chain and that functional groups can easily 
be incorporated in the polymer side-chains by employing functional monomers, as long as they 
are non-nucleophilic. Without going into too much detail, there exist a number of 2-oxazoline 
monomers containing heteroatoms such as, nitrogen, phosphor, oxygen and sulfur. The most 
important ones were already briefly described as methyl ester containing 2-oxazoline monomers, 
which can easily serve as a post-functionalization platform via direct amidation, referring to the 
work of Mees et al.204 In general, functional monomers are not always straightforward to 
synthesize, disregarded from the fact that their polymerization conditions have to be carefully 
evaluated compared to the 2-alkyl-2-oxazoline monomers. To name one specific example, the 
monomers with a Boc protected amino group (C4NHBocOx) could only be polymerized using 
an oxazolinium salt as initiator while the use of methyl triflate resulted in the formation of 
undefined low molar mass products due to side reactions.205  
As already mentioned, the choice of 2-oxazoline monomers for the CROP is only limited 
by the incompatibility of nucleophilic reactive groups, such as hydroxyls, amines, aldehydes, 
thiols and carboxylic acids, with the CROP. However, PAOx with these functional groups can be 
prepared by the CROP of ´protected´ monomers, including Boc protected amines and methyl 







Figure 21. Synthesis routes for PAOx with amino, carboxy, hydroxyl, aldehyde and thiol groups in the side-chains by post-
polymerization deprotection.  
Finally, 2-oxazoline monomers with perfluoroalkyl substituents have been reported, 
which can be used for the preparation of extremely hydrophobic PAOx. 2-Perfluoroalkyl-2-
oxazolines were found to be much less reactive than 2-alkyl-2-oxazolines and therefore difficult 
to polymerize.206  
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Even though a large number of (functional) 2-oxazoline monomers and PAOx 
homopolymers have been reported, only few of them are of interest for this PhD project, in terms 
of ease of synthesis, scalability, properties, etc. (vide infra). In this aspect, for the SD formulations 
of poorly water-soluble APIs PMeOx, PEtOx and PnPrOx with a MW of 50,000 g/mol are of interest, 
since a water-soluble matrix, that can undergo some hydrophobic interactions with the 
hydrophobic API, is preferably used in order to increase their water solubilization rate. In contrast, 
higher MW and/or more hydrophobic polymers, such as 140,000 g/mol PEtOx or 50,000 to 100,000 
g/mol PnPrOx matrices are desired for the formulation of highly water-soluble APIs to slow down 
their solubilization in SRF. 
1.3.5  Thermal properties of poly(2-oxazol ine) homopolymers  
The alkyl-PAOx polymers are stable up to temperatures of approximately 300 °C and 
more171,193 enabling applications and processing over a broad temperature range. Alkyl-PAOx 
with varying length of the side-chains have been widely studied in terms of their structure-
property relationships. Figure 22 shows an overview of the Tg and melting temperatures (Tm) 
obtained from differential scanning calorimetry (DSC) of alkyl-PAOx with 1-17 carbon atoms in 
the side-chain. 
 
Figure 22. Glass transition and melting temperatures of poly(2-n-alkyl-2-oxazoline)s with varying side-chain length 
obtained from DSC. Data are taken from refs. 128, 170, 172, 182,187 
PAOx polymers with 1-5 carbon atoms in the side-chain (PMeOx to PnPentOx) show a 
Tg that decreases linearly with increasing side-chain length which can be explained by the 
increasing flexibility of the side-chains. For PMeOx, PEtOx and PnPrOx no melting peaks were 
observed by differential scanning calorimetry, while polymers with 4 or more carbon atoms in 
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the side-chain were found to be semi-crystalline with a Tm around 150 °C independent of the 
side-chain length indicating side-chain crystallization. In contrast, Litt and co-workers113 reported 
melting temperatures also for PMeOx and PnPrOx by differential temperature analysis (DTA) 
based on a difference in birefringence. This discrepancy might originate from different 
processing of the polymers, potentially resulting in alignment of the main-chains and 
crystallization if enough time is given.207,208 Remarkably, the fatty-acid based PSoyOx revealed a 
much lower Tm (88.4 °C) than PAOx with long linear saturated alkyl side-chains due to the cis-
double bonds in the side-chains that disturb the crystallization and results in the lower Tm.209 Fully 
amorphous PAOx with a low Tg can be prepared using monomers with branched alkyl side-
chains as demonstrated for  poly(2-(1-ethylpentyl)-2-oxazoline) (EPOx), poly(2-(3-ethylpentyl)-2-
oxazoline) (P3EPOx) and poly(2-(3-ethylheptyl)-2-oxazoline) (PEHOx) (Figure 23), the latter being 
the amorphous poly(2-oxazoline) with the lowest reported Tg to date, being -6 °C, which may be 
suitable to prepare rubbery-like block copolymers, analogous to styrene-butadiene-styrene 
(SBS), materials with a soft middle block.210 
PAOx with cycloalkyl side-chains exhibit interesting thermal properties. While PcPrOx is 
amorphous with a higher Tg (79 °C) than its linear analogue PnPrOx;192 PcButOx, PcPentOx and 
PcHexOx are semi-crystalline high performance polymers with an extraordinary high Tm of 243, 
251 and 306 °C, respectively.193 Noteworthy, the degradation temperature of PcButOx and 
PcPentOx is approximately 100 °C higher than their Tm, making them promising candidates for 
application as heat-resisting materials with a large processing window. In addition, also high 
melting points have been reported for adamantyl-containing PAOx.211  Furthermore, poly(2-n-
perfluoroalkylethyl)-2-oxazoline)s represent very hydrophobic PAOx. Interestingly, their melting 
temperatures are much higher compared to their hydrocarbon analogues and unlike the alkyl-
PAOx, the melting points of the perfluoro-PAox increase as the side-chain length increases, as 




Figure 23. Structures of low Tg PAOx polymers with alkyl branched side-chains; i.e. poly(2-(1-ethylpentyl)-2-oxazoline) 
(EPOx), poly(2-(3-ethylpentyl)-2-oxazoline) (P3EPOx) and poly(2-(3-ethylheptyl)-2-oxazoline) (PEHOx). 
Next, by looking at phenyl containing PAOx polymers, such as PPhOx and fluoro-
substituted phenyl PAOx, a higher Tg (between 103 °C and 135 °C, respectively), compared to 
PMeOx and PEtOx, is found as a consequence of the rigid aromatic phenyl ring present in all the 
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polymers. 113, 128, 171,212 Finally, if one has a look towards functional PAOx polymers, which have 
been synthesized and investigated with regard to thermal properties, it is found that all reported 
functional polymers are amorphous, thus possess only a Tg. For example, the methyl ester 
containing PAOx, C2MestOx and C3MestOx, have a Tg of 39 °C and -1 °C, respectively; as been 
published by Bouten et al.194 A more complete table of all Tg´s reported for functional PAOx, can 
be found in the review by Glassner et al.158 
Mechanical properties of poly(2-oxazoline) homopolymers 
There are only very few reports on the mechanical properties of PAOx homopolymers 
as the majority of polymers have a rather low molar mass leading to very poor (brittle) 
mechanical properties, thereby obstructing mechanical testing. The mechanical properties of 
low molar mass alkyl-PAOx (DP = 60) have been reported based on nano-indentation of spin-
coated polymer films. These measurements revealed that the mechanical properties are closely 
related to the trends seen in the thermal properties of alkyl-PAOx (vide supra, Figure 22). Upon 
increasing the length of the alkyl side-chain from methyl to butyl, the elastic modulus at room 
temperature decreases almost linearly172,207 (Figure 24) related to the decrease in Tg. 
 
Figure 24. Indentation moduli of poly(2-n-alkyl-2-oxazoline)s with DP  60 at low and ambient humidity. The lines are 
added to guide the eye only. Reproduced from Ref.207   
The polymers with more than four carbon atoms in the side-chain are semi-crystalline 
and have a Tg below ambient temperature. Therefore the measurements at room temperature 
were performed above their respective Tg resulting in moduli of ca. 0.8 GPa, which is common 
for polymers tested between their glass transition and melting temperatures.213 It should be noted 
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that the mechanical properties of PMeOx, PEtOx and Pn-PrOx strongly depend on the humidity 
due to the hygroscopic nature of these polymers. As can be seen from Figure 24, the plasticizing 
effect of incorporated water significantly reduces the indentation moduli.207 It is expected that 
more in depth mechanical properties of PAOx will become available in the near future based 
on the fact that defined high molar mass PAOx have become synthetically accessible. 
1.3.6  Solution properties of poly(2-oxazol ine) homopolymers  
The variation of the side-chain structure of PAOx enables the tuning of the properties 
from very hydrophilic (PMeOx) to very hydrophobic (long (branched or linear) alkyl or perfluoro 
alkyl side-chains) polymers. Consequently, the solution behavior of PAOx strongly depends on 
the side-chain structure. Table 6, gives an overview of the solubility of various alkyl-PAOx in water 
and common organic solvents, such as methanol, chloroform, acetonitrile, etc. Obviously, to 
prepare defined PAOx polymers via the living CROP it is necessary that both monomer and 
polymer structure are soluble at all times during the polymerization.166 Some reports, e.g. on the 
polymerization of poly(2-iso-butyl-2-oxazoline), show uncontrolled polymerization as a 
consequence of phase separation occurring during the CROP.188 
In addition to the solvents listed in Table 6, the less common solvent sulfolane was found 
to be a good solvent for preparing high molar mass PMeOx, vide chapter 2.214  In contradiction 
to the good solubility of the series of alkyl-PAOx, the semi-crystalline polymers, i.e. PcBuOx, 
PcPentOx and PcHexOx, show poor solubility in many common organic solvents, but are found 
to be soluble in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) and formic acid at ambient temperature 
that disrupt interchain interactions.193 The behavior of PAOx in aqueous solutions has been widely 
studied, because of their potential in biomedical applications. Mainly, their behavior is 
influenced by the hydration of the polymer and the accompanied loss in entropy. With 
increasing temperature, the entropy loss increases and at the phase transition temperature it 
becomes more favorable to release the water molecules into the bulk water resulting in phase 
separation of the polymers chains (Figure 25).  
Therefore, many PAOx exhibit a lower critical solution temperature (LCST). Two 
comprehensive reviews about thermoresponsive PAOx by Weber et al.215 and Hoogenboom 













Figure 25. Schematic representation of a polymer phase transition in aqueous solution, as in lower critical solution 
behaviour (Left); scheme of a LCST phase transition diagram presented as the temperature as a function of polymer 
concentration in a particular solvent with LCSC the lower critical concentration at the LCST transition and T CP, as the 
cloud point temperature at another concentration anywhere else on the graph apart from the lowest point, which is 
the LCST.  Adapted from ref. 217,218 
 
Table 6. Solubility of PAOx with hydrocarbon side-chains in water and various organic solvents.  
+ = soluble, - = insoluble, +/- = partially soluble, LCST = lower critical solution temperature, apoor solubility for molar mass 
>∼ 20kDa, bsoluble after heating, precipitated on cooling, csoluble after heating 
 PMeOx has been claimed to be even more hydrophilic than PEG based on HPLC 
analysis79 as well as based on the poor solubility of higher molar mass PMeOx in organic solvents 
like acetonitrile in which higher molar mass PEG is well soluble.214 As a result, PMeOx is fully water 
soluble from 0-100 °C while PAOx with longer alkyl side chains are either water insoluble or are 
only soluble in water at a certain concentration, i.e. exhibit LCST behavior. An overview of the 
cloud point temperatures (TCP, the temperature where the transmittance rapidly decreases due 
to phase separation of the polymer) of PAOx homopolymers with increasing hydrophobicity is 
given in Figure 26. It should be noted that the TCP depends on the molar mass, the concentration, 
the polymer end-groups and the conditions of the measurement218 and therefore comparisons 






PMeOx + + - +/-a  - + 
PEtOx LCST + + + + + + 
PnPrOx LCST + + +  + + 
PnNonOx -  + - -  + 
PPhOx -  + + +  + 
PcBuOx - -  +/-b  +/-b +/-b 
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of TCP's reported in the literature should be handled with care, as Zhang et al. reported very 
recently.218 
 
Figure 26. PAOx with hydrocarbon side-chains with increasing hydrophobicity (from left to right) and consequently 
decreasing cloud point temperature. 
The LCST behavior of high molar mass PEtOx was first reported in 1988 by Lin et al. with 
TCP's from 61-69 °C dependent on the concentration.219 Lowering the molar mass of PEtOx 
homopolymers results in a significant increase of the TCP in aqueous solution.177,220  
Amongst thermo-responsive polymers, those with a LCST close to body temperature are 
of special interest for applications in drug delivery or bioengineering.41,221 Interestingly, PAOx with 
propyl side-chains namely PnPrOx, PcPrOx and PiPrOx have a Tcp in this range. It was first reported 
in 1992 that PiPrOx exhibits LCST behavior with the TCP decreasing from 39 to 35 °C with increasing 
polymer concentration (0.1 – 1 wt%).184 More detailed investigations of PiPrOx with varying molar 
mass revealed that the TCP decreases with increasing molar mass and that the concentration 
dependence becomes less pronounced with increasing molar mass.160,161,186 All of these studies 
found the phase transition to be reversible with a small heating-cooling hysteresis. However, it 
was later discovered that the transition becomes irreversible after keeping the dispersion longer 
above the cloud point due to isothermal crystallization of the (partially) dehydrated polymer 
chains.222,223 
 It was recently shown that cyclic PiPrOx exhibits a much higher TCP compared to linear 
PiPrOx with the same molar mass.224 As much as 15 years after the LCST behavior of PiPrOx was 
discovered, it was reported that PnPrOx also exhibits LCST behavior in aqueous solutions.95 The 
TCP was found to be more than 10 °C lower compared to PiPrOx with a similar molar mass which 
is in accordance with the higher hydrophobicity. As previously observed for PiPrOx, the TCP of 
PnPrOx also decreases with increasing molar mass.177 The cyclic side-chain structure of PcPrOx 
results in an intermediate hydrophobicity compared to PiPrOx and PnPrOx and consequently its 
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In contrast to PiPrOx the phase transitions of the amorphous PnPrOx and PcPrOx are 
fully reversible, even when kept above TCP for a prolonged time. PAOx with methyl ester side-
chains were first reported 1968,150 but it was only recently reported that these polymers exhibit 
thermo-responsive LCST behavior in aqueous solution.224 Their TCP’s strongly depend on the length 
of the alkyl spacer. PC2MestOx shows a very similar solution behavior as PEtOx with a TCP around 
100 °C for a polymer with DP 100 while PC3MestOx exhibits a TCP around 25 °C similar to PnPrOx. 
In contrast to the LCST behavior, there are no poly(2-oxazoline)s reported that show an upper 
critical solution temperature (UCST) in water. However, UCST behavior was observed for PAOx 
with phenyl, benzyl or alkyl side-chains longer than propyl in ethanol-water mixtures,224 which 
results from the change in polarity of these non-ideal solvent mixtures upon heating.225 Figure 27  











Figure 27. Solubility overview for poly(2-oxazoline)s with hydrocarbon side-chains in water-ethanol mixtures (5 mg/mL). 
Reproduced from ref. 224  
1.3.7  Application of poly(2 -oxazol ine)s in the biomedical field 
Almost 25 years after the ´discovery´ of the CROP of 2-oxazolines and resulting PAOx 
polymer structures, studies by D´ejardin et al. and Goddard et al.226,227 in 1989 showed a first 
indication of protein resistance, later called ´stealth behaviorv´, of PAOx (co)polymers based on 
investigation of the biodistribution of (radio-labeled) PMeOx polymers in mice. Furthermore, 
Zalipsky et al. and Woodle et al. reported on enhanced blood circulation times of PMEOx and 
                                                                
v Stealth literally means ´making invisible´; related to drug delivery a material that possesses stealth behavior can be regarded 
as non-recognizable by the immune system. 
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PEtOx polymers in the 1990s, similar to the ´gold standard´ in the field PEG/PEO polymers.228,229 
Additional studies on the biodistribution of PAOx polymers followed approximately 15 years later 
with the work of Gaertner et al. and very recently the renal clearance limit of PEtOx was reported 
to be around 40 kDa.230,231 Since the years 2000, the number of literature papers and reviews on 
the use of PAOx polymers in biomedical applications increased tremendously, which can be 
elucidated from the graph in Figure 28. From 2007 up to now, over 300 publications on PAOx in 
a biomedical context have been published, with a number of interesting reviews by 
Hoogenboom et al., Verbraeken et al., Schlaad et al., Adams et al. and Sedlacek et al. 
describing the high potential of PAOx and their use in all types of biomedical applications.109, 
118,119, 134,164,165 A wide range of applications is described with a focus on PAOx-protein and drug 
conjugates,122,232–236 PAOx-based micelles for drug encapsulation (non-covalently) and triggered 
drug release,200,237–239 as well as hydrogels (Figure 29).238,240 Another important application of 
PAOx can be found in gene delivery for which it serves as a precursor for the synthesis of linear 
poly(ethylene imine) (PEI) or PEtOx-EI copolymers. Different studies showed or described the 
improved effect of gene therapy by the use of linear PEI over branched PEI.118, 153,241–244 In 
addition, an important study, by De Geest et al., related to the acid hydrolysis of PEtOx revealed 
their chemical resistance over more than 40 hours, under conditions of the gastrointestinal tract 








Figure 28. Number of publications, over the last 50 years, including poly(2-oxazoline)s and biomedical applications, 
according to entry in Scifinder®.  
It will be clear that the use of a large variation of PAOx (co)polymer architectures and 
designs have been reported related to drug or protein delivery. However, only very few 
examples can be found for the application of PAOx as matrix excipient for solid dispersions or 
sustained release formulations. In 2012, Claeys et al. published work based on HME/IM of 
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Aquazol® (i.e. poorly defined PEtOx, Ð approximately 3-4) of poorly and good water-soluble 
drugs110 and in that same year Bender et al.246 filed a patent on the protection capabilities of 
Aquazol® for cannabinoids. Also, Policianova et al. published two papers on acetylsalisylic acid 
solid dispersions, including comparison between state-of-the-art excipients, such as PVP, PEG, 
and PEtOx polymers.247,248  Despite these promising results, the lack of further use of PAOx 
polymers as matrix excipient may be related to the inability to synthesize defined PAOx 
(co)polymers with a molecular weight higher than 20,000 g/mol; which will be necessary for 
further widespread application. Higher MW PAOx polymers are desired for better processability 
and mechanical properties of the polymers resulting from chain entanglements. 
Figure 29. Overview of the different architectures and designs based on poly(2-oxazoline)s for the application in the 
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1.4  CONCLUSIONS FROM LITERATURE AND OUTLINE THESIS 
Based on the literature review it can be concluded that the use of biocompatible 
polymers in oral drug formulations is a growing research field with enormous potential. 
Nonetheless, the state-of-the-art polymers that are used do not provide a tunable platform for 
the formulation of a wide variety of APIs. Introducing the PAOx polymer family in this field, as a 
tunable polymer platform for oral drug formulation of APIs, may further stimulate the use of 
polymers as matrix excipient. The summary of advantages for PAOx polymers include their high 
chemical and physical stability, their tunability and easy processing. It is important to mention 
that the wide variety of potential structures can also be seen as a disadvantage as the 
possibilities are indefinite. The ideal drug carrier or polymer carrier should succeed in release of 
the drug in the appropriate time frame, vide sustained or immediate release, provides long-term 
shelf-life stability, i.e. after at least one year it should provide the same release profile and possess 
the same properties as measured after processing. Furthermore, a polymer carrier should be 
able to be used for formulation of a wide range of APIs. 
In this thesis a combination of polymer synthesis and pharmaceutical research is 
performed to explore PAOx as matrix excipient for oral drug formulations, dividing the thesis work 
in a polymer synthesis part and a pharmaceutical applications part (overview in Figure 30). 
Figure 30. Schematic outline thesis existing of a synthesis part (chapter 2-4) and a drug formulation part (chapter 5-6). 
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In the first part, fundamental research has been done on the optimization and up-scaling 
of the CROP of 2-oxazolines. In chapter 2, the route towards defined poly(2-methyl-2-oxazoline) 
is described, including polymerizations carried out in extremely polar solvents such as sulfolane. 
Further, in chapter 3, the optimization of the CROP for the preparation of the most used 
hydrophilic and biocompatible polymer in the PAOx familiy, i.e. poly(2-ethyl-2-oxazoline), is 
investigated at different temperatures with regard to different solvents ranging from apolar to 
polar. A first step towards the green synthesis, in terms of biocompatibility, is set by using ethyl 
acetate as non-harmful solvent for the polymerization of 2-ethyl-2-oxazoline.  
In chapter 4, upscaling of the synthesis of defined high molar mass PAOx is highlighted. 
The importance of reproducible synthesis for the defined high MW PAOx is stressed, together with 
some pitfalls and difficulties in obtaining them.  
In the second part of the PhD thesis, the focus is put on the pharmaceutical applications 
of these defined high MW PAOx synthesized in the previous chapters. In chapter 5, the use of 
PAOx polymers in solid dispersions is described. Mainly, the influence of different PAOx polymers 
have been evaluated for the formulation of poorly water-soluble drugs and the corresponding 
increased release rate and solubility of the drug. Finally, in chapter 6, more hydrophobic PAOx 
polymers are tested in drug formulations of highly water-soluble APIs, in the so-called sustained 
release formulations. The obtained results show a remarkable difference in the use of PEtOx 
compared to poly(2-n-propyl-2-oxazoline)s and poly(2-sec-butyl-2-oxazoline)s, for 
controlled/extended release of the used model APIs.  
In chapter 7, conclusions and future perspectives will be given on the use of defined (high 
molecular weight) PAOx polymers as matrix excipient for solid dispersions and sustained release 
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CHAPTER 2 
2 A JOURNEY TOWARDS DEFINED POLY(2-METHYL-2-
OXAZOLINE) 
 
ABSTRACT The synthesis of poly(2-methyl-2-oxazoline)s (PMeOx) and poly(2-oxazoline)s 
(PAOx) in general, dates back from the late 1960s.1,2 Thereby it was already clear that interfering 
impurities would play a crucial role in the cationic ring-opening polymerization (CROP) of 2-
oxazolines, as clearly reported by Litt and coworkers.3 In this chapter first the challenges, either 
found in literature or experimentally determined in my PhD, associated to the CROP of MeOx will 
be discussed. Herein, the search for alternative solvents for the cationic ring-opening 
polymerization (CROP) of 2-methyl-2-oxazoline (MeOx) is driven by the poor solubility of higher 
molar mass PMeOx in polymerization solvents such as acetonitrile (CH3CN) and chlorobenzene 
as well as in MeOx itself. Next, the polymerization of MeOx in sulfolane, as most suitable but rather 
exotic solvent, is described. Since this solvent is quite rare within polymerizations of any kind, an 
exclusive part is dedicated towards its use. Unexpectedly, an increased propagation rate 
constant (kp) was found for the CROP of MeOx in sulfolane. Further extended kinetic studies at 
different temperatures (60 °C- 180 °C), revealed that the acceleration is due to an increase in 
frequency factor while the activation energy (Ea) of the reaction is unaffected compared to the 
CROP in CH3CN. In order to explore the versatility of sulfolane as polymerization solvent for the 
CROP of 2-oxazolines in general, also the polymerization kinetics of other 2-oxazoline monomers, 
such as 2-ethyl-2-oxazoline (EtOx) and 2-phenyl-2-oxazoline (PhOx), have been studied in 
sulfolane resulting in a general acceleration of the CROP of these monomers as well as a PMeOx-
b-PhOx block copolymer. Finally, a straightforward synthesis for a defined 50,000 g/mol PMeOx 
polymer in sulfolane is elaborated at the end of this chapter to emphasize the importance of 
sulfolane as enabling solvent for preparing poly(2-methyl-2-oxazoline)s (PMeOx) (co)polymers. 
PMeOx is especially relevant for biomedical applications as most hydrophilic polymer in the 
poly(2-alkyl-2-oxazoline) family. 
Contributors to this work 
Bart Verbraeken and Bryn D Monnery were involved in conceptual discussions. 
Contribution of the candidate 
Performed all the experiments and wrote first author paper: 
Vergaelen, M et al., Sulfolane as common rate accelerating solvent for the cationic 
 ring-opening polymerization of 2-oxazolines, ACS Macroletters, 2015, 4, 85-828.  
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2.1  TROUBLESHOOTING THE CROP OF 2-METHYL-2-OXAZOLINE: INTRODUCTION 
During the past decades, researchers have been searching for alternative biocompatible 
polymers that ‘outperform’ the gold standard in the field, poly(ethylene glycol).4–6 In this respect, 
poly(2-alkyl/aryl-2-oxazoline)s (PAOx), more specifically poly(2-methyl-2-oxazoline) (PMeOx) and 
poly(2-ethyl-2-oxazoline) (PEtOx), have been widely investigated for their use in biomedical 
applications.4,7–9 PAOx are prepared by living cationic ring-opening polymerization (CROP) of 2-
oxazolines and their polymerization mechanism has been studied widely (vide chapter 1).10 One 
of the main advantages of the CROP of 2-oxazolines is that its living nature provides good control 
over the PAOx molar mass distribution, i.e. narrow dispersity (Đ), and very high end-group 
fidelity.1,11 Additionally a broad range of structures and polymer properties are easily accessible 
by variation of the monomer structures.12–15 The CROP of 2-oxazolines consists of three steps, 
namely the initiation, propagation and termination as discussed in chapter 1 (Figure 1).16–23 The 
CROP of 2-oxazolines is often proposed to occur in an ideal living manner assuming that no chain 

















Figure 1. Table of content of the respective article published on the use of sulfolane as a ‘universal’ solvent for the 
cationic ring-opening polymerization of poly(2-alkyl/aryl-2-oxazoline)s.  
The propagation rate constant (kp) of the CROP of 2-oxazolines determines the rate of the 
overall polymerization and is influenced by different parameters such as the type of monomer, 
initiator and solvent.26–31 In earlier research, by, amongst others, the groups of Litt and Nuyken, a 
variety of parameters have already been discussed.1, 25,32 Litt explored the effect and possible 
interference of solvents with different functional groups on the CROP of 2-oxazolines, in order to 
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explain the mechanism of polymerization. In this early research 2,4-dimethyl sulfolane was 
already mentioned as a non-interfering solvent, which was proven by a normal infrared 
spectrum of the polymer that was obtained for the CROP of 2-(n-pentyl)-2-oxazoline in 2,4-
dimethyl sulfolane.33,34 
The CROP of 2-oxazolines is most commonly performed in CH3CN,33,35 using MeOTs as 
initiator. However, CH3CN seems to be less suitable for the polymerization of MeOx due to the 
poor solubility of PMeOx in CH3CN, resulting in reduced control over the CROP of MeOx due to 
phase separation when aiming for higher degrees of polymerization (DP’s). The low solubility of 
PMeOx in CH3CN can be explained by a significant change in hydrophilicity upon polymerization 
due to the isomerization of the cyclic imino ether structure (MeOx) to a tertiary amide structure 
(PMeOx). The same reasoning can be applied to explain the poor solubility of PMeOx in other 
common polymerization solvents, including chlorobenzene and even its own monomer, 
obstructing bulk polymerization. 
According to Tilstam et al., sulfolane is a quite eccentric solvent compared to other dipolar 
aprotic solvents such as N,N-dimethyl acetamide, dimethyl sulfoxide, etc. It is mostly used in oil 
refineries, for the recovery of high- purity aromatic products and the purification of gas streams. 
If one looks at its characteristics it is an extremely high boiling solvent, has the ability to dissolve 
strong cations and polarizable intermediates because of its strong solvency power and it 
dissolves in almost any organic/inorganic medium, except for tert-butyl methyl ether.35 If one 
looks at the use of sulfolane as polymerization solvent only one recent publication by Mendes et 
al.36 describes its use in copper mediated ATRP as universal solvent.  
In order to tackle the optimization of the CROP of MeOx to obtain defined high MW PMeOx 
a solvent screening will be carried out to check alternative solvents compared to the CROP of 
MeOx in acetonitrile (section 2.3.1). In section 2.3.2, sulfolane is explored as a valuable 
alternative for the CROP of MeOx. Therefore, a complete set of kinetic experiments at different 
temperatures is set up, to investigate the CROP of MeOx in sulfolane. Furthermore, the CROP of 
EtOx and PhOx in sulfolane are studied, to question the use of sulfolane as common solvent for 
the CROP of 2-oxazolines.  In order to verify the livingness of the CROP of 2-oxazolines in sulfolane 
the synthesis of a poly(MeOx-block-PhOx) copolymer is reported in sulfolane (section 2.3.3). 
Finally, in section 2.3.4, the synthesis of a defined 50,000 g/mol PMeOx polymer is described in 
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2.2  MATERIALS AND METHODS     
2.2.1  Materials and equipment 
Materials 
Methyl p-toluenesulfonate (MeOTs), 2-phenyl-2-oxazoline (PhOx) and solvents (sulfolane, 
N,N-dimethylacetamide (DMA), acetonitrile (CH3CN), chlorobenzene) (HPLC quality) were 
purchased from Sigma-Aldrich. 2-Methyl-2-oxazoline (MeOx), barium oxide and potassium 
hydroxide were purchased from Acros Organics. 2-Ethyl-2-oxazoline (EtOx) was kindly donated 
by Polymer Chemistry Innovation. CH3CN was purified over aluminum oxide by means of a 
solvent purification system from J.C. Meyer.  
Purification methods 
All 2-oxazolines were distilled over barium oxide under inert argon atmosphere (MeOx and 
EtOx) or under reduced pressure (PhOx) before use in the polymerizations. MeOTs was distilled 
over CaH2 under reduced pressure. Purification of sulfolane was performed according to the 
procedure described in the book ‘Purification of Laboratory Chemicals’, 6th edition.37 Initially, 
small portions of solid KMnO4 were added to the sulfolane (at 50 °C) until the color remains up 
to one hour. This is mainly to deal with 3-sulfolene and 2-sulfolene impurities. Thereafter, a 
dropwise addition of MeOH is performed to destroy the excess of KMnO4 followed by filtering the 
solution. Note: to clean the filter afterwards (MnO2 is quite harsh to remove) concentrated sulfuric 
acid was used. Trace amounts of MeOH were removed on the rotavap for a few minutes. Then 
CaH2 was added as a drying agent and the mixture was stirred overnight. Afterwards a distillation 
was carried out under high vacuum (hot plate > 90 °C and 10-2 mbar), without any condenser 
(sulfolane becomes a solid at ca. 30 °C). The whole distillation set-up was covered in aluminum 
foil to increase the heat transfer and only the receiving flask was cooled with ice. 
Equipment 
Conversions of the CROP of the selected 2-oxazoline monomers were monitored by gas 
chromatography (GC) analysis. GC was performed on an Agilent 7890A system equipped with 
a VWR Carrier-160 hydrogen generator and an Agilent HP-5 column of 30 m length and 0.320 
mm diameter. An FID detector was used and the inlet was set to 240 °C with a split injection of 
ratio 25:1. Hydrogen was used as carrier gas at a flow rate of 2 mL/min. The oven temperature 
was increased with 20 °C/min from 50 °C to 120 °C, followed by a ramp of 50 °C/min. to 240 °C. 
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All stock solutions and samples were prepared in a VIGOR Sci-Lab SG 1200/750 Glovebox 
System with an atmospheric water content ≤ 0.1 ppm. For the polymerizations, a Biotage Initiator 
EXP Microwave System with Robot Sixty was used. During the polymerizations the microwave 
synthesizer operated at a constant set temperature which is monitored by the IR-sensor. 
Size-exclusion chromatography (SEC) was performed on an Agilent 1260-series HPLC system 
equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid sampler (ALS), 
a thermostatted column compartment (TCC) at 50 °C equipped with two PLgel 5 µm mixed-D 
columns in series, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). 
The used eluent is DMA containing 50 mM of lithium chloride at an optimized flow rate of 0.593 
ml/min. The spectra were analyzed using the Agilent ChemStation software with the GPC add 
on. Molar mass and dispersity (Đ) values were calculated against polymethylmethacrylate 
standards from PSS. 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker Avance 
300 MHz spectrometer, at room temperature. The chemical shifts are given relative to 
trimethylsilane (TMS). 
2.2.2  Experimental methods 
Kinetic studies of the CROP 
To perform the kinetic studies, 45 mL stock solutions have been made and divided over 
different 2.5 mL microwave vials, each filled with 700 µL to 800 µL of this stock solution. For each 
kinetic run at a certain temperature, 7 microwave vials have been filled and heated for a certain 
time. The stock solutions (Table 1) consist in general of a 3 M monomer (MeOx, EtOx or PhOx) 
concentration, 30 mM initiator (MeOTs) concentration and sulfolane as the polymerization 
solvent (except the polymerizations in CH3CN and DMA). All calculations have been done in 
order to synthesize polymers with a M:I ratio, i.e. a target degree of polymerization (DP), of 100.  
Table 1: Calculations for the kinetic study for the homopolymerization of MeOx, EtOx and PhOx. 
*M= Monomer; I= Initiator; S = Solvent [ ] = concentration; V( ) = Volume 
Monomer [M]/[I] [M] V (Stock, total) [I] V (I) V (M) V (S) 
Name ratio mol/L mL mol/L µL mL mL 
MeOx 100 3 45 0.03 210 11.5 33.3 
EtOx 100 3 45 0.03 210 13.7 31.1 
PhOx 100 3 45 0.03 210 17.7 27.1 
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After the reaction, GC samples were made by sampling 100 µL of the reaction medium into 
a sample vial and adding 900 µL of chloroform, as non-interfering solvent. For the SEC analysis, 
the samples were terminated with 500 µL of a methanolic KOH solution (1 M), followed by 100 µL 
sampling of the reaction medium and addition of 900 µL of DMA. All samples were carefully 
filtered over 0.13 µm filters (FE1322) before SEC analysis. In table 2 the Arrhenius parameters 
resulting from the kinetic studies are listed. The one second sample is regarded as time zero were 
the reaction temperature reached 140 °C. 
Table 2: Overview of the Arrhenius parameters as a function of monomer and solvent; activation energy and frequency 
factor. 
Monomer Solvent Activation energy* Frequency factor* 
  
kJ/mol A (10 8 Lmol-1s-1) 
MeOx sulfolane 81.1 ± 2.7 64.0 ± 2.5 
MeOx CH3CN 75.4 ± 0.5 5.1 ± 1.2 
EtOx sulfolane 74.3 ± 1.6 4.8 ± 0.1 
EtOx CH3CN 73.4 ± 0.5 2.0 ± 0.9 
PhOx sulfolane 85.2 ± 4.7 31.5 ± 2.0 
PhOx CH3CN 84.4 ± 0.5 14.9 ± 2.8 
*The activation energy and frequency factor are based on data sets at five different temperatures. The data for 
acetonitrile are gathered froma literature reference by Wiesbrock et al.12  
Synthesis of poly(2-methyl-2-oxazoline)50-block-(2-phenyl-2-oxazoline)50 
The synthesis of this block copolymer (DP 100) consists of a two-step one-pot reaction. In a 
10 mL microwave vial, a stock solution of MeOx (1.67 mL), MeOTs (0.061 mL) and sulfolane (4.78 
mL) was prepared and reacted for 5 min at 140 °C. The reaction time was calculated according 
to the kinetic data of the homopolymerization of MeOx. After polymerization of the first block, a 
SEC sample was made of the prepared PMeOx block with DP 50 followed by sequential addition 
of the second monomer, PhOx (1.18 mL). This polymerization mixture was heated for 14 min at 
160 °C under diluted conditions (1 M; sulfolane 4.18 mL) resulting in the poly(2-methyl-2-
oxazoline)50-block-(2-phenyl-2-oxazoline)50 block copolymer. The final work-up of the polymer 
was performed by precipitation in tetrahydrofuran allowing complete removal of sulfolane. 
Approximate yield, 70 %. 
Synthesis of defined 50,000 g/mol poly(2-methyl-2-oxazoline)  
For the synthesis of the defined 50,000 g/mol PMeOx polymer the sacrificial initiator method 
(SIM) was used according to a recently filed patent procedure by Monnery et al. (vide chapter 
4, for a detailed description).39 Shortly it describes the polymerization of 2-oxazolines via 
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purification of the MeOx and sulfolane over a sacrificial amount of initiator, being a 2-phenyl-2-
oxazolinium tetrafluoroborate salt (HPhOx-BF4). After the purification step, a static distillation is 
performed of the solvent and the remaining monomer towards a polymerization flask in which 
the amount of initiator needed for the polymerization reaction is already present. For the 
polymerization mixture comprising of 45 mL MeOx (3 M) and 131 mL sulfolane, 1.24 g of HPhOx-
BF4 initiator was used to purify the reaction mixture in situ. In the polymerization flask 151 mg of 
HPhOx-BF4 (3.6 mM) was added to obtain a PMeOx polymer with a target DP of 823 (target Mn 
70,000 g/mol at 100 % conversion). In order to obtain a 50,000 PMeOx polymer, 70 % conversion 
is targeted. Therefore, the reaction mixture is put in an oil bath at 60 °C, for 75 hours. After the 
reaction, 4 mL of a methanolic KOH solution (1 M) was added. The purification is performed by 
precipitation of the polymer from the reaction mixture in cold diethyl ether followed by a second 
precipitation in tetrahydrofuran (THF). Final drying is performed by dissolution in water and 
consequent freeze drying of the solution to obtain the PMeOx as a white powder. 
2.3  RESULTS AND DISCUSSI ON    
2.3.1  Solvent screening for the CROP of 2-methyl-2-oxazol ine 
In the search for more polar solvents for the CROP of MeOx, we initially proposed N,N-
dimethyl acetamide (DMA) and sulfolane. DMA has been identified as solvent according to the 
similarity towards the tertiary amide backbone of the PMeOx structure. Sulfolane was chosen as 
an alternative dipolar aprotic solvent, which is mostly used as an industrial solvent but recently 
also used as a universal solvent for ATRP.36 Apart from the extremely high dipole moment (4.7 D), 
high boiling point and high chemical stability, sulfolane has a high solvency power for cations 
(i.e. high Hildebrand solubility parameter), which is expected to be favorable for the CROP of 2-
oxazolines.35 In both DMA and sulfolane, MeOx and PMeOx are found to be solublei (Table 3), 
making them promising candidates for the CROP of MeOx. Furthermore, sulfolane is regarded 
as class II solvent, which has to be limited for human consumption but not completely avoided.39 
After the solvent solubility screening, a series of kinetic studies was performed for the CROP 
of MeOx with a target DP of 100 in DMA and sulfolane at 140 °C under microwave conditions, in 
order to compare the results with the conventional polymerization of MeOx in CH3CN. Note that 
                                                                
i The PMeOx solublity is based on the visual determination of the homogeneity of the polymerization mixture after termination. 
Insolubility of PMeOx in e.g. chlorobenzene is based on the cloudiness of the polymerization mixture. The exact solubility is not 
determined, because of the difficulty to solubilize these high polymerization concentrations of the polymer in a particular solvent. 
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PMeOx with a DP of 100 is still soluble in CH3CN enabling the kinetic study, but higher DP PMeOx 
is no longer well-soluble in CH3CN. All polymerizations showed linear first-order kinetics (Figure 2). 
Table 3. Overview of the tested polymerization solvents with corresponding dipole moments, Hildebrand parameters 
and solubility of PMeOx in each solvent. 
 
 
aExperimentally determined; bnot determined 
Remarkably, the microwave polymerization in sulfolane revealed a 3-fold increase of 
the kp (kp = 393*10-3 L mol-1s-1) compared to the polymerization in CH3CN (kp = 133*10-3 L mol-1s-1) 
and DMA (kp = 103*10-3 L mol-1s-1). The size exclusion chromatography (SEC) traces of the final 
polymers reveal that DMA offers rather poor control over the CROP of MeOx, most likely due to 
trace impurities, that are very difficult to remove from DMA, whereas the SEC traces for the 
polymers obtained in CH3CN and sulfolane reveal quite well-defined PMeOx with Đ values lower 








Figure 2. Comparison of the linear first order plots of the monomer consumption versus time for the living CROP of MeOx 
in sulfolane with MeOTs as initiator, at 140 °C with a DP of 100 (left); corresponding SEC-traces with DMA/LiCl as SEC 
eluent (right). 
2.3.2  Kinetic studies at different temperatures  for the CROP of 2-
methyl-2-oxazol ine, 2-ethyl -2-oxazol ine and 2-phenyl-2-
oxazol ine in sulfolane 
In order to gain further insights in the CROP of MeOx in sulfolane, the CROP was investigated 
at different temperatures, i.e. 60 °C; 80 °C; 100 °C; 120 °C and 140 °C (Figure 3A). From the 
Arrhenius plot (ln kp vs 1/T) the respective Arrhenius parameters with regard to equation (2) could 
Solvent Dipole moment 35 Hildebrand solubility35 P(MeOx) solubilitya 
Chlorobenzene 1.54 9.5 - 
DMA 3.73 23.3 + 
CH3CN 3.44 11.9 +/- 
Sulfolane 4.69 27.2 ++ 
MeOx n.d.b n.d.b - 
14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
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 Sulfolane: Mn 16.9 kDa Ð 1.17 
 CH
3
CN: Mn 13.6 kDa Ð 1.16
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be derived, revealing an activation energy (Ea) of 81.1 kJ/mol in sulfolane, which is in the range 
of the reported Ea for the CROP of MeOx in CH3CN (Wiesbrock et al., Ea = 75.4 kJ/mol). The 
frequency factor (A), however, shows a large increase, with a value of 63.96 x 108 s-1 for the CROP 



















Figure 3. First-order kinetic plots, for the monomer consumption as a function of time for the cationic ring-opening 
polymerization of MeOx (A), EtOx (B) and PhOx (C) in sulfolane at 3 M monomer concentration with MeOTs as initiator 
and target DP of 100. (left) Since the kinetic plots are determined at different temperatures for each monomer in 
sulfolane, the corresponding Arrhenius plots could be determined; as a reference the Arrhenius plots for the 
polymerization of the corresponding monomers in CH3CN are also shown.12 (right) 
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Figure 4. Size-exclusion chromatography traces for PMeOx (A), PEtOx (B) and PPhOx (C) polymers obtained in sulfolane. 
For good comparison and simplification of the results from the kinetic studies, all the samples wi th conversion over 90 
%, at the different temperatures, are shown. (left) The relationship between the dispersity and the experimental and 
theoretical number average molecular weight versus the conversion is plotted for the CROP of MeOx, EtOx and PhOx. 
(right) 
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The frequency factor, A, can be interpreted as the fraction of collisions that possess enough 
kinetic energy for the reaction to proceed. Therefore, the experimental observations mean that 
the CROP of MeOx in sulfolane leads to a higher frequency of effective collisions than the CROP 
of MeOx in CH3CN. A possible explanation for this high ‘A’ value can be found in the higher 
polarity and dielectric constant of sulfolane in comparison to CH3CN, which may result in higher 
rotational energy of the sulfolane molecules and may eventually lead to a higher rate of 
successful collisions. Finally, this leads to a higher kp value for the CROP of MeOx in sulfolane as 
the rate of successful collisions, i.e. the product of A and the Ea term, is defined as the kp. 
To extend the scope of sulfolane as accelerating polymerization solvent for the CROP of 2-
oxazolines, kinetic studies for the CROP of EtOx (hydrophilic) and PhOx (aromatic and 
hydrofobic) were also performed at different temperatures (Figure 3 B-C). Both the kp’s for the 
CROP of EtOx (kp140 °C = 185 x 10-3 L mol-1s-1) and PhOx (kp140 °C = 46 x 10-3 L mol-1s-1) at 140 °C in 
sulfolane revealed faster polymerizations compared to the CROP of the respective monomers in 
CH3CN, i.e. EtOx (kp140 °C = 104 x 10-3 L mol-1s-1) and PhOx (kp140 °C = 32 x 10-3 L mol-1s-1). Although 
the polymerization solvent has been changed from CH3CN to sulfolane, the order of kp remains 
unchanged with the CROP of MeOx being faster than EtOx, followed by PhOx. However, it is 
remarkable that the acceleration of the CROP of MeOx is significantly higher than for the EtOx 
and PhOx polymerizations in sulfolane, compared to CH3CN (Table 4). This observation can be 
explained by the higher solvent compatibility (in terms of polarity) of MeOx for sulfolane, 
compared to EtOx and PhOx. From the Arrhenius plots (Figure 3, Table 2 experimental) it can be 
concluded that for all the 2-oxazoline monomers the Ea for their CROP in sulfolane remains more 
or less unchanged compared to the Ea in CH3CN. On the contrary, the CROP of 2-oxazolines 
show a higher A value in sulfolane compared to the CROP in CH3CN, which demonstrates clearly 
the solvent induced acceleration by sulfolane. 
Table 4. Comparison of the propagation rate constants (kp) at 140 °C in sulfolane and CH3CN, including acceleration 
ratios. 
Monomer Solvent Kp (140 °C) Acceleration 
  
L mol-1s-1 Ratio (kp/kp,CH3CN) 
MeOx sulfolane 393  2.95 
MeOx CH3CN 133 - 
EtOx sulfolane 185 1.78 
EtOx CH3CN 104 - 
PhOx sulfolane 46 1.44 
PhOx CH3CN 32 - 
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1H chemical shift (ppm)
DMA-SEC analysis demonstrated that all synthesized PAOx polymers have a Đ of 1.1 to1.3, 
which is similar to the previous reported results for the CROP of 2-oxazolines in CH3CN (figure 4).35 
A slight increase in the Đ is observed when lowering the polymerization temperature, which 
could be an indication of slower initiation. Furthermore, the linear relationship between the 
degree of conversion and the experimental Mn demonstrates the livingness and controlled 
character of the CROP of MeOx, EtOx and PhOx. It is important to note that the experimental Mn 
values are calculated against polymethylmethacrylate standards. Therefore, the experimental 
Mn values are overestimated for the hydrophilic polymers PMeOx and PEtOx and 
underestimated for the hydrophobic polymer PPhOx (Figure 4). 
2.3.3  Synthesis of a poly(2-methyl -2-oxazol ine)-block-(2-phenyl-2-
oxazol ine) copolymer  
As a final proof for the livingness of the CROP of 2-oxazolines in sulfolane, a block copolymer 
has been synthesized consisting of a first block of PMeOx followed by a second block of PPhOx. 
Here, the PMeOx block was synthesized first, to assure fast initiation of the second PPhOx block 
after sequential addition of the PhOx monomer. The SEC analysis (Figure 5) shows the first PMeOx 
block, sampled before addition of the second monomer, and the resulting PMeOx-block-PPhOx 
copolymer, with Đ values of 1.1. The NMR analysis further confirmed the desired structure. 
Importantly, the prepared diblock copolymer has a significantly lower Đ than the previously 
reported analogue that was prepared in CH3CN (Ð = 1.25), which may be a result of improved 







Figure 5. Size exclusion chromatography trace of first PMeOx50 block and resulting PMeOx50-block-PPhOx50 copolymer. 
(left) Corresponding NMR analysis of block copolymer after precipitation in tetrahydrofuran. (right) 
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2.3.4  Synthesis of high molecular weight poly(2 -methyl-2-
oxazol ine) 
In a final attempt to demonstrate the importance of sulfolane as solvent, it is shown that 
the polymerization of a 50,000 g/mol PMeOx polymer can be achieved in sulfolane as 
polymerization solvent. The reaction mixture is purified according to the SIM (vide supra section 
2.2.2) and performed at 60 °C for 75 hours. After purification of the prepared PMeOx by 
precipitation and freeze drying, the characterization results from the size-exclusion 
chromatogram in Figure 6 show an Mn of 45,000 g/mol, Mp of 63,600 g/mol and a relatively high 
Ð value of 1.4. The SEC trace indicates non-ideal conditions for SEC measurements with this HPLC 
system set-up; as the extremely hydrophilic PMeOx polymer might show atypical band-
broadening and tailing to low molar mass which might be the result of column interactions. The 
fact that low molar mass tailing is observed without a higher molar mass coupling shoulder 
indicates that the tailing is likely not due to chain-transfer side reactions, although these cannot 
fully be excluded. Nevertheless, the experiment proved the ability of sulfolane to act as a solvent 
to homogeneously prepare high molar mass PMeOx polymers in a relatively defined manner.  
Although the synthesis of this 50,000 g/mol PMeOx polymer has succeeded, there is still 
room for improvement, in terms of obtaining a defined polymer or improving the SEC analysis. 
Improvements can be done e.g. by purifying sulfolane over sacrificial initiator every time prior to 
polymerization, separately from the MeOx monomer. In this way higher temperatures can be 
used for its purification, without doing any harm to the monomer. Also the search for other 















Figure 6. Size-exclusion chromatography result for a 50,000 g/mol PMeOx polymer, in N,N-dimethyl acetamide against 
PMMA standards.  
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2.4  CONCLUSIONS AND OUTLOOK 
In conclusion, it is clearly shown that sulfolane can be used as a polymerization solvent for 
the CROP of hydrophilic and aromatic (hydrophobic) 2-oxazoline monomers, such as MeOx, 
EtOx and PhOx. The overall polymerization rate is found to be faster in sulfolane, compared to 
the standard polymerization solvent CH3CN, which opens tremendous possibilities towards 
further optimization of the CROP of 2-oxazolines with regard to decreasing reaction times for the 
synthesis of PAOx, albeit at the cost of more complicated solvent purification and removal. If 
one compares the Arrhenius parameters for the CROP of 2-oxazolines in sulfolane compared to 
acetonitrile, the Ea is found to be similar but the frequency factor is significantly larger. In future 
research, the synthesis of high molar mass PMeOx will be targeted and investigated, which is 
facilitated by the good solubility of PMeOx in sulfolane, enabling further use of PMeOx in 
biomedical applications. Finally, the fact that the acceleration of the MeOx, EtOx and PhOx 
monomers are relatively different compared to the polymerization in CH3CN, further formation 
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CHAPTER 3 
3 SOLVENT OPTIMIZATION FOR THE CATIONIC RING-OPENING 
POLYMERIZATION OF 2-ETHYL-2-OXAZOLINE 
 
ABSTRACT Insights in the polymerization of 2-ethyl-2-oxazoline (EtOx) are of extreme 
importance since PEtOx is the most common poly(2-oxazoline) polymer for biomedical 
applications resulting from its high water-solubility, good monomer availability, relatively easy 
CROP as well as its widespread comparison in literature studies against poly(ethylene glycol) 
(PEG), which is regarded as the golden standard in this field. In this chapter different solvents 
were investigated to challenge the current state of the art polymerization of EtOx in acetonitrile 
in order to check the influence of the polymerization solvent on the reaction kinetics, the polymer 
structure in terms of molar mass distribution (i.e. dispersity, Ð) and the higher molecular weight 
(MW) polymer synthesis. Both overall reaction speed and green synthesis methods were 
investigated to strengthen the case of PEtOx used as a biomedical friendly polymer. Furthermore, 
optimized methods for the synthesis of both defined low and high molecular weight PEtOx are 
proposed, according to trends seen in extended kinetic studies for a series of solvents bearing 
different functional groups. 
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3.1  STATE OF THE ART: THE CATIONIC RING-OPENING POLYMERIZATION OF 2-
ETHYL-2-OXAZOLINE  
Up to now, poly(2-ethyl-2-oxazoline) (PEtOx) is the only PAOx polymer that is commercially 
available on ton scale by Polymer chemistry innovations (PCI). This commercial grade is called 
Aquazol® and consists of ill-defined (Ð  3-4) PEtOx with a broad range of molecular weights 
(MW). Aquazol® is produced via a bulk polymerization process, explaining these poor molar mass 
distribution characteristics and poor batch-to-batch reproducibility. Furthermore, Aquazol® is 
mainly used for large scale applications such as paint fillers, lubricants and adhesives.1 Its 
exceptional water solubility and thermal processing capability makes it an excellent alternative 
for polymers like poly(vinyl pyrrolidone) (PVP) and poly(vinyl alcohol) (PVOH) as stated by PCI. 
Despite the commercial availability of Aquazol®, it is not suitable for pharmaceutical use, 
because of the poorly controlled production process and solvent residues. Recently, also 
defined PEtOx has been made commercially available on kg scale by Ultroxa®, a spin-off 
company by Hoogenboom et al.2  
The last decades, PEtOx has gotten most attention in the field of biomedical and 
pharmaceutical applications (as explained in chapter 1).3–6 In the literature, many examples can 
be found from its use in, for example polymer-prodrug conjugates, hydrogels and nanofibers.7–10 
Besides those examples, PEtOx can also undergo acidic (or basic) hydrolysis of the side chains, 
leading to linear poly(ethylene imine) (PEI). At present, PEtOx is still the preferred precursor for 
the synthesis of PEI, which is mostly known as transfection agent for DNA delivery.11–13 Additionally, 
PEtOx-EI statistical copolymers can be prepared by partial hydrolysis of PEtOx, which can be 
utilized for post-polymerization modification.14,15  
Furthermore, if we consider the cationic ring-opening polymerization (CROP) and its 
mechanism, PEtOx is relatively easy to synthesize compared to PMeOx (vide chapter 2), which is 
more prone to chain transfer and coupling reactions. Another drawback for PMeOx, is its poor 
solubility in a wide variety of organic solvents, which makes it difficult to control its polymerization 
and to do post-polymerization modifications. Conversely, 2-ethyl-2-oxazoline and the resulting 
PEtOx polymer are easily solubilized in a series of polar and even apolar solvents, which is an 
important asset to keep control over the CROP of 2-oxazolines. This makes it very interesting to 
investigate the CROP of EtOx for the preparation of PEtOx, which is illustrated by the numerous 
literature articles and reviews on this topic. In first instance different initiator systems have been 
studied using EtOx as standard monomer, including alkyl sulfonates, such as methyl 
p-toluenesulfonate (MeOTs), which is most frequently found in literature 
p-nitrobenzenesulfonates (nosylates) and trifluoromethanesulfonates (triflates), alkyl, benzyl and 
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acetyl halides, oxazolinium salts and lewis acids.16–21 Secondly a large variety of terminating 
groups, including all possible nucleophiles, have been investigated revealing a dual mechanism 
of termination on respectively the 5 position, for strong nucleophiles, and the 2 position for 
weaker nucleophiles and water.22,23 Besides these chain-end functionalizations, several studies 
show accelerated copolymerization behavior with EtOx as reference comonomer.24–26 
Nevertheless, a broad comparative on different polymerization solvents, to look at the effects of 
ion-pairing, cationic versus covalent oxazolinium species, viscosity and polymerization speed, for 
the CROP of EtOx, has never been performed.  
Key literature examples on the effect of solvents on the CROP of 2-oxazolines include the 
evaluation of solvents bearing different functional groups, as published by Litt et al. in the late 
60s,27 the CROP of MeOx by Dworak28 and the low temperature polymerization of 2-isopropyl-2-
oxazoline in chlorobenzene, published by Monnery et al.29 Up to date most of the kinetic studies 
on the CROP of 2-oxazolines were limited to different monomers in a common organic solvent, 
e.g. in acetonitrile, but we are not aware of a broad solvent screening for the polymerization 
kinetics of the CROP of EtOx at different temperatures . Most probably because the combination 
of either the use of acetonitrile, for high temperature polymerizations of short PEtOx polymers 
and chlorobenzene for the synthesis of high MW PEtOx at low temperature, serves the needs for 
the preparation of PEtOx. Despite that these solvents work well, it may be interesting to challenge 
them with other solvents to find out if other options turn out to outperform these findings. 
In this chapter first the kinetics of the CROP of EtOx are investigated in a series of solvents 
such as acetonitrile,30,31 chlorobenzene, anisole, nitrobenzene, sulfolane, 1,3-
dimethyltetrahydropyrimidin-2(1H)-one (DMPU) and ethyl acetate (Figure 1). The choice for 
aromatic solvents was inspired by the successful polymerization of EtOx in chlorobenzene at low 
temperatures. Next to chlorobenzene, anisole and nitrobenzene were selected to study the 
influence of different electron withdrawing or donating substituents on the aromatic ring and 
the potential cation-π effecti on the overall polymerization speed. Since sulfolane as highly polar 
solvent showed increased reaction kinetics, DMPU was also selected as highly polar solvent to 
study the generality of the observations discussed in chapter 2. Ethyl acetate, was initially chosen 
to evaluate whether it can accelerate the CROP due to the electronic similarity with methyl ester 
bearing 2-oxazoline (MestOx) monomers. In a literature article, by Bouten et al., it is described 
that the carbonyl moiety of the MestOx monomers stabilizes the oxazolinium chain-end during 
                                                                
i The cationic oxazolinium chain-end can be stabilized by π-electrons; increasing the electrophilicity on the other end of the 
oxazolinium ring (5-position); rate acceleration is noticed for the CROP of methyl ester bearing 2-oxazoline monomers. 
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propagation, thereby increasing the reactivity of the 5-position of the oxazolinium ring leading 
towards faster propagation.32,33  
Finally, it is of utmost importance for biomedical applications that the synthesized defined 
PEtOx polymers, are safe to use and non-toxic. However, it is known that after the CROP of EtOx 
residues of the toxic monomer and solvents can remain in the final obtained PEtOx polymer. 
Moreover, the use of polymerization solvents such as chlorobenzene is deleterious for the 
environment. Therefore, the question is raised if ́ a green method can be applied for the synthesis 
of defined (high MW) PEtOx polymers?’. In this regard, ethyl acetate may be considered as a 
green solvent.34,35 If one looks at energy related costs for the environment, ethyl acetate is not 
ideal, but for health and safety related issues, ethyl acetate is one of the best non-harmful 
solvents together with small alcohols. If one looks at the specific application, to synthesize PEtOx 
polymers for the food and drug industry, ethyl acetate seems an ideal match for its production 










Figure 1. Proposed screening for the cationic ring-opening polymerization of 2-ethyl-2-oxazoline in different solvents. 
Overview of the investigated solvents with their most important properties 
The CROP of 2-oxazolines is commonly carried out in acetonitrile, which is a relative 
polar solvent compared to most common organic solvents. The polarity of acetonitrile enables 
fast and efficient heating in microwave reactions, i.e. also for the CROP of 2-oxazolines.36–38 Even 
though acetonitrile is commonly used within PAOx polymerizations, it has disadvantages 
concerning side-reactions and impurities (extrinsic) (vide chapter 1, insights in the reaction 
mechanism). An overview of the different structures and properties related to all the different 
solvents used for the CROP of EtOx can be found in Scheme 1 and Table 1. 
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Scheme 1. Overview of the different structures for the solvents used for the CROP of EtOx screening drawn with 
increasing polarity from left to right. 
 
Table 1.  Overview of the different characteristics, including dipole moment, the dielectric constant, the Hildebrand 
solubility parameter, the boiling point, the Dimroth solvent polarity, the viscosity and the molair volume; for the different  















 D -  °C Kcal mol-1 cp mL mol-1 
Anisole 1.38 4.33 9.9 154 37.1 0.778 109.2 
Chlorobenzene 1.54 5.62 9.5 132 36.8 0.8 101.8 
Ethyl acetate 1.88 6.02 9.1 77 38.1 0.45 97.8 
Acetonitrile 3.44 37.5 11.9 82 45.6 0.38 52.5 
DMPU 4.17 36.12 9.3 246 42.1 1.9 120.5 
Nitrobenzene 4.28 34.8 10 211 41.2 1.8 102.3 
Sulfolane 4.68 44 27.2 285 44 10.3 95.4 
In this chapter, first an overview of the different properties, including polarity, viscosity, etc., 
of the different solvents used for the screening of the CROP of EtOx will be given (section 3.3.1). 
In section 3.3.2, the kinetic data for the CROP of EtOx in different solvents at varying temperature 
regimes are discussed. Furthermore, the kp´s are determined to achieve a direct comparison 
between the different solvents. Finally, a size-exclusion chromatography (SEC) analysis will be 
performed to confirm the conversions by MW and the controllability of the polymerization as a 
function of solvent. In section 3.3.3, the thermodynamics of the CROP of EtOx in terms of the 
solvents is examined by investigation and determination of the Arrhenius plot and corresponding 
parameters, as basis for interpretation of the observed kinetics in section 3.3.2. Lastly, in section 
3.3.4., the green polymerization in ethyl acetate is further investigated in terms of reproducibility 
and the synthesis of high MW PEtOx.  
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3.2  MATERIALS AND METHODS     
3.2.1  Material s and equipment 
Materials 
Methyl p-toluenesulfonate (MeOTs), drying agents (barium oxide, calcium hydride, sodium 
pallets), potassium hydroxide and solvents (sulfolane, acetonitrile (CH3CN), chlorobenzene, 
anisole, nitrobenzene, DMPU and ethyl acetate) (HPLC quality or Acroseal®) were purchased 
from both Sigma-Aldrich and Thermofisher/Acros organics. 2-Ethyl-2-oxazoline (EtOx) was kindly 
donated by PCI. CH3CN was purified over aluminum oxide by means of a solvent purification 
system from J.C. Meyer.  
Purification methods 
 EtOx was distilled over barium oxide under inert argon atmosphere before its use in the 
polymerizations. MeOTs was distilled over CaH2 under reduced pressure. Purification of sulfolane 
was performed according to the procedure described in the book ‘Purification of Laboratory 
Chemicals’, 6th edition.44 Initially, small portions of solid KMnO4 were added to the sulfolane (at 
50 °C) until the color remains up to one hour. This is mainly to deal with 3-sulfolene and 2-sulfolene 
impurities. Thereafter, a dropwise addition of MeOH is performed to destroy the excess of KMnO4 
followed by filtering the solution. Note: to clean the filter afterwards (MnO2 is quite harsh to 
remove) concentrated sulfuric acid was used. Trace amounts of MeOH were removed on the 
rotavap for few a minutes. Then CaH2 was added as a drying agent and the mixture was stirred 
overnight. Afterwards a distillation was carried out under high vacuum (hot plate > 90 °C and 10-
2 mbar), without any condenser (sulfolane becomes a solid at ca. 30 °C). The whole distillation 
set-up was covered in aluminum foil to increase the heat transfer and only the receiving flask 
was cooled with ice. For the purification of chlorobenzene, first a washing step with sulfuric acid 
is performed. To 500 mL chlorobenzene, 60 mL sulfuric acid is added. The mixture is stirred at 850 
rpm for 30 min. Afterwards a liquid-liquid separation is performed, with the chlorobenzene as 
upper phase and sulfuric acid as lower phase. This procedure is repeated until the sulfuric acid 
phase remains colorless, which is typically the case after three washing steps. The chlorobenzene 
is then washed three times with 50 mL of an aqueous solution of sodium bicarbonate (13.05 g in 
150 mL water). Between each washing step, the solution is stirred for 30 min at 1000 rpm. During 
separation, the chlorobenzene is at the lower phase with the aqueous upper phase. During the 
first washing step some heavy bubbling is observed, due to the formation of carbon dioxide. 
Finally, the chlorobenzene is washed three times with (distilled) water. Between each step the 
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mixture is again stirred for 30 min at 1000 rpm. After these washing steps, the chlorobenzene is 
dried over magnesium sulphate, which is followed by filtration and an additional drying step over 
barium oxide is performed. This solution is stirred overnight at 60°C at 850 rpm. The final distillation 
to dryness is performed under argon overpressure. Anisole, DMPU and nitrobenzene were all 
dried over barium oxide and fractionally distilled. The center cut was then distilled again over 
barium oxide. Ethyl acetate was purchased from Fisher Scientific in an anhydrous grade and 
used as received.  
Equipment 
Conversions for the CROP of the selected 2-oxazoline monomers were monitored by gas 
chromatography (GC) analysis. GC was performed on an Agilent 7890A system equipped with 
a VWR Carrier-160 hydrogen generator and an Agilent HP-5 column of 30 m length and 0.320 
mm diameter. An FID detector was used and the inlet was set to 240 °C with a split injection of 
ratio 25:1. Hydrogen was used as carrier gas at a flow rate of 2 mL/min. The oven temperature 
was increased with 20 °C/min from 50 °C to 120 °C, followed by a ramp of 50 °C/min. to 240 °C. 
All stock solutions and samples were prepared in a VIGOR Sci-Lab SG 1200/750 Glovebox 
System with an atmospheric water concentration below 0.1 ppm. For the polymerizations, a 
Biotage Initiator EXP Microwave System with Robot Sixty was used. During the polymerizations 
the microwave synthesizer operated at a constant set temperature which is monitored by the 
IR-sensor. 
Size-exclusion chromatography (SEC) was performed on an Agilent 1260-series HPLC system 
equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid sampler (ALS), 
a thermostatted column compartment (TCC) at 50 °C equipped with two PLgel 5 µm mixed-D 
columns in series, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). 
The used eluent is DMA containing 50mM of lithium chloride at an optimized flow rate of 0.5 
mL/min. The spectra were analyzed using the Agilent ChemStation software with the GPC add 
on. Molar mass and dispersity (Đ) values were calculated against polymethylmethacrylate 
standards from PSS. 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker Avance 
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3.2.2  Experimental  methods 
Synthesis of Homopolymers 
To perform the kinetic studies, 45 mL stock solutions have been made and divided over 
different 2.5 mL microwave vials, each filled with 700 µL to 800 µL of this stock solution. For each 
kinetic run at a certain temperature, 7 microwave vials have been filled and heated for a certain 
time. The stock solutions consist in general of a 3 M monomer (EtOx) concentration, 30 mM 
initiator (MeOTs) concentration and the polymerization solvents. All calculations have been 
done in order to synthesize polymers with a M:I ratio, i.e. a target degree of polymerization (DP), 
of 100 (Table 2). 
Table 2. Calculations for the kinetic study for the homopolymerization of EtOx in diferent solvents (M= Monomer; I= 
Initiator; S = Solvent [ ] = concentration; V( ) = Volume). 
After the reaction, GC samples were made by sampling 100 µL of the reaction medium into 
a sample vial and adding 900 µL of chloroform, as non-interfering solvent. For the SEC analysis, 
the samples were terminated with 500 µL of a methanolic KOH solution, followed by 100 µL 
sampling of the reaction medium and addition of 900 µL of DMA. Additionally, all samples were 
filtered through 0.13 µm filters before SEC analysis (FE1322). In Table 3 the resulting propagation 
rate constants (kp) are listed.  
Table 3. Summary of the kp’s for the kinetic studies for the CROP of EtOx in a series of different solv ents at different 
temperatures. 
kp (*103 L/mols) 60°C 100°C 140°C 
Anisole 0.68 ± 0.03 13.05 ± 0.29 140.7 ± 6.6 
Chlorobenzene 1.26 ± 0.06 19.66 ± 0.63 134.3 ± 4.8 
Ethyl acetate 0.66 ± 0.03 11.56 ± 0.27 95.4 ± 1.5 
Acetonitrile36 0.57 9.91 99.1 
DMPU 0.63 ± 0.02 11.03 ± 0.51 133.0 ± 6.7 
Nitrobenzene 0.79 ± 0.08 22.06 ± 0.67 211.3 ± 11.1 
Sulfolane 0.99 ± 0.04 20.67 ± 0.49 185.3 ± 19.5 
Monomer [M]/[I] [M] V (Stock, total) [I] V (I) V (M) V (S) 
Name Ratio mol/L mL mmol/L µL mL mL 
EtOx 100 3 45 30 210 17.7 27.1 
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3.3  RESULTS AND DISCUSSI ON    
3.3.1  Kinetic studies of  the CROP of 2-ethyl -2-oxazol ine in di fferent 
solvents at varying temperatures 
For the kinetic investigation on the CROP of EtOx a standard monomer to initiator (M:I)  
ratio, i.e. degree of polymerization (DP) of 100 repeating units, was chosen together with a 3 M 
monomer concentration. Furthermore, three temperatures were chosen, being 140 °C, 100°C 
and 60 °C.  The high temperature region of 140 °C, is chosen to compare against the state-of-
the-art synthesis of short PEtOx polymers in acetonitrile. At 140 °C, some solvents such as 
acetonitrile, chlorobenzene and ethyl acetate will exceed its boiling point, which might give an 
influence on the kinetics for the CROP of EtOx. The low temperature region of 60 °C, is chosen 
because high MW polymers are preferably made at lower temperatures, to limit side reactions 
(as explained in chapter 1). This is analogous to the low temperature polymerization in 
chlorobenzene.29 In order to have a first idea on the Arrhenius parameters and thermodynamics 
of the CROP of EtOx in the different solvents, at least three different temperatures should be 
considered. Therefore, the middle temperature of 100 °C has been selected. It should be noted 
that for the kinetic studies for the CROP of EtOx in acetonitrile and sulfolane two additional 
temperatures (i.e. 80 and 120 °C) are included in the Arrhenius plot (Figure 5) based on the results 
of Wiesbrock et al. and chapter 2, respectively. 
Some general conclusions can be drawn based on the first order kinetic plots retrieved 
from GC analysis and the MW data retrieved from SEC analysis. The details on the first order 
kinetic plots for the CROP of 2-oxazolines and how to extrapolate the kp from the slope of the 
graphs is explained in chapter 1. Since the CROP is a controlled polymerization and the 
propagation should follow linear first order kinetics, the MW is also expected to be linear with 
conversion. This will be confirmed by SEC. In this section, the kinetics for the CROP of EtOx at the 
three different temperatures will be discussed separately (Figure 2-4).  
Kinetic study of the CROP of EtOx at 140 °C  
 In the results (Figure 2) at 140 °C one can clearly see that the most polar solvents 
nitrobenzene and sulfolane induce the highest kp and yield polymers with a slightly higher overall 
Ð in the CROP of EtOx. The kp in DMPU, chlorobenzene and anisole is lower while the slowest 
CROP is observed in acetonitrile and ethyl acetate. This last observation might be related to the 
fact that the boiling point of the solvent is exceeded at 140 °C leading to pressurization of the 
reactions. Note that It is rather unexpected that DMPU does not follow the trend of acceleration 
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of nitrobenzene and sulfolane while it has only a slightly lower polarity than nitrobenzene. All 
solvents led to controlled polymerization as indicated by the linear increase of molar mass with 
conversion and the rather low Ð. Related to the molar mass distribution of the obtained polymer 
samples, the apolar solvents such as ethyl acetate, chlorobenzene and anisole, show lower Ð 











Figure 2. Kinetics for the CROP of EtOx in different solvents at 140 °C; beneath the solvent structures/names one can 
see the depicted values for the kp at 140 °C in L/mol.s. A) first order kinetic plot; B) number average molecular weight 
Mn and dispersity (Ð) versus conversion plot. 
Kinetic study of the CROP of EtOx at 100 °C  
 In the results (Figure 3) at 100 °C one can clearly see that the highly polar solvents like 
nitrobenzene and sulfolane still have the highest kp. Remarkably, chlorobenzene now follows the 
trend of the highly polar solvents at 100 °C, which is under its boiling point. The other solvents 
including anisole, DMPU, ethyl acetate and acetonitrile (in respective order) follow similar trends 
a observed at 140 °C, within errors. It should be noted, however, that the CROP of EtOx in 
acetonitrile and ethyl acetate is relatively faster at 100 °C compared to 140 °C. Also at this lower 
polymerization temperature, the CROP is controlled as indicated by the linear increase of molar 
mass with conversion as well as the low Ð values. Related to the molar mass distribution of the 
obtained polymer samples, the apolar solvents, show lower Ð compared to the polar solvents. 
 















































































Figure 3. Kinetics for the CROP of EtOx in different solvents at 100 °C; beneath the solvent structures/names one can 
see the depicted values for the kp at 100 °C in L/mol.s. A) first order kinetic plot; B) number average molecular weight 
Mn and dispersity (Ð) versus conversion plot. 
Kinetic study of the CROP of EtOx at 60 °C  
 At 60 °C, the CROP of EtOx shows the highest kp in chlorobenzene and sulfolane (Figure 
4). The acceleration in chlorobenzene may be attributed to coordination and stabilization of the 
oxazolinium chain-end by cation-π interactions, thereby increasing the nucleophilicity of the C5 
carbon on the oxazolinium ring (place of attack by subsequent monomers in the propagation 
step of the CROP of 2-oxazolines). The reason why the other aromatic solvents do not follow the 
same trend is unclear; a possible explanation for the slower polymerization in nitrobenzene could 
be related to the bulkiness of the nitro group as well as lower electron density together with 
potential coordination of the high electron density of the nitro group with the cationic 
oxazolinium moiety preventing cation-π interactions. For anisole, the lower polarity and inductive 
effect of the substituent, compared to chlorobenzene, may lower the kp for the CROP of EtOx at 
60 °C. The molar mass of the obtained polymers also increases with conversion at this 
temperature, but there is some scatter of the data and the final Ð values are higher compared 
to the other solvents indicating that the control over the polymerizations is somewhat less. 
Related to the molar mass distribution of the obtained polymer samples, the apolar solvents such 
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as ethyl acetate and chlorobenzene, with exception from anisole, show lower Ð compared to 
the polar solvents sulfolane, DMPU and acetonitrile hinting towards the occurrence of less side 










Figure 4. Kinetics for the CROP of EtOx in different solvents at 60 °C; beneath the solvent structures/names one can see 
the depicted values for the kp at 60 °C in L/mol.s. A) first order kinetic plot; B) number average molecular weight Mn 
and dispersity (Ð) versus conversion plot. (Note: the linear fit for nitrobenzene has been made on the first five points)  
3.3.2  Discussion on the Arrhenius parameters  and trends for the 
polymerization of 2-ethyl -2-oxazol ine in di fferent solvents  
Based on the kinetic study reported in 3.3.2, an Arrhenius plot was prepared by plotting 
the ln of the kp’s versus the inversed temperature. A linear correlation is expected (Figure 5) 
providing insights on the thermodynamics via the Arrhenius equation (eq. 1-2). One can 
determine the activation energy (Ea) from the slope and the Arrhenius frequency fractor (A) from 
the y-axis intercept of the Arrhenius plots for the given reactions in the different solvents.  
                                        𝑘 = 𝐴 𝑒
−𝐸𝑎
𝑅𝑇                                        (1)                               
                                   ln 𝑘 = ln 𝐴 −  
𝐸𝑎
𝑅𝑇
                                  (2) 
The Ea represents the energy needed for the reaction to happen, being a successful 
collision. The Arrhenius frequency factor, A, gives the amount of successful collisions when the 
molecules have enough energy for the reaction to proceed.  
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First of all, if we look at Figures 5-6 and Table 4 that list the Arrhenius plot/parameters 
and trends for the CROP of EtOx in the different solvents, it is difficult to generalize the conclusions 
based on these data as there is no direct correlation with e.g. polarity, dipole moment or 
dielectric constant of the solvents. 
 














Figure 5. A) Arrhenius plot, giving the correlation of the ln of the propagation rate constant versus the inverse 
temperature. B) Zoom of the high temperature region at 140 °C. C) Zoom in the low temperature region, at 60 °C. 
Nevertheless, some interesting observations are made. Based on the visualized trends 
of the kp’s as well as some characteristics as function of solvent in Figure 6, it appears that the 
kp´s for the CROP of EtOx at the different temperature do best correlate with the boiling points 
of the different polymerization solvents. At this moment it is not clear why the kp’s correlate well 
with the boiling point of the solvents nor whether this is a just a coincidence rather than a real 
correlation. Another complication that obstructs hard conclusions on the correlation between 
the boiling points and the kp´s is that in some cases the reaction temperature exceeds the boiling 
point of the particular solvent. Finally, a speculation about the boiling point is also complicated 
by the large variations in the MW of the utilized solvents that will also have some influence on the 
polymerizations. As a results, it is too early to make hard conclusions and more experiments would 
be required with different solvents. 
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Table 4. Overview of the Arrhenius parameters gathered from figure 5. for the CROP of EtOx in the different solvents. 
The values of the standard solvent, acetonitrile, are given as a reference value to interpret the other obtained values. 
 Ea (kJ) A (108) 
Anisole 76.2 ± 0.1 6.09 ± 0.01 
Chlorobenzene 66.9 ± 2.7 0.41 ± 0.02 
Ethyl acetate 70.8 ± 3.0 0.89 ± 0.05 
Acetonitrile36 73.4 ± 0.5 1.99 ± 0.9 
DMPU 76.4 ± 1.6 5.90 ± 0.16 
Nitrobenzene 80.2 ± 3.9 32.35 ± 1.89 













Figure 6. Overview of all the trends for kp´s at 140 °C, 100 °C and 60 °C, and the Arrhenius parameters (Ea and freq. 
factor A) for the CROP of EtOx in the different solvents, sorted according to dipole moment. (Left) All the trends of the 
different parameters described in Table 3 for the different solvents, which are sorted according to dipole moment. 
(Right) 
The Ea and frequency factors for the CROP of EtOx in the different solvents (Table 4), 
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seen for nitrobenzene, which explains the fastest CROP at 140 °C and the slowest at 60 °C. The 
complete opposite is observed for chlorobenzene, which has the lowest Ea and frequency factor 
A, explaining the relative increase in kp towards lower polymerization temperatures. If we try to 
generalize the trends by any solvent parameter, it is shown that chlorobenzene is rather an 
exception than the rule, which may be related to the occurrence of specific cation-π 
interactions between the solvent and the oxazolinium chain ends.   
3.3.3  Green synthesi s method for the polymerization of 2-ethyl -2-
oxazol ine in ethyl  acetate  
 Initial studies on the use of ethyl acetate as polymerization solvent for the CROP of EtOx, 
were performed to investigate potentially increased reaction rates, due to the electronic 
similarity of ethyl acetate with methyl ester bearing 2-oxazoline (MestOx) monomers. In a 
literature article, by Bouten et al., it is described that the carbonyl moiety of the MestOx 
monomers stabilizes the oxazolinium chain-end during propagation, thereby increasing the 
reactivity of the 5-position of the oxazolinium ring leading towards faster propagation.32,33 
Consequently, we questioned if the carbonyl moiety of ethyl acetate will have the same 
influence on the propagation rate as observed for the MestOx monomers. 
Additionally, it is of utmost importance for biomedical applications that the final product, 
i.e. the defined PEtOx polymers, are non-harmful and non-toxic for use in humans, provoking the 
question if a green method can be applied for the synthesis of defined (high molecular weight) 
PEtOx polymers? (Figure 7). In this regard, ethyl acetate can be considered as a green solvent, 
that is a much better candidate for environmental reasons compared to the state-of-the-art 
polymerization of EtOx in acetonitrile or chlorobenzene.  
Jessop et al. and Capello et al. reported that it is crucial to stress the difference between 
on the one hand energy related costs for environment and on the other hand health and safety 
related issues which can both be accepted as ‘green’ chemistry concepts.34,35 If one looks at 
energy related costs for the environment, ethyl acetate is not ideal. But for health and safety 
related issues, ethyl acetate is one of the best non-harmful organic solvents together with small 
alcohols, that are impossible to use as polymerization solvent for the CROP of 2-oxazolines due 
to their nucleophilicity. If one looks at the specific application - to synthesize PEtOx polymers for 
the food and drug industry - ethyl acetate seems to be an ideal match for its production process.  
Up to date only one publication of C. Guerrero-Sanchez et al. mentions the efforts towards 
a green synthesis method for PEtOx polymers, using ionic liquids.45 Here, the use of ethyl acetate 
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could also overcome the drawbacks related to using ionic liquids, including cost price, synthesis 
and purification. 
 At first, a test polymerization ii  of EtOx in ethyl acetate was successfully performed, 
showing the conceptual idea of its use as polymerization solvent. In order to verify its further 
value, a full kinetic study on the CROP of EtOx in ethyl acetate is completed at different 
temperatures (60 °C, 100 °C and 140 °C; Figure 8A) under microwave irradiated conditions, 
revealing linear polymerization kinetics as expected for the CROP of EtOx in absence of 
termination reactions. It should be noted that the reaction kinetics were performed in triplicate, 
to both show reproducibility and statistical errors on the measured polymerization data. This 
means that every data point consists of three different reactions (out of three different stock 
solutions) and every reaction is measured at a certain temperature for at 8 different time points, 
which gives in total 72 different polymerization reactions.  
Figure 7. Investigated reaction conditions for the green synthesis of poly(2-ethyl-2-oxazoline). 
The monomer consumption versus time at different temperatures is plotted in a linear 
first order kinetic plot in Figure 8A, together with the kp´s. Furthermore, there is a linear correlation 
between the Mn and the monomer conversion which shows control over the MW for the CROP 
of EtOx in ethyl acetate indicative of the absence of significant chain transfer reactions (Figure 
7B). Finally, in Table 5 the kp´s of both the CROP in ethyl acetate and acetonitrile are listed, for 
their direct comparison.   
                                                                
ii A test polymerization consists of the synthesis of a DP 100 PEtOx polymer under standard microwave conditions used for the 
CROP of EtOx in acetonitrile, i.e. 140 °C, MeOTs as initiator, 3 M monomer concentration, 12 min reaction time and ethyl acetate. 
SEC analysis of the PEtOx polymer from the test polymerization should give a Ð value below 1.2, to be successful. 
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Table 5. Propagation rate constants (kp) for the CROP of EtOx in ethyl acetate and acetonitrile. 
CROP of EtOx Ethyl acetate Acetonitrile46 
kp x 10-3 L mol-1s-1 x 10-3 L mol-1s-1 
140°C 95.4 ± 1.50 99.1 
100°C 11.6 ± 0.269 9.91 
60°C 0.66 ± 0,0267 0.57 
Figure 8. A) First order kinetic plot for the CROP of EtOx, showing linear reaction kinetics for the propagation. B) Number 
average molecular weight (Mn) and molar mass distribution, as dispersity (Ð) versus conversion plot, showing linear 
correlation indicative of control over molecular weight. All size-exclusion chromatography results for these plots were 
calculated against PMMA standards, for good comparison to previous obtained results in literature for the 
polymerization of EtOx in acetonitrile. 
 Since the kinetic study is performed at three different temperatures, an Arrhenius plot 
can be made giving insights in the polymerization thermodynamics (Figure 9A). As stated before, 
with the results from the kinetic study, the previously measured thermodynamic data for the 
CROP of EtOx in acetonitrile, by Wiesbrok et al.,46 correspond well to the data obtained for ethyl 
acetate.  
Furthermore, since higher molecular weight PEtOx polymers are desired for further 
applications, regarding drug delivery with longer retention times and the application of PAOx as 
excipient for oral drug formulation, a preliminary test to synthesize a defined higher molecular 
weight PEtOx polymer was performed in ethyl aceate. Thereby a PEtOx with target molecular 
weight of 70,000 g/mol is made, at 60 °C. The synthesis is performed in accordance to a recently 
filed patent application, which describes the possibility to synthesize defined high molecular 
weight PAOx in the presence of chlorobenzene as polymerization solvent.47 The synthesis involves 
the use of the sacrificial initiator method (SIM, more details vide chapter 4). Thereby, the 
polymerization mixture, consisting of EtOx and ethyl acetate, is purified over a crystalline 2-
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phenyl-2-oxazolinium tetrafluoroborate salt. After the purification, the mixture is distilled into a 
polymerization flask containing the amount of initiator needed for the reaction. Finally, after 7 
days’ reaction time (at 60 °C) the PEtOx polymer was obtained.  
In Figure 9B the size-exclusion chromatography (SEC) results are shown against PEtOx 
standards, revealing an Mn of 78,000 g/mol and Ð of 1.26 despite the presence of some low 
molecular weight tailing and the appearance of a double molecular weight shoulder. This first 
test reveals the feasibility of ethyl acetate for the synthesis of high MW synthesis of PEtOx, albeit 
there is still some room for further optimization (see chapter 4, page 135; herein the synthesis of a 









Figure 9. A) Arrhenius plot showing the linear correlation between the ln of the propagation rate constant versus the 
inverse temperature for the CROP of EtOx in acetonitrile (red) and ethyl acetate (green) . B) Size-exclusion 
chromatography (SEC) plot for the CROP of EtOx in ethyl acetate for PEtOx polymers with M:I 100 and M:I 700. SEC was 
performed in N,N-dimethyl acetamide containing LiCl and all data samples were compared against PEtOx standards.   
Another, last important concern about the green synthesis method rises when looking 
towards the work-up conditions of the reaction. State-of-the-art polymer synthesis of PAOx 
nowadays involves evaporation of the polymerization solvent, followed by re-dissolving the 
residue in dichloromethane and precipitation in cold diethyl ether Furthermore, if a degree of 
conversion below 100 % is targeted, monomer residues are still present, which are harmful and 
toxic.  
In contradiction to previously reported work-up methods, the work-up performed of the 
PEtOx synthesized in ethyl acetate only involved the co-evaporation with water, followed by 
dialysis and freeze drying. In Figure 10, the 1H NMR spectrum of the purified 78,000 g/mol PEtOx 
polymer is shown revealing the absence of traces of ethyl acetate. Although those 
improvements to the work-up procedure could in principle also be performed after the CROP of 
EtOx in e.g. acetonitrile, it is experimentally observed that ethyl acetate is more easily removed. 
1k 10k 100k 1M
B
EtOx in ethyl acetate            Mn (g/mol)        Ð                                                           Mn (g/mol)       Ð
  140 °C 3 M M:I 100           10.3               1.13         60 °C 4.8 M M:I 700          78.8               1.26    
  100 °C 3 M M:I 100           10.2               1.14         60 °C 4.8 M M:I 100             8.3              1.21
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Figure 10. Proton NMR (300 MHz, Bruker) in deuterated chloroform of the purified poly(2-ethyl-2-oxazoline) polymer with 
a molecular weight of 78,000 g/mol. (CH2CH2 backbone, 3.5ppm (s); CH2 side-chain, 2.4 ppm (d) and CH3 side-chain, 
1.2 ppm (s)) 
3.4  CONCLUSIONS AND OUTLOOK    
In this chapter an overview is provided for the CROP of EtOx in different aromatic, highly 
polar and green solvents.  It is remarkable that both high temperature and low temperature 
regimes, i.e. 140 °C and 60 °C respectively, show different trends in polymerization rates. 
In general, at high temperatures one can say that high boiling, highly polar solvents such 
as sulfolane and nitrobenzene can increase the propagation rate by two-fold, compared to the 
standard polymerization solvent, acetonitrile. Although it is found that the double MW shoulder 
is more present in more polar solvents, these solvents are suitable for a fast and straightforward 
synthesis PAOx polymers with an Mn below 20,000 g/mol for which chain transfer reactions are 
less detrimental. An exception to this observation, which cannot be directly explained, is the 
results found for DMPU with only a 1.3-fold acceleration of kp compared to acetonitrile.    
Otherwise, at 60 °C it is shown that the non-polar aromatic solvent chlorobenzene 
accelerates the CROP up to 1.5 fold. From the other solvents which were screened, only sulfolane 
shows the same increased kp, which could be attributed to its high polarity. Since, more defined 
polymers are obtained in apolar solvents, high MW PEtOx should preferably be synthesized in 
chlorobenzene.  
The kp´s at the different temperatures do best correlate with the boiling points of the 
different polymerization solvents, with exception for the CROP of EtOx in chlorobenzene. 
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A final interest raised from the possible polymerization in ethyl acetate. In the mindset of 
using PAOx for biomedical applications, the synthesis is preferably performed in a non-toxic and 
green solvent. Therefore, in the last part of the chapter we discuss the polymerization kinetics 
and reproducibility of the CROP of EtOx in ethyl acetate. In addition to the other kinetic studies 
in the previous sections, we compared the data of three different stock solution at all three 
different temperatures, for reproducibility. Finally, to check the possibility of synthesizing high MW 
PEtOx in ethyl acetate as polymerization solvent, a rather well-defined 78,000 g/mol PEtOx 
polymer (Ð 1.26) has been prepared and characterized successfully.  
In future research, the CROP of EtOx could be investigated in even more solvents, e.g. 
by screening more aromatic solvents with different substituents such as dichloro and 
trichlorobenzene as well as bromobenzene compared to the ones that have been investigated. 
In addition, although it is difficult to find an alternative solvent with the same properties of 
sulfolane, hexamethylphosphoric triamide (HMPT) is reported to be one of the most polar solvents 
that exist. Despite HMPT´s high toxicity and carcinogenic properties, it could be examined as 
solvent for the CROP of 2-oxazolines to confirm the observed trends for sulfolane. Finally, 
theoretic modelling of the CROP of EtOx in the different solvents could be applied to gain more 
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CHAPTER 4 
4 LARGE SCALE SYNTHESIS OF POLY(2-OXAZOLINE)S 
 
ABSTRACT Upscaling a polymerization reaction asks tremendous efforts beyond the 
generally known issues, such as heat-transfer and mass transfer. First of all, it is important to work 
with optimized reagents, including solvent and initiator system, and to ensure that these are 
available at large enough scale. From chapters 2 and 3, it could be concluded that for the 
synthesis of high molar mass poly(2-oxazoline)s, it is best to work with apolar solvents, such as 
chlorobenzene or ethyl acetate, and at low temperatures, to obtain a defined PAOx polymer. 
Secondly, the importance of the use of a right initiator system, i.e. a preformed oxazolinium salt, 
will be elaborated throughout the introduction of this chapter. Preliminary data of Monnery et 
al. showed the use of such initiator system for the preparation of defined high molar mass PAOx, 
to be successful. Nevertheless, all of these earlier experiments were performed on small scale (1 
g), and the optimal conditions need to be confirmed at large scale. Therefore, in this chapter 
an overview is given on all the efforts (and failures) being done to increase the scale of the 
synthesis of defined high molecular weight PAOx via the sacrificial initiator method. It is hereby 
crucial to achieve good batch-to-batch reproducibility, high purity of the final polymers and 
simplified procedures for the larger scale production of defined high molar mass PAOx polymers. 
This, in order to make the synthesis valuable for larger scale pharmaceutical applications, such 
as oral drug formulation. Especially for approval of the regulatory agencies the repeatability of 
the synthesis is highly important. 
Contributors to this work 
Dr. Bryn D Monnery: Pioneer that performed the synthesis of the high molar mass poly(2-oxazoline)s on small scale and 
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4.1  SACRIFICIAL INITIATOR METHOD: INTRODUCTION  
Poly(2-oxazoline)s are highly interesting for biomedical applications, as repeatedly stated in 
literature and in the previous chapters.1–4 Nevertheless, it is relatively hard to deal with their 
synthesis. The cationic ring-opening polymerization (CROP) of 2-oxazolines encounters similar 
challenges as anionic polymerization techniques, requiring high purity of reagents and solvents, 
and moisture free conditions. It was even believed to be impossible to synthesize defined PAOx 
polymers exceeding a molecular weight (MW) of 20,000 g/mol.5,6 Only two years ago a patent 
publication by Monnery et al. described the synthesis of defined high MW PAOx polymers.7 
Thereby it is of utmost importance to work with extremely pure reagents, high vacuum schlenk 
line techniques and low temperature polymerization; to limit extrinsic and intrinsic side reactions, 
such as chain-transfer by β-elimination.8 The method proposed for the synthesis of those high MW 
PAOx polymers, is the so-called sacrificial intiator method (SIM) closely resembling anionic 
polymerization techniques.9,10 This SIM comprises the stringent purification of reagents, i.e. solvent 
and monomer, over a ´sacrificial´ amount of initiator, being an oxazolinium salt.6,11,12 The idea is 
that the final residual impurities react towards PAOx oligomers, followed by a static distillation of 
the remaining ultrapure monomer and solvent into the final polymerization flask, containing a 
second amount of oxazolinium initiator needed for the polymerization.  
Preliminary data (Figure 1), from Monnery et al. as published in the patent,7 show size-
exclusion chromatography (SEC) results for the synthesis of defined high MW PEtOx standards 
with a MW up to 110,000 g/mol prepared on small scale (1-10 g scale) at a low temperature of 
42°C in the non-polar, rate accelerating, polymerization solvent chlorobenzene. Apart from 
these data no literature publication has ever reported the synthesis of high MW PAOx, so far.  
The ability to synthesize high MW PAOx polymers opens up possibilities to use them in e.g. 
PAOx-drug conjugates, which need a long circulation time in the blood after administration.1,13–
17 Also for the use of PAOx as matrix excipient for oral solid dosage formulations - the goal of this 
thesis - high MW polymers are preferred.18–22 Within this application, it is important to reduce or 
avoid absorption and improve the processability and the mechanical properties of the polymer, 
by making the polymer ´long enough´, while drug delivery is either enhanced or sustained, 
depending on the nature of the drug (hydrophilic vs hydrophobic). This will be completely 
elaborated in chapter 5 and 6; and is only briefly mentioned here to stress the importance of the 
work described in this chapter.  
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Additionally, it is highly desired, taking into account all these interesting application 
possibilities, to scale up (initially towards ± 200g scalei) the synthesis of these high MW PAOx 
polymers, in a reproducible manner. Even though, this upscaling may sound straightforward, a 
lot of challenges, optimization and insights in the polymerization mechanism of 2-oxazolines is 
needed to achieve this. Of course many examples can be found in literature, on the difficulties 
that are encountered during upscaling. An overview of the efforts that have been made during 
this thesis, to develop large scale synthesis of defined high MW alkyl-PAOx polymers can be 
found in this chapter including the state-of-the- polymerization, large scale synthesis steps for 
monomer and initiator towards high MW PAOx polymers, synthesis of the standards and the 
variation on sampling a big scale reaction to probe the homogeneity.  
Figure 1. A) An example of a typical set-up for the sacrificial initiator method consisting of a two-manifold schlenk line, 
including vacuum and high purity argon. A static distillation bridge with two round bottom flasks and three-way taps. 
B) The results of a series of poly(2-ethyl-2-oxazoline) polymers with varying molecular weight of 5,000-110,000 g/mol, and 
dispersity, Ð, of less than 1.1. From ref.7 
One of the biggest challenges in my project, besides the optimization of the CROP of 
2-oxazolines that can be found in chapter 2 and 3, was to ´produce´ (reproducible ii) large 
batches of defined high MW PEtOx and poly(2-n-propyl-2-oxazoline) polymers (and at a later 
stage also PMeOx polymers) to be used as excipients for oral drug formulations. Preferably a 
series of different MW should have been synthesized. This challenge of increasing the production 
scale can be divided in some sub-challenges, including in a first step upscaling of monomer 
                                                                
i Because of limitation reaction vessel with regard to uniform heating and stirring capacity of normal stir bars, supposed to be 
easily translatable towards 1 kg scale with the help of mechanical stirring and homogenous heating. 
ii which is desirable for the regulatory agencies (FDA, EMA) and use of these polymers in pharmaceutical applications 
B) A) 
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synthesis and solvent purification methods (section 4.3.1), secondly upscaling of the initiator 
synthesis (section 4.3.2) and finally applying the SIM on a larger scale (section 4.3.3 and 4.3.4).  
4.2  MATERIALS AND METHODS     
4.2.1  Material s and equipment 
Materials 
EtOx was kindly donated by polymer chemistry innovations (PCI). BaO, HBF4 aqueous 
solution, H2SO4, NaHCO3, MgSO4, MeOH, 2-phenyl-2-oxazoline, butyronitrile, ethanolamine, 
zincacetate and chloromethyl(trimethyl)silane (TMS-Cl) are bought from Sigma Aldrich. 
Chlorobenzene and ethyl acetate (acroseal® grade) were purchased from thermofisher 
scientific. Diethylether, dichloromethane, petroleum ether and acetone were obtained from 
Merck.  
Purification methods 
 EtOx was distilled over barium oxide under inert argon atmosphere before its use in the 
polymerizations. For the purification of chlorobenzene, first a washing step with sulfuric acid is 
performed. To 500 mL chlorobenzene, 60 mL sulfuric acid is added. The mixture is stirred at 850 
rpm for 30 min. Afterwards an extraction is performed, with on top the chlorobenzene and at the 
bottom the sulfuric acid phase. This procedure is repeated until the sulfuric acid phase remains 
colorless, which is mostly the case after three washing steps. The chlorobenzene is then washed 
three times with 50 mL of an aqueous solution of sodium bicarbonate (13.05 g in 150 mL water). 
Between each washing step, the solution is stirred for 30 min at 1000 rpm. During extraction, the 
chlorobenzene is at the bottom and the aqueous phase is on top. During the first washing step 
some heavy bubbling is observed, due to the formation of carbon dioxide. Finally, the 
chlorobenzene is washed three times with (distilled) water. Between each step the mixture is 
again stirred for 30 min at 1000 rpm. After these washing steps, the chlorobenzene is dried over 
magnesium sulphate, which is followed by an additional drying step over barium oxide is 
performed. This solution is stirred overnight at 60 °C at 850 rpm. The final distillation to dryness is 
performed under argon overpressure. Note: As final distillation step EtOx, nPrOx, chlorobenzene 
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Equipment 
Conversions of the CROP of the selected 2-oxazoline monomers were monitored by gas 
chromatography (GC) analysis. GC was performed on an Agilent 7890A system equipped with 
a VWR Carrier-160 hydrogen generator and an Agilent HP-5 column of 30 m length and 0.320 
mm diameter. An FID detector was used and the inlet was set to 240 °C with a split injection ratio 
of 25:1. Hydrogen was used as carrier gas at a flow rate of 2 mL/min. The oven temperature was 
increased with 20 °C/min from 50 °C to 120 °C, followed by a ramp of 50 °C/min. to 240 °C. 
All SIM solutions (and samples) were prepared in a VIGOR Sci-Lab SG 1200/750 Glovebox 
System with a water concentration ≤ 0.1 ppm.  
Size-exclusion chromatography (SEC) was performed on an Agilent 1260-series HPLC system 
equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid sampler (ALS), 
a thermostatted column compartment (TCC) at 50 °C equipped with two PLgel 5 µm mixed-D 
columns in series, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). 
The used eluent is N,N-dimethylacetamide (DMA) containing 50 mM of lithium chloride at an 
optimized flow rate of 0.5 mL/min. The spectra were analyzed using the Agilent ChemStation 
software with the GPC add on. Molar mass and dispersity (Đ) values were calculated against 
polymethylmethacrylate standards from PSS and in-house PEtOx standards, with confirmed mass 
from SEC with multi-angle light scattering (MALS) detector. 
Light scattering (LS) measurements are performed on a 3-angle static light scattering (MALS) 
detector, i.e. miniDAWN TREOS, from Wyatt Technology. The detector is coupled on-line to an 
Agilent 1260 infitiny HPLC system (vide DMA-SEC), and used to determine absolute molar mass 
of the analyzed polymer samples. The measurements are performed at ambient temperature, 
i.e. no temperature control unit is supplied/installed with the above mentioned LS detector. The 
refractive index (RI) increment (dn/dc) values (vide experimental details) are either used as 
reported for the certain polymer in DMA or determined via online size-exclusion chromatography 
(SEC) equipped with an RI detector, which measures the RI increase for a 1-10 mg/mL 
concentration series of the mentioned polymers. The LS results are further analyzed with the 
provided Astra 7 software, also designed by Wyatt Technology.  
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker Avance 
300 MHz spectrometer, at room temperature. The chemical shifts are given relative to 
trimethylsilane (TMS). 
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Liquid chromatography coupled to electrospray ionization-mass spectrometry (LC ESI-MS) 
spectra were acquired on a quadrupole ion trap LC mass spectrometer (Thermo Finnigan MAT 
LCQ mass spectrometer) equipped with electrospray ionization (ESI). 
4.2.2  Experimental  methods 
Monomer purification 
Distillation of EtOx is performed with an extra-large set-up, starting from a 3 L round bottom flask. 
After each monomer purification a test polymerization for the preparation of a PEtOx DP100 
polymer that should have a Ð below 1.2 is performed to ensure the purity of every distilled batch 
of monomer. 
Synthesis of 2-phenyl-2-oxazolinium tetrafluoroborate salt HPhOx-BF4:  initiator 
The initiator synthesis consists of two main steps including the purification of the 2-phenyl-2-
oxazoline (PhOx) followed by the precipitation of PhOx in tetrafluoroboric acid (HBF4). First a 
vacuum distillation of PhOx (preferably high vacuum <10-1-10-2 mbar) is performed (Boiling point: 
94 °C at 10-2 mbar; DrySyn temperature: 120 °C). The first fraction, 5 mL, was discarded when the 
temperature was stable. Then, the 2-way receiving joint was switched to the final receiving flask 
(Note: the flask should not be distilled to dryness). The resulting colorless PhOx is kept in the fridge 
after distillation. For the following step, 100 mL of purified PhOx is added dropwise to a solution 
of 100 mL HBF4 and 100 mL methanol that is cooled to 0 °C in a 500 mL Erlenmeyer, while stirring, 
via an addition funnel. After addition, the solution is brought up to room temperature.  For the 
crystallization of the initiator salt, the solution is put in the freezer at -20 °C overnight. Filtration was 
also performed in the freezer, since the crystals very easily re-dissolve when the solution warms 
up. Repeated recrystallization of the HPhOx-BF4 in methanol is necessary until a white and non-
smelly product is obtained. The final white product, HPhOx-BF4 product, has been stored in a 
vacuum oven at 50 °C until use. Characterization is performed by proton NMR and LC ESI-MS 
revealing more than 99 % purity. Proton NMR chemical shifts: 12.2 ppm, oxazolinium proton; 8.5-
7.5 ppm, aromatic protons; 5.2 ppm, proton next to O and 4.3 ppm, proton next to N of the 
oxazoline ring. 
Synthesis of 2-n-propyl-2-oxazoline 
Butyronitrile (384,72 ml; 4.42 mol) and ethanolamine (293,45 ml; 4,86 mol) were mixed 
together, and zincacetate (19,40 g; 0,0884 mol) was added in a catalytic amount.6,23–25 The 
mixture was heated to 130 °C for 3 days while stirring at 850 rpm. A Vigreux column was put on 
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top of the round bottom flask to permit the mixture to reflux. During the reaction the system was 
flushed with argon to permit the formed ammonia to escape. Ammonia will act as a nucleophile 
during the polymerization and it is highly important to remove all the ammonia. Over time a color 
change of the solution was observed, going from colorless to yellow to red and finally to black. 
This is due to the oxidation of ethanolamine. 
Directly after the reaction, the residual mixture was fractionally distilled at 75 °C and 10-1 
mbar. The first 20 mL were discarded and the distillation was not performed until dryness. The 
nPropOx was dried by adding BaO and ninhydrin (both as indicator for ammonia and to react 
away the residual ammonia). Further purification proceeds by adding sodium and heating the 
mixture for 2 h at 120 °C (molten sodium purification). A last purification step was done by adding 
HPhOxBF4 salt to polymerize a small fraction of the monomer followed by distillation. 
Synthesis of 50g scale poly(2-oxazoline) standards at low temperature of 42 °C and synthesis 
of 200g scale poly(2-oxazoline)s at 60 °C. 
 Both the 50 g scale synthesis of the PEtOx standards and the 200 g scale synthesis of the 
defined high MW PEtOx and PnPrOx polymers, are made according to the sacrificial initiator 
method (SIM). In Figure 2, the set-up for the 50 scale synthesis is shown, including the glassware 
for the static distillation (Figure 2, n° 5) which can be connected to the schlenk line and taps 
(Figure 2, n° 3 and 4) to isolate either the ´cleaning´ (Figure 2, n° 2) or polymerization flask (Figure 
2, n° 1). Every flask is foreseen of a rare-earth magnetic stir bar (Figure 2, n° 6). A similar, but larger, 








Figure 2 Experimental set-up that was used for the synthesis of the PEtOx standards at 50g scale. 
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 In the following, the different steps for the CROP of EtOx via the SIM are described. 
Step 1: Silanization of the reaction set-up to remove water attached to the glassware 
First the set-up, which is connected to the Schlenk line, is silanized with TMS-Cl. The TMS-Cl is 
spread over the set-up by performing one freeze-pump-thaw cycle iii . After the silanization 
procedure the set-up is dismantled from the Schlenk line and cleaned with water, acetone and 
petroleum ether. 
Step 2: Addition and melting of the initiator (HPhOx-BF4) 
Before the ´cleaning´ and polymerization flasks are connected to the Schlenk line, they are filled 
with the required amount of initiator. Generally, the amount of initiator used to purify the 
monomer and solvent mixture in the cleaning flask is 1 mol% of the monomer concentration. The 
initiator is molten under vacuum and left for drying overnight. 
Step 3: Addition of the monomer and solvent to the cleaning flask 
The monomer and solvent are volumetrically added in a glove box. Then, the flask is connected 
to the set-up on the Schlenk line. Afterwards the mixture is being polymerized to purify the 
monomer and solvent for 30 min at 60 °C. 
Step 4: Freeze-pump-thaw cycles monomer and solvent (under high vacuum) 
The mixture in the cleaning flask is after the ́ cleaning/purifying´ in step 3, cooled down with liquid 
nitrogen. Next, the completely frozen mixture is subjected to high vacuum (< 10-3 mbar), for 15 
min, while kept frozen. After closing the vacuum connection to the schlenk line, the mixture is 
thawed completely and undergoes a degassing step. This freeze-pump-thaw cycle is repeated 
at least three times, while kept under vacuum.  The mixture is degassed until the vacuum does 
not go above 10-2-10-3 mbar anymore, i.e. the vacuum is kept stable for the static distillation.  
Step 5: Static distillation monomer and solvent to the polymerization flask 
While kept under vacuum, the cleaning flask is thawed for the last time. Simultaneously, the 
polymerization flask is cooled down with liquid nitrogen. Due to the reversed temperature 
gradient, a static distillation is carried out whereby the monomer and solvent from the cleaning 
flask are distilled into the polymerization flask. The distillation is completed when the cleaning 
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flask only contains residues of oligomer impurities. Note: for the 200 g scale, an oil bath is used 
for heating the cleaning flask to 40 °C to 60 °C to accelerate the static distillation. Additional 
heating tape is applied on the distillation bridge, with a temperature set at 30 °C to 50 °C, 
generally 10 °C lower than the temperature set of the oil bath to ensure that the monomer and 
solvent remain in the gaseous phase. 
Step 6: Start of the polymerization 
The system is brought under argon after the static distillation. The polymerization flask is then 
disconnected from the schlenk line set-up and put in an oil bath at 60 °C, for the time needed 
for the polymerization. 
 An overview of all the amounts of initiator, monomer and solvents that were used for 
the large scale polymerizations of PEtOx and PnPrOx polymers as described in section 4.3, can 
be found in Table 1 together with their theoretical MW, reaction times and reaction scale. 
Table 1. Overview of all the polymerization reactions which are performed at large scale including the target length of 
the polymer, concentration of monomer, amount of initiator, solvent and monomer, and polymerization times. (DP = 
degree of polymerization, PhCl = chlorobenzene and EtOAc = ethyl acetate)  
Polymer type MW (theoret.) 











PEtOx_50kDa_1 500 / 50 1.003 PhCl/ 322.5 4.8/ 305.1 5 200 
PEtOx_50kDa_2 500 / 50 1.003 PhCl/ 322.5 4.8/ 305.1 5 200 
PEtOx_50kDa_3 500 / 50 1.003 PhCl/ 322.5 4.8/ 305.1 5 200 
PEtOx_100kDa_1 1000 / 100 0.426 PhCl/ 472.7 3.5/ 259.2 12 200 
PEtOx_100kDa_2 1000 / 100 0.426 PhCl/ 472.7 3.5/ 259.2 12 200 
PEtOx_100kDa_3 1000 / 100 0.426 PhCl/ 472.7 3.5/ 259.2 12 200 
PnPrOx_50kDa_1 443/ 50 1.006 PhCl/ 238.6 4.8/ 312.5 5.5 200 
PnPrOx_50kDa_2 443/ 50 1.006 PhCl/ 238.6 4.8/ 312.5 5.5 200 
PnPrOx_50kDa_3 443/ 50 1.006 PhCl/ 238.6 4.8/ 312.5 5.5 200 
PEtOx_25kDa_1 250 / 25 1.903 EtOAc/ 301 4.8/ 285.7 2-3 200 
PEtOx_25kDa_2 250 / 25 1.903 EtOAc/ 301 4.8/ 285.7 2-3 200 
PEtOx_25kDa_3 250 / 25 1.903 EtOAc/ 301 4.8/ 285.7 2-3 200 
PEtOx_12kDa_50g 100/ 10 1.169 PhCl/74.56 4.8/ 71.4 4 50 
PEtOx_23kDa_50g 200/ 20 0.587 PhCl/75.142 4.8/ 71.4 5.5 50 
PEtOx_44kDa_50g 400/ 40 0.293 PhCl/75.44 4.8/ 71.4 14.5 50 
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PEtOx_69kDa_50g 600/ 60 0.197 PhCl/130 4/ 71.4 28 50 
PEtOx_96kDa_50g 800/ 80 0.147 PhCl/130 3.5/ 71.4 41 50 
PEtOx_191kDa_50g 1600/ 160 0.0735 PhCl/130 3.5/ 71.4 81 50 
Refractive index increment determination (dn/dc) via online size-exclusion 
chromatography for PMeOx, PEtOx and PnPrOx homopolymers 
In order to able to measure the absolute molar mass of the synthesized polymers (vide 
infra) via SEC-MALS, the refractive index increment (i.e. the dn/dc value; Figure 3) of these 
particular polymers has to be determined. Therefore, six different concentrations of a polymer 
standard, with a particular MW and chemical composition, were measured on SEC. Preferably 
the molar mass of this standard sample is known and is situated in the middle range of the 
absolute MW determination. Nonetheless, for homopolymers the dn/dc holds almost for the 
whole range of MW and is almost unaffected as a function of molar mass. In Figure 3 an overview 
is given of the determined dn/dc values for the series of PAOx homopolymers, PMeOx, PEtOx 
and PnPrOx. One can see that the dn/dc values increase with the increment in polarity of the 









Figure 3. Overview of the refractive index increment as a function of concentration for a DP100 PMEOx, PEtOx and 
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4.3  RESULTS AND DISCUSSI ON    
4.3.1  Upscal ing monomer synthesi s and solvent puri ficat ion 
Since the EtOx monomer is commercially available (by PCI), only the nPrOx monomer 
needed to be prepared and purified on large scale. Also the solvent purification has been 
perfomed on large scale. 
Synthesis of 2-n-propyl-2-oxazoline 
The nPropOx was synthesized on a large scale (400 mL) via the Witte Seeliger method, 
since the corresponding nitrile is commercially available. The synthesis is performed according 
to a described literature procedure by Hoogenboom et al.26 (for a detailed description vide 
experimental, section 4.2.2). The exact mechanism for this reaction is not reported, but it most 










Figure 4. The scheme (left) shows the Witte-Seeliger reaction starting from butyronitrile towards 2-n-propyl-2-oxazoline 
including the expected amidine intermediate. Also, the proton NMR spectrum of nPrOx is shown (right), after final 
purification by distillation. 
When performing the reaction on large scale, it was found to be difficult to get rid of 
the residual ammonia. Because of the nucleophilic character of ammonia, even the presence 
of low concentrations will induce termination during the CROP of nPrOx. Certainly, when aiming 
for high MW synthesis of PnPrOx this will negatively influence the reproducibility of the results. 
Therefore, stringent purification is performed including at minimum three distillations. A 
combination of a distillation over molten sodium, followed by a distillation over BaO and 
ninhydrin, was experimentally found to be the most effective. The purity of nPrOx was confirmed 






H Chemical shift (ppm)
a
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by proton NMR spectroscopy (Figure 4). Trace amounts of butyronitrile (± 5 %) were still present, 
but these do not interfere with the CROP and will act as additional solvent. 
4.3.2  Large scale ini tiator synthesi s  
The initiator synthesis on a 100 g scale (Figure 5) is fairly easy and straightforward. The 
basic PhOx (2) monomer acts as a base and captures the proton from the tetrafluoroboric acid 
(1). The difficult part in the synthesis of the initiator is the purification. This has also been observed 
with other oxazolinium salts, which are generally difficult to isolate. The initiator has to be 
recrystallized multiple times from methanol, and the precipitate is only stable at -20 °C or lower 
as above this temperature the crystals redissolve. It is necessary to get this initiator extremely 
pure, since this is the starting point of the SIM. Experimentally we developed a purification 
procedure in which at least three recrystallizations were involved. The product was determined 








Figure 5. Synthesis scheme for the preparation of the PhOx tetrafluoroborate oxazolinium (left); Proton NMR spectrum 
of the initiator in deuterated dimethyl sulfoxide (d6-DMSO) (right). (chemical shifts: 12.2 ppm, oxazolinium proton (a); 
8.5-7.5 ppm, aromatic protons (b); 5.2 ppm, proton next to O (c) and 4.3 ppm, proton next to N of the oxazoline ring  
(d).) 
4.3.3  Tr ipl icated synthesi s of high molecular weight poly(2 -ethyl -2-
oxazol ine)s via SIM 
As stated earlier in the introduction of this chapter, the synthesis via the SIM was 
originally developed on a small scale of approximately 1-10 g per batch (at 42 °C). Within this 
project to develop PAOx as polymer platform for oral drug formulations, larger amounts of 
polymer are needed. This upscaling process included much failure and the described results 
(vide infra) are a summary of all efforts that brought the production process successfully to a 
12 10 8 6 4 2 0
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scale where 200 g of polymer could be synthesized per batch at 60 °Civ. These failures were 
related to impurities in monomers and solvent, poor vacuum quality, leaks in the SIM set-up 
during static distillation and insufficient stirring. 
Every single size-exclusion chromatogram in this section resembles a polymer batch of 
200 g and each polymer was at least synthesized three times to demonstrate the reproducibility 
of the final optimized process (vide pharmaceutical regulatory agencies and GMP) that is shown 








Figure 6. Picture of the large scale SIM set-up consisting of two 2 L round bottom flasks, a distillation bridge, a three-way 
tap to isolate the prepared polymerization mixture; all connected to a two-manifold schlenk line (left). Picture of the 
SIM cleaning step set-up consisting of a heating plate at 40-60 °C, heating tape is applied around the distillation bridge 
which is set at a lower temperature compared to the heating plate, and a liquid nitrogen or diethyl ether/dry ice baths 
to trap the liquids during static distillation (right). 
 Synthesis of 50,000 g/mol poly(2-ethyl-2-oxazoline) 
The 50 kDa PEtOx polymer was the first polymer that was synthesised in triplicate on large 200 g 
scale (Figure 7). The optimal monomer concentration for a DP500 polymer was kept at 4.8 M, 
which was found to be the optimal concentration according to observations by Monnery et al.7 
To reduce the reaction time to 5 days at 60 °C, it was opted to target a higher DP and terminate 
the reaction at ± 70 %. Since the CROP of EtOx follows linear pseudo-first order kinetics, it is 
inherent that the conversion slows down over time, depicted as the ´slow plateau´ region of the 
degree of conversion versus time plot (Figure 7, right). It is important to stay in the ´initial fast´ 
region when aiming for a relatively fast polymerization reaction. As an example a 50,000 g/mol 
PEtOx polymer can be produced in ± 5 days reaction time when a DP700 is targeted and 
terminated at ± 70 % conversion; whereas a ± 8 days reaction time is required when a DP525 is 
terminated at 95 % conversion. An optimum should be found between time and conversion, 
                                                                
iv For the large 200 g scale synthesis of the high MW PAOx polymers it was opted to synthesize the polymers at 60 °C, to reduce 
the reaction times. 
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because 30 % of monomer feed is lost when aiming for 70 % conversion, which however may be 







Figure 7. Triple synthesis of 50,000 g/mol poly(2-ethyl-2-oxazoline) in chlorobenzene on 200 g scale (left); degree of 
conversion versus time plot for the linear first order kinetics resembling the reaction mechanism for the CROP of EtOx. 
(right). 
Table 3. Molecular weight analysis for the triple synthesis of a 50,000 g/mol PEtOx polymer by SEC analysis  calculated 









(PMMA) Ð Mp (LS) Ð (LS) 
 kDa kDa  kDa kDa  kDa  
PEtOx-50kDa-1 54 62 1.22 85 93 1.15 55.5 1.1 
PEtOx-50kDa-2 51 54 1.14 84 89 1.12 48.7 1.04 
PEtOx-50kDa-3 47.2 56.3 1.15 85.0 96.9 1.11 np np 
Average and standard 
deviation 
50.7 ± 3.4 57.4 ± 4.1 1.17 ± 
0.04 






Synthesis of 100,000 g/mol poly(2-ethyl-2-oxazoline) 
The synthesis for the 100,000 g/mol PEtOx is similar to that of the 50,000 g/mol PEtOx polymer that 
is described above. The only additional difficulty that is encountered is the increased viscosity of 
the reaction medium, that comes along with making very high MW polymers in general. 
Therefore, the optimal monomer concentration was found to be 3.5 M. At this concentration, 
control over the molar mass and Ð is maintained, as seen in the results in Figure 8 and Table 4. 
The reaction time for this polymer is approximately 12 days, when aiming for a DP 1400 and ± 70 
% conversion. It is observed that below this concentration boundary, the control over the CROP 
of EtOx was lost, with both low and high MW tailing in the molar mass distribution. This poorer 
control could be attributed to the very low initiator concentration present in the solution. It is 
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First order kinetic plot: example for CROP of 2-oxazolines
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experimentally observed that it does not work below an initiator concentration of 2.5 mM, but 
not known why. One can also see that the double MW shoulder of the 100,000 g/mol PEtOx 
(prepared at 3.5 M) increases, compared to the SEC diagram of the 50,000 g/mol polymer (4.8 
M monomer concentration). This is a general trend that is observed for the CROP of 2-oxazolines 
when aiming for higher MW, because the likelihood of chain transfer to monomer increases 
when twice the MW is targeted and, thus, more monomer is present.5 It should be noted that for 
the intended goal of this project, i.e. the use of PAOx for drug formulation, high MW tailing does 
not necessary disqualify the polymer for the application. In fact, low MW tailing and 










Figure 8. Size-exclusion chromatography results for the triple synthesis of 100,000 g/mol poly(2-ethyl-2-oxazoline) in 
chlorobenzene on 200 g scale. 
Table 4. Molecular weight analysis for the triple synthesis of a 100,000 g/mol PEtOx polymer by SEC analysis calculated 









(PMMA) Ð Mp (LS) Ð (LS) 
 kDa kDa  kDa kDa  kDa  
PEtOx-100kDa-1 96 99 1.19 134 139 1.16 98.7 1.1 
PEtOx-100kDa-2 105 108 1.23 167 169 1.19 103 1.09 
PEtOx-100kDa-3 107 125 1.35 169 193 1.29 - - 
Average and standard 
deviation 
103 ± 6 111 ± 13 1.26 ± 
0.08 
157 ± 20 167 ± 27 1.21 ± 
0.07 
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Synthesis of 50,000 g/mol poly(2-n-propyl-2-oxazoline) 
The next challenge that was addressed is the synthesis of a 50,000 g/mol PnPrOx. This 
large scale CROP concerns a non-commercially available monomer for which the purification is 
crucial. In section 4.3.1, the description regarding the upscaling of the nPrOx monomer synthesis 
can be found. Initially problems were found during the polymerization, which could most likely 
be attributed to the presence of trace amounts of ammonia resulting from the monomer 
synthesis. It was found that a harsh purification step of the nPrOx monomer over molten sodium 
is unavoidable for the production of high MW PnPrOx. A clear difference with the PEtOx 
polymers, is the lower double MW shoulder for PnPrOx 50,000 g/mol polymers that can be 
observed from the SEC diagram in Figure 9 and Table 5. This observation can provide insights in 
the β-elimination process, during the CROP of 2-oxazolines. (vide chapter 1) It is proposed in 
literature that chain coupling occurs less in relation to increased β-substitution of the alkyl side-
chain of 2-oxazolines due to enhance steric hindrance.6 The observation that the PnPrOx SEC 
traces reveal similar low molar mass tailing but less double MW coupling products, indicates that 
the occurrence of chain transfer by β-elimination is similar while coupling occurs less for nPrOx. 
The slightly lower Mn (PEtOx) values compared to the Mp (LS) for the PnPrOx polymers observed 
in Table 5 is due to the calculation of the Mn of the synthesized PnPrOx polymers against the more 









Figure 9. Size-exclusion chromatography results for the triple synthesis of 50,000 g/mol poly(2-n-propyl-2-oxazoline) in 
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Table 5. Molecular weight analysis for the triple synthesis of a 50,000 g/mol PnPrOx polymer by SEC analysis calculated 









(PMMA) Ð Mp (LS) Ð (LS) 
 kDa kDa  kDa kDa  kDa  
PnPrOx-50kDa-1 42.8 53.8 1.14 66.6 80.5 1.11 51.58 1.03 
PnPrOx-50kDa-2 40.0 44.9 1.13 61.3 80.2 1.18 51.19 1.05 
PnPrOx-50kDa-3 45.1 56.1 1.16 69.8 83.4 1.12 53.49 1.04 
Average and 
standard deviation 
42.6 ± 2.6 51.6 ± 5.9 1.14 ± 
0.02 
65.9 ± 4.3 81.4 ± 1.8 1.14 ± 
0.04 
52.1 ± 1.2 1.04 ± 
0.01 
 
Synthesis of 25,000 g/mol poly(2-ethyl-2-oxazoline) in ethyl acetate 
In chapter 3, it is reported that the CROP of EtOx can be conducted in the fairly ´green´ 
solvent ethyl acetate. A 25,000 g/mol PEtOx polymer is produced in triplicate to confirm that 
PEtOx can be reproducibly prepared in this solvent. SEC results are represented in Figure 10 and 
Table 6 to show the reproducibility and controllability of the CROP of EtOx in ethyl acetate as 











Figure 10. Size-exclusion chromatography results for the triple synthesis of 25,000 g/mol poly(2-ethyl-2-oxazoline) in ethyl 
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Table 6. Molecular weight analysis for the triple synthesis of a 25,000 g/mol PnPrOx polymer by SEC analysis calculated 









(PMMA) Ð Mp (LS) Ð (LS) 
 kDa kDa  kDa kDa  kDa  
PEtOx-25kDa-1 26.9 30.7 1.10 50.6 57.1 1.08 22.7 1.03 
PEtOx-25kDa-2 24.6 32.2 1.17 36.3 45.9 1.13 25.6 1.03 
PEtOx-25kDa-3 24.4 29.4 1.13 45.8 54.7 1.11 24.9 1.06 
Average and 
standard deviation 
25.3 ± 1.4 30.8 ± 1.4 1.13 ± 
0.04 
44.2 ± 7.3 52.6 ± 5.9 1.11 ± 
0.03 
24.4 ± 1.5 1.04 ± 
0.02 
4.3.4  Synthesi s of PEtOx molar mass standards on large scale 
Until now literature reports describe the MW characteristics of PAOx as measured via 
SEC mostly against commercial standards, such as PMMA or PEG, because it was not possible to 
synthesize highly defined PAOx polymers with a broad range of MW. On the contrary, we already 
described (vide supra) the MW determination of the synthesized PAOx polymers calculated 
against PEtOx standards, made by Monnery on a small (1 g) scale.27 However, the synthesis of 
the PEtOx standards having molar masses ranging from 10,000 g/mol – 200,000 g/mol is a 
challenge on large scale (50 g scale). In contradiction to the PAOx polymers described in section 
4.3.3, polymers that need to serve as molar mass standard need to be as defined as possible (Ð 
 1.01-1.05). Therefore, the synthesis of the PEtOx standards on large scale is performed at a 
reaction temperature of 42 °C (analogous to the literature and patent by Monnery et al.).6,7 Only 
for the synthesis of the 160,000 g/mol PEtOx standard, a temperature of 60 °C was utilized to 
reduce the extremely long reaction time. In general, it was observed that lower polymerization 
temperatures yield more defined PAOx polymers, i.e. due to a decrease in the amount of side 
reactions.6,7 Figure 11 shows the comparison between the SEC traces of the PEtOx standards 
made on 1 g versus 50 g scale. PEtOx standards below 100,000 g/mol show a ± 10 % higher Ð 
and double MW shoulder (in the SEC traces), if the PEtOx_50 g standards are compared to the 
PEtOx_1 g standards. This can probably be explained by the fact that stirring on large scale is 
less efficient than on small scale, inducing less homogenous reaction mixture conditions, which 
could give higher conversionv locally. Proof for this explanation is provided in the next section 
                                                                
v At higher conversions chain coupling becomes more significant due to higher relative concentration of less reactive enamine 
compared to the 2-oxazoline monomer, which induces relatively more chain coupling. 
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(4.3.5) of this chapter, where a large scale reaction is sampled at different spots in the reaction 
mixture.  
Figure 11. Size-exclusion chromatograms for the series of PEtOx standards, ranging from 10,000 g/mol to 200,000 g/mol 
prepared on 50 g scale (this work) and on 1 g scale as reported by Monnery et al.7 
Even though, Ð values (analyzed by LS, Table 7) of the polymers prepared at 50 g scale 
(except PEtOx-std-191kDa) are situated below 1.1, efforts to use these standards as calibration 
for our SEC system failed. When peak molar mass values were compared (1 g versus 50 g PEtOx 
standards) a difference of > 5,000 g/mol could be found. Unfortunately, this is unacceptable if 
one wants a calibration that gives relevant and reliable results on the MW of the respective 
polymer. The reason for the observed broader Ð for the synthesis of the PEtOx standards at larger 
scale is proposed to be inhomogeneity of the large scale reactions as will be further explored in 
section 4.3.5. 
To improve the Ð, it was investigated to execute fractionation experiments, to separate 
e.g. the double MW shoulder of the polymer by preparative SEC methods. Although good 
observations were made using preparative SECvi (prepSEC), it is still only possible for small scale 
                                                                
vi Manual size-exclusion chromatography column 
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experiments where 1 g of polymer sample can be purified during a prepSEC column run. A 
feasible solution to purify these large scale PEtOx standards at once was not found up to date. 
Table 7. Molecular weight analysis for the standard synthesis of a series of PEtOx polymers by SEC analysis  calculated 









(PMMA) Ð Mp (LS) Ð (LS) 
 kDa kDa - kDa kDa - kDa - 
PEtOx-std-12kDa 13.9 15.9 1.07 21.4 25.5 1.10 12.32 1.02 
PEtOx-std-23kDa 23.0 28.3 1.11 36.3 45.7 1.13 23.49 1.02 
PEtOx-std-44kDa 44.6 53.9 1.13 61.6 72.2 1.10 43.68 1.05 
PEtOx-std-69kDa 56.2 63.4 1.16 86.5 97.0 1.17 68.70 1.08 
PEtOx-std-96kDa 74.7 84.4 1.17 116.6 130.9 1.19 95.74 1.09 
PEtOx-std-191kDa 160 237 1.40 181.6 243.4 1.24 190.7 1.22 
4.3.5  Homogeneity of large scale reactions 
Following the described synthesis and discussion on the results for the large scale PEtOx 
standard series, it is proposed that variations occur due to scaling up of these PAOx polymer 
reactions. Since the variation on the molar mass distribution or the Ð is more pronounced for the 
larger MW PEtOx standards, we started thinking if the stirring capacity on large scale is still 
sufficient enough. The high viscosity of the polymerization mixtures could make it difficult to 
homogenize the mixture, during polymerization on large scale. The question raised, if e.g. on the 
edges of the round bottom flask, the characteristics of the synthesized polymer are comparable 
with the ones found in close proximity of the stir bar, or not. In conclusion, we designed an 
experiment where during the polymerization samples were taken from three different places. In 
this way we try to provide proof to our above mentioned concerns of homogeneity of the 
polymerization mixture. 
In order to understand the partial loss of control for the large scale PEtOx standard 
synthesis, we developed an experimental set-up to probe the homogeneity during the synthesis 
of a 200 g PEtOx 70,000 g/mol polymer. Everything is carried out according to the explained 
procedures in the experimental methods. However, during the polymerization, samples were 
taken at three different places in the polymerization mixtures at different time points. An example 
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of the set-up is shown in Figure 12, together with the obtained results of the MW versus degree of 



















Figure 12. Molecular weight (Mn and Mp) as a function of degree of conversion plot; including error bars and Ð values. 
(left top and bottom) An example of the set-up of the polymerization of EtOx in ethyl acetate; showing the different 
sampling positions during the reaction. (right, top) 
If one looks at the data obtained by sampling of the reaction at different places it is 
observed that until approximately 50 % conversion, no significant variation is found. From that 
moment on, however, the standard deviation and Ð goes up. It is remarkable that different SEC 
results are obtained depending on the place of sampling, which can be attributed to failure of 
efficient stirring during the reaction. This only becomes apparent at higher conversion where the 
viscosity of the polymerization mixture becomes higher. It must be noted that the increased Ð 
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may also (partially) be affected by the sampling procedure; causing some termination even 
though it is performed under inter atmosphere. It is impossible to completely cancel out the 
introduction of impurities while sampling. Nonetheless, this experiment shows the importance of 
stirring and homogenization during process upscaling. The issue that we face can be easily 
solved by e.g. mechanical stirring of the polymerization mixture which could not be developed 
anymore within this PhD research. In conclusion, the results from this paragraph can serve as a 
plausible explanation why we failed to upscale the obtained results for the synthesis of PEtOx 
standards at small scale; as described in the patent by Monnery et al.7 This can explain also the 
fact that the PEtOx polymers that were synthesized at 200 g scale and higher temperature (60 
°C), as reported in chapter 3, show slightly higher ± 10 to 15 % Ð values as a result of both 
inhomogeneity of the reaction mixture and higher polymerization temperatures. 
4.4  CONCLUSIONS AND OUTLOOK    
Since PAOx are gaining more and more interest in biomedical and pharmaceutical 
applications, the question was raised if it is feasible to produce defined (Ð < 1.3) PAOx 
(co)polymers on a larger scale. Therefore, this chapter focused on the reproducible synthesis of 
high MW PAOx on large scale; since this is a prerequisite to advance the PAOx polymers through 
the regulatory procedures. Previous work was performed at 1 g scale, which is inefficient for the 
targeted applications in this PhD thesis, which includes testing the PAOx platform for oral drug 
formulation development. One hot-melt extrusion test run already requires 5-10 g of polymer, 
depending on the drug content.  
 A lot of challenges had to be overcome, including upscaling of the (non-) commercial 
monomers and initiator synthesis. Additionally, results are included for the ´first´ successful 
upscaling tests (up to ± 200 g scale) for the CROP of 2-oxazolines. All polymerization reactions 
were performed in triplicate revealing good reproducibility. The PAOx polymers which were 
synthesized on large scale include PEtOx 25,000 g/mol, PEtOx 50,000 g/mol and PEtOx 100,000 
g/mol as well as PnPrOx 50,000 g/mol.  As a conclusion of these results, in general broader (but 
reproducible) Ð´s are observed during upscaling. A reason for the higher Ð, can be that the 
reactions were performed at higher temperature (60 °C vs 42 °C).  Furthermore, the higher Ð´s 
also result from inefficient stirring which is inherent to the scale increase. In order to verify these 
observations, an experiment was performed to examine the influence of sampling at different 
places in the reaction mixture clearly revealing that stirring is insufficient at higher monomer 
conversions. In further development this could be improved by applying mechanical stirring. Yet, 
because of time constraints, this could not be tested within this PhD research.  
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In conclusion, this chapter describes a prosperous method for the upscaling (200 g scale) 
of defined high MW PEtOx and PnPrOx polymers with a range of different MW ranging from 
25,000 g/mol up to 250,000 g/mol. Further optimization will be needed to reach out to other 
polymers in the PAOx family. Further upscaling will require the use of e.g. larger reactors, 
mechanical stirring, etc. In the long run, chemistry manufacturing controls (CMC) and good 
manufacturing practice (cGMP) facilities and procedures must be enforced to further realize 
the use of PAOx polymers in pharmaceutical and biomedical applications according to FDA or 
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CHAPTER 5 
5 THE USE OF POLY(2-OXAZOLINE)S IN SOLID DISPERSIONS. 
 
ABSTRACT Many newly developed drugs are disqualified for a validation trajectory because 
of their extremely low (slow) water solubility (rate) and high crystallinity. Different strategies have 
been targeted to overcome this low water solubility by e.g. the use of biocompatible polymers 
as excipient in so-called solid dispersions (SD). In this chapter, an overview of the results regarding 
the use of defined (high) molecular weight (MW) poly(2-alkyl-2-oxazoline)s (PAOx) for SD is 
described. SD formulations with model active pharmaceutical ingredients (APIs) having low 
water solubility and high crystallinity are described to demonstrate the potential of the PAOx 
polymer platform for oral drug formulation development. Both fenofibrate (FBT) and 
flubendazole (FLU) have been investigated with different formulation techniques, such as hot-
melt extrusion/injection molding (HME/IM), electrospinning and solvent casting.  
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5.1  SOLID DISPERSIONS: WHAT TO DO WITH POORLY WATER SOLUBLE ACTI VE 
PHARMACEUTICAL INGREDIENTS? 
In general, poorly water-soluble drugs or active pharmaceutical ingredients (APIs) with high 
crystallinity are difficult to formulate, as widely discussed in the introduction chapter (vide 
chapter 1). Although different formulation strategies have been described with a wide range of 
excipients, we will focus on polymers, especially poly(2-alkyl-2-oxazoline)s (PAOx), as 
pharmaceutical excipient. An interesting type of formulations are so-called solid dispersions (SD), 
which means that an API is dispersed in a (non-active) excipient or aiding substance, preferably 
the API is completely dissolved in the carrier, indicated by the absence of crystalline API 
fragments. The importance of having the API in an amorphous form rises from the fact that the 
API is trapped in a ́ high energy state´, i.e. the energy for breaking the crystalline lattice has been 
overcome during formulation, which generally leads to an increase in solubility rate. The 
challenges for the excipient consist of preventing crystallization of the API in the formulation as 
well as during and after its release from the SD, eventually leading to higher absorption at the 
site of delivery in the body, e.g. the stomach or the small intestines.  
 In this research chapter, formulations with PAOx and model APIs; such as fenofibrate (FBT) 
and flubendazole (FLU), will be highlighted and discussed. As PAOx polymers, the 50,000 g/mol 
poly(2-methyl-2-oxazoline) (PMeOx), poly(2-ethyl-2-oxazoline) (PEtOx) and poly(2-n-propyl-2-
oxazoline) (PnPrOx) polymers, which synthesis is discussed in chapters 3 and 4, will be evaluated 
as excipient for the aforementioned APIs. Also for the FBT formulations, comparison with the ill-
defined commercial PEtOx polymers, i.e. Aquazol®, is made since Aquazol:FBT formulations were 
already described in a research article by Claeys et al.1 In that same year, Bender et al. filled a 
patent on the protection capabilities of Aquazol® for cannabinoids. Also, Policianova et al. 
published two papers on acetylsalisylic acid solid dispersions, including comparison between 
state-of-the-art excipients, such as PVP, PEG, and PEtOx polymers.3,4 Nevertheless, it is unlikely 
that Aquazol® will ever be used as excipient, due to its irreproducible production processi which 
can never pass the regulatory trajectory. Therefore, the obtained results from Claeys et al. are 
considered as comparison for the behavior of defined PAOx polymers. Typical screening results 
will contain differential scanning calorimetry (DSC) and powder X-ray diffraction (XRD) to gather 
information on the crystallinity of the API in the formulation. Additionally, dissolution studies in sink 
conditions are performed to show improved release kinetics compared to the bare API in 
solution. Both pH 1 (simulated stomach conditions) and pH 6.8 are used as dissolution medium, 
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to simulate the release in the gastrointestinal (GI) tract and to check the influence of pH on the 
dissolution of the API. 
FBT is a model API and class II drug in the biopharmaceutics classification system (BCS), 
i.e. it is classified as a poorly water-soluble drug with high permeability through the membrane 
of the stomach and small intestines. FBTs poor water-solubility originates from its high tendency 
to crystallize leading to a low water-solubilization rate; impairing its overall bioavailability. The 
fact that FBT has a low water-solubilization rate and bioavailability, makes it widely studied as a 
model API in formulation strategy studies. Aside from that, FBT is mainly used for the treatment of 
high cholesterol and triglyceride levels in the blood. Its chemical structure resembles a synthetic 
analogue of phenoxy-isobutyric acid derivatives (Figure 1, left). Currently, FBT is marketed as 
tablets under the trade names Tricor™ (nanocrystal; 2004), Fenoglide® and Triglide® (insoluble 
drug delivery microparticle; 2005) and as capsules under the trade names Antara® and Lipofen®. 
The main excipients nowadays used for the formulation of FBT are poly(vinyl pyrrolidone) (PVP), 
polyglycolized glycerides and gelatin, in the abovementioned types of formulations.5–8 
Flubendazole is an API that belongs to the class IV drugs in the BCS system, i.e. it is 
classified as poorly water soluble and possesses low permeability through membranes in the 
body, thus overall poor bioavailabilty is observed. Chemically its structure is part of the 
benzimidazoles (Figure 1, right), which hold a range of active anthelmintic drugs, also known as 
anti-worm agents that are mostly used in veterinary science or medicine. A few commercial 
formulations are available under the tradenames, Flubenol, Flumoxal, Biovermin, etc. Mostly, 
excipients such as titanium dioxide, lactose monohydrate, sodium lauryl sulphate, hypromellose, 
PVP, PEG and brewers´ yeast are used in these flubendazole formulations. So far, enabling solid 
dosage forms of disclosed composition have only been reported by Vialpando et al. who 
constructed ordered mesoporous silica and spray-dried the FLU with cellulose derivatives and 
Vigh et al., who reported very recently (appeared while our research with the electrospinning of 
FLU was already ongoing) the electrospinning of PVP solutions containing FLU for its immediate 




Figure 1. Model active pharmaceutical ingredients (APIs) used for formulation in solid dispersions , including fenofibrate 
(FBT, left) and flubendazole (FLU, right). 
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First, in section 5.3.1, SD with FBT will be discussed, inspired by a study by Claeys et al.1 on 
the use of Aquazol® as matrix excipient for FBT SD, processed by hot-melt extrusion coupled to 
injection moulding (HME/IM). In this new study, first the influence of the possibility of using defined 
PEtOx polymers was investigated compared to the use of ill-defined PEtOx. Secondly, the effect 
of changing the hydrophilic nature of the PAOx matrix on the formulation of FBT, is investigated. 
Therefore, formulations with FBT and PMeOx or PnPrOx are compared with the formulations 
made with the PEtOx matrix, as a function of their immediate release capabilities of FBT. In 
section 5.3.2, the road towards FLU containing SD formulations is described using solvent casting, 
freeze drying and electrospinning methods, as a proof-of-concept study for its formulation. 
Herein, preliminary data on release kinetics of SD containing 10 % FLU and 90 % Aquazol® 200, 
are shown.  
 
5.2  MATERIALS AND METHODS     
5.2.1  Material s and equipment 
Materials 
All the defined high MW PMeOx, PEtOx and PnPrOx polymers, which are used in this chapter, 
are synthesized according to methods described in chapter 2-4 and will not be further discussed 
here. An overview of the average number average molecular weight (Mn) is given in Table 1. 
Fenofibrate and flubendazole were purchased from Alibaba group. Aquazol® 50, 200 and 500 
were kindly donated by Polymer Chemistry Innovations (PCI). The Aquazol® polymers were 
dissolved in water and freeze dried before use. 
Table 1. PMeOx, PEtOx and PnPrOx polymers synthesized in chapter 2 and 4; with Mn calculated against PMMA 
standards and the glass transition temperatures (Tg). 
Polymer name Mn (in g/mol) Ð Tg  (in °C) 
PMeOx_50kDa 45,000 1.4 80 
PEtOx_50kDa 84,700a 1.13 60 
Aq 200 47,000 4.61 60 
Aq 500 249,000 3.62 60 
PnPrOx_50kDa 65,900 1.14 40 
aagainst PEtOx standards the Mn is 50,700 g/mol. 
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Equipment 
Size-exclusion chromatography (SEC) was performed on an Agilent 1260-series HPLC system 
equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid sampler (ALS), 
a thermostatted column compartment (TCC) at 50°C equipped with two PLgel 5 µm mixed-D 
columns in series, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). 
The used eluent is N,N-dimethyl acetamide (DMA) containing 50 mM of lithium chloride at an 
optimized flow rate of 0.5 mL/min. The spectra were analyzed using the Agilent ChemStation 
software with the GPC add on. Molar mass and dispersity (Đ) values were calculated against 
polymethylmethacrylate standards from PSS. 
High-performance liquid chromatography (HPLC) is performed with a Phenomenex, Luna 
3u C18 (2) 100A, 50 x 2.00 mm, 3-micron column set and a guard column of Grace, Alltima C18 
5u, 7.5 x 2.1mm. The column temperature and sample compartment are maintained at room 
temperature of 20 °C. Eluens A is H2O + 0.1% formic acid (FA) and eluens B is acetonitrile (ACN). 
The flow rate was set on 0.20 mL/min, 80% A20%B, a back pressure of 102 bar with a runtime of 
17 min. The injection volume used was 15 µL. 
High resolution powder X-ray diffraction (XRD) was performed on a Thermo Scientific™ 
ARL™ X'TRA Powder Diffractometer from Thermo Fisher Scientific. The power source used is a Kα 
(Cu) 1.54, 40 kV and 30 mA. Furthermore, the scan type includes the 2 theta range, from 5 
degrees to 70 degrees, the step size 0.02 degrees and the scan rate 1,000,000 in continuous 
mode. 
Differential scanning calorimetry (DSC) is performed on a Mettler Toledo DSC1 Star system 
under nitrogen atmosphere with a heating rate of 10 °C/min from 20 °C to 200 °C (FBT containing 
dispersions) and 20 °C to 300 °C (FLU containing dispersions). Glass transition temperature (Tg) 
values are reported from the first heating run. 
Hot-melt extrusion coupled to injection moulding (HME/IM) is performed on a Haake MiniLab 
extruder coupled to a Haake MiniJet system. 
Freeze drying was performed on a Martin Christ Alpha 2-4 LDPlus with an ice condenser 
temperature of -85 °C and capacity of 4 kg. 
Dissolution testing and drug release from the tablets is determined using the paddle method 
on a VK 7010 dissolution system (VanKel Industries, New Jersey, USA) with a speed of 100 rpm. 
Chapter 5 
- 152 - 
 
Spectrophotometric measurements were performed on a UV-1650PC system from Shimadzu 
Benelux.  
Electrospinning set-up; All electrospinning experiments were carried out on a mononozzle 
setup using the solvent electrospinning technique with an 18 gauge Terumo mixing needle 
without bevel. A stable Taylor cone was achieved at a flow rate of 0.5 mL/h, selecting a tip-to-
collector distance of 10 cm, and applying a voltage between 15-20 kV depending on the 
polymer concentration. It should be noted that at higher tip-to-collector distances, e.g. 20 cm, 
flat fibers, i.e. ribbons, were formed instead of round nanofibers. After electrospinning, the 
nanofibers were stored in an inert environment (N2). 
All nanofibrous samples were analyzed by scanning electron microscopy (SEM) using an FEI 
Quanta 200 FFE-SEM at an accelerating voltage of 20 kV. Samples were prepared prior to 
analysis by applying a gold coating using a sputter coater (Balzers Union SKD 030). The nanofiber 
diameters were measured using ImageJ. The average diameters and their standard deviations 
were based on 50 measurements per sample. 
5.2.2  Experimental  methods 
Preparation of FBT solid dispersions 
For the preparation of FBT hot-melt extrudates, a total weight of 20-30 g of the polymer:FBT 
mixture was mixed with a FBT content of 20 and 40 %. Prior to HME, the polymer-API mixture was 
cryo-milled for homogenization of the mixture. In table 2, the optimal process and mold 
temperatures are displayed, together with the pressures applied for the HME/IM experiments for 
each FBT:PAOx mixture. The optimal HME/IM conditions were determined according to the 
empiric rule of 50 °C above the Tg of the polymer used and taking into account the degradation 
temperature of the API. Starting from a temperature of Tg + 50 °C, adjustments of 5 – 10 °C were 
screened until torque values were obtained between 500 and 1000 Nm.  
Table 2. Overview of the process temperatures and mold temperatures used to make FBT:PAOx SD via hot-melt 









Pressure Post pressure 
SD1 PEtOx 50 kDa  20 % 115 °C 45 °C 800 bar (5 s) 400 bar (3 s) 
SD2 PEtOx 50 kDa  40 % 115 °C 30 °C 800 bar (5 s) 400 bar (3 s) 
SD3 Aquazol® 500 20 % 120 °C 25 °C 800 bar (5 s) 400 bar (3 s) 
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SD4 Aquazol® 500 40 % 125 °C 25 °C 800 bar (5 s) 400 bar (3 s) 
SD5 PMeOx 50 kDa  20 % 125 °C Not possible Not possible Not possible 
SD6 Aquazol® 200 20 % 115 °C 25 °C 800 bar (5 s) 400 bar (3 s) 
SD7 Aquazol® 200  40 % 120 °C 25 °C 800 bar (5 s) 400 bar (3 s) 
SD8 PnPrOx 50 kDa 20 % 90 °C 25 °C 800 bar (5 s) 400 bar (3 s) 
Preparation of flubendazole containing nanofibers 
Electrospinning solutions were prepared by dissolving a specific amount of Aquazol® 200 in 
a 30/70 acetic acid/formic acid (AA/FA) solution (Table 3). Mass concentrations are expressed 
by weight percentages (wt%) defined by the ratio of the polymer mass and the sum of the 
polymer and solvent mass. For the flubendazole-containing nanofibers, a specific amount of 
flubendazole was first dissolved in the AA/FA solvent system after which the polymer was added. 
The amount of flubendazole is expressed in weight percentage (wt%) and is defined by the ratio 
of the flubendazole mass on polymer mass. The (dynamic) viscosity of the solutions was 
determined using a Brookfield viscometer LVDV-II (spindle S18, viscosity range of 1.5 - 3.0 x 105 
cP, average error of 8%). As expected, the viscosity and nanofiber diameter increase with 
increasing polymer concentration.  
Table 3. Overview of the viscosity and nanofiber diameter according to the Aquazol® 200 concentration and 
flubendazole content before and after electrospinning.  
 
 
AQ200 concentration Flubendazole concentration Viscosity (cP) Nanofiber diameter (nm) 
20 wt% - 1366 261 ± 84 
30 wt% - 4439 848 ± 156 
20 wt% 2 wt% 1251 319 ± 92 
4 wt% 1546 192 ± 68 
6 wt% 1546 304 ± 58 
25 wt% 2.5 wt% 3788 442 ± 82 
5 wt% 4394 532 ± 82 
7 wt% 4276 719 ± 108 
27 wt% 3 wt% 5573 702 ± 193 
6 wt% 11413 952 ± 154 
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Dissolution tests 
Drug release from the tablets is determined using the paddle method on a VK 7010 
dissolution system (VanKel Industries, New Jersey, USA) with a speed of 100 rpm. Phosphate buffer 
saline (PBS) in water (pH 7) was used as dissolution medium (900 mL) at 37 °C ± 0.5 °C. Samples 
were withdrawn at predetermined time points (5, 10, 20, 30, 40, 50, 60, 120, 180 and 240 min) and 
spectrophotometrically (UV-1650PC, Shimadzu Benelux, Antwerp, Belgium) analyzed using a 
wavelength of 289 nm for FBT. No filtration step was included before the analysis of the UV/vis 
samples. For each SD type formulation three tablets were dissolved and analyzed in three 
separate dissolution baths, the error bars in the release profiles are provided.  
For the dissolution tests of the PEtOx:FLU SD, the electrospun fibers (three times +/- 500 mg) 
were put in a dissolution basket as such, without additional compressing or tableting step. The 
analysis for the PEtOx:FLU SD was done by a custom made HPLC method, since 
spectrophotometric determination was impaired by the inability of setting-up a calibration curve 
of FLU in water due to its too low solubility. HPLC analysis is performed in water + 0.1% FA (eluens 
A) and ACN (eluens B), the gradient analysis is varied from A:B = 80:20 to 2:98 to 80:20. As a 
standard FLU and amino-FLU were used. 
Statistical evaluation of the dissolution tests 
Statistical evaluation was performed with Origin Pro 8.5 Statistics, using a one-way ANOVA, with 
Tukey’s post-hoc test to assess the differences between the means of the cumulative release 
profiles of Figure 6. Significance level was chosen at a probability of p < 0.05, in order to assess 
the significance difference between the different profiles to be random or not. In the 
attachments (vide 5.6), a complete overview of the output data from ANOVA is provided. 
Calibration curve FBT 
A stock solution is prepared by dissolving 100.25 mg FBT in 1000 mL PBS (concentration 100.25 
mg / mL). This stock solution is respectively diluted 2, 4, 6, 8 and 10 times. From these 5 samples 
the absorbance is measured by UV-VIS spectroscopy at 289 nm. (Table 4) Each measurement is 
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Table 4. UV/VIS spectroscopy results for the calibration curve of FBT, ranging from 10 – 50 mg/mL. 
Sample  Concentration 
(mg / L) 




1 10.03 0.158 0.162 0.163 0.161 0.002646 
2 12.53 0.197 0.198 0.198 0.198 0.000577 
3 16.71 0.258 0.262 0.263 0.261 0.002646 
4 25.06 0.401 0.406 0.409 0.405 0.004041 









Figure 2. Standard calibration curve for FBT in PBS buffer, analysed via UV-VIS spectroscopy.  
 
5.3  RESULTS AND DISCUSSI ON    
5.3.1  Sol id dispersions wi th fenofibrate as API   
Recently, in 2012, a first study was done by Claeys et al.1 on the use of PAOx polymers 
for SD formulation of FBT. The results (summarized in Figure 3) are based on Aquazol® (Aq), that is 
commercially available ill-defined (Ð~3-4) PEtOx, SD formulations with 20-40 % FBT content 
produced by HME/IM. As a first conclusion, it was found that formulations could be obtained 
with all the molecular weights (MW) of Aquazol®, i.e. Aq 50, Aq 200 and Aq 500. Secondly, no 
crystalline API fractions could be observed by DSC and XRD, up to 20 % FBT content.  Formulations 
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with 40 % of FBT showed the appearance of crystalline fractions, and were not subjected for 
drug dissolution tests.  
The in vitro dissolution tests of the Aq:FBT (80:20) SD showed increased dissolution 
compared to the pure FBT, which shows slow release up to 20-30 % after three hours (Figure 3, 
right). In contrast, the Aquazol SD with FBT show an immediate release with faster dissolution with 
lower MW of the Aq (Aq 500 – Aq 50) polymers. 
  
Figure 3. State-of-the-art formulation of Aquazol® with FBT processed by hot-melt extrusion/injection moulding by Claeys 
et al.1 Injection moulded tablet after hot-melt extrusion (left); structure of fenofibrate, a model class II drug with very 
low water solubility (middle); and in vitro dissolution profile for the Aq 50, Aq 200 and Aq 500 (kDa) based SD and the 
release profile of the pure FBT drug. (right) 
 It has to be noted that there are some limitations of this work that are inherent to the 
use of Aq as excipient for SD. For example, the value of Aq for its application in SD is quite low, 
since its production process is not optimized to reproduce the exact polymer structure but rather 
to reproduce the polymer viscosity specifications. Furthermore, the polymers themselves lack a 
defined structure. In this particular case, Aq 50 gives the best result as excipient for the immediate 
release of FBT within an hour, but cannot be used as such since the Aq polymers are not made 
according to FDA or EMEA regulations. Additionally, the Aq 50 might be co-absorped during 
drug release, due to the presence of a low MW fraction.ii Also the Aq 200 and Aq 500 do not 
posses narrow specification parameters in terms of MW and Ð, making it impossible to implement 
them in regulated pharmaceutical formulation processes, cfr. current good manufacturing 
practice (cGMP). Therefore, as a conclusion, these preliminary data showed the potential of 
PAOx polymers as excipient for SD, but one can ask the question if defined PAOx polymers will 
display the same potential as an excipient for SD formulations, as the Aq used in the proof-of-
concept study by Claes et al.?1 
                                                                
ii The absorption is limited at ± 8 nm, all polymers with a hydrodynamic radius above this limit will not be absorbed. 
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 Hence, as a follow-up, we have examined the influence of defined PAOx on the SD 
formulations of FBT, produced by HME/IM. PEtOx 50,000 g/mol with Ð < 1.2 and Aq 200 and Aq 
500 (Figure 4) have been formulated for comparison of defined versus ill-defined PAOx polymers 
on SD thereof.  
From the tablet production process, by HME/IM, it is observed that it is more difficult to 
process the defined PEtOx polymer compared to the Aq grades indicating that low MW fractions 
in Aq make it easier to make the polymer flow in the extrusion and mold compartments. In 
addition, it seems that the highly crystalline FBT acts as an ́ anti-plactisizer´ for the PAOx polymers. 
Since the FBT:PAOx formulations look more brittle compared to the pure polymer. The aq 









Figure 4. Size-exclusion chromatography results for PEtOx 50,000 g/mol, Aq 200 and Aq 500 polymers used in the FBT 
formulations. The number average MW (Mn) and Ð values are given, calculated against PMMA standards. 
 Characterization of the 20% FBT containing SD with PEtOx by DSC and XRD 
measurements (Figure 5) shows for all PEtOx 50,000 g/mol and Aq 200-500 formulations the 
absence of a crystalline fraction or crystalline structure, independent on the characterization 
technique which is performed.  
Dissolution tests are performed to investigate the FBT release from the SD formulations 
according to the excipient used. In contrast to the previous tests in literature which are 
performed at pH 1, these tests are performed in PBS buffer (pH ~ 7). It is expected that the release 
will not be influenced by pH as the PEtOx matrix is highly chemically resistant, including its proven 
resistance against hydrolysis under acidic conditions and residence time in the stomach.19 
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                                      Mn (kDa)      Ð
 PEtOx 50kDa   84.0            1.15
  Aq 200             47.0            4.61




























Figure 5. XRD profile of the 20 % FBT HME/IM formulations of respectively PMeOx 50,000 g/mol; Aquazol® 500 and PEtOx 
50,000 g/mol (Left); DSC thermogram of the same FBT HME/IM formulations including the DSC of pure FBT, with a melting 
peak situated around 80 °C; as expected from literature. (Right)  
 This pH independence of the release is also confirmed by the immediate release profiles 
for the Aq polymer based tablets in Figure 6; which correspond well to the earlier obtained 
release profiles at pH 1 by Claeys et al.1 The release profile for the PEtOx 50,000 g/mol matrix 
tablets with FBT is situated right in between the release profiles observed for the Aq 200 and Aq 
500 polymers that revealed a faster and slower release, respectively. Besides this observation, 
statistical analysis (via ANOVA) does not provide any significant difference in release between 
the three excipients used for the formulation for FBT. Thus, it can be concluded that the use of 
defined PEtOx gives the same release profiles as Aq 200 and 500.  
 
Figure 6. Results of the cumulative release of FBT from the different formulations, including pure FBT; Aquazol ® 200/500 
and PEtOx 50,000 g/mol. All formulations contain 20 or 40 wt% of FBT. (left; Zoom in for the region up to 60 min of release. 
(Right) ANOVA statistics test gives no significant difference (p = 0.05) for the means for the PEtOx and Aquazol SD of FBT 
(detailed description vide 5.6.1). 
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Relating to the FBT content used, it is noticed that the release curves for PEtOx:FBT 80:20 
and 60:40 containing 20 and 40 % of FBT are superimposed upon each other for all polymers. This 
indicates that the supersaturation state of FBT is not reached. Nevertheless, partial crystallization 
of the FBT in the 40 % SD is observed directly after processing, by XRD and DSC, which can be 
harmful for the long-term stability of these formulations (Figure 7). Therefore, in the following 
experiments, it is examined if crystallization of FBT in the SD occurs over time. A SD formulation 
with high stability should keep the API in its amorphous form at all times. The presence of any 
crystalline form of the API in the SD, directly after processing, can induce further recrystallization 
over time.  
Stability tests of the FBT:PEtOx SD are important to evaluate crystallization of the API over 
time, resulting in a slower and possibly incomplete release, thus lower bioavailability of the FBT. 
As the FBT is present in its amorphous form for the 20 % FBT formulation, recrystallization has lower 
chances to happen compared to the 40 % FBT SD which contains crystallized fractions of FBT 
already after processing. The presence of crystallinity just after processing can indicate 
supersaturationiii (vide chapter 1) of the matrix used for the preparation of the SD. Therefore, 
additional DSC measurements of the tablet containing the high-defined PEtOx were performed 
after 20 days (Figure 7, left). From the DSC spectrum it is clear that the tablet containing a drug 
load of 20% remained stable in the amorphous form, while the FBT in the formulation with a drug 
load of 40% completely crystallized. This could also be observed from the color change of the 






Figure 7.  DSC measurement of stability tests comparing PEtOx:FBT SD formulations with 20 % and 40 % drug load after 
20 days under inert atmosphere (Ar) (Left); Image of the IM tablets after 20 days, clearly showing recrystallization at 40 
% of FBT loading. (Right) 
                                                                
iii Supersaturation is defined as the drug which is present in the solid dispersion at concentrations higher than the maximum 
concentration possible.  
PEtOx:FBT 
80:20              60:40 
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  In order to check the influence of relative humidity on the stability (i.e. storage 
conditions), the tablets with 20 % FBT were stored under argon or air. Since the PEtOx polymers 
are hygroscopic in nature, the uptake of water induces lowering of the Tg, which increases the 
mobility of the polymer chains and the API. The improved mobility can induce faster 
recrystallization of the FBT in the SD. As expected, the PEtOx:FBT SD stored under air turned into a 
white opaque formulation indicating crystallization, while the ones stored under inert 
atmosphere remained their amorphous state, resulting in an absence of the crystallization peak 







Figure 8. DSC measurement of stability tests comparing PEtOx:FBT SD formulations with 20 % drug load after 20 days 
under inert atmosphere and under air with a relative humidity of ± 70-80 % (Left); Image of the IM tablets after 20 days, 
clearly showing crystallization after storage under air. (Right) 
  Since the formulation results of FBT with a defined PEtOx polymer have shown the same 
promising and comparable results in solubility improvement of FBT as Aquazol®, we investigated 
if the polymer side-chain would influence the interactions with the API and if this would improve 
the release of FBT in SD even more. Therefore, PMeOx and PnPrOx 50,000 g/mol polymers were 
evaluated as excipient. 
Unfortunately, it proved to be very difficult to formulate FBT containing formulations with 
PMeOx, since this matrix is most probably too hydrophilic to strongly interact with the FBT 
structure. The produced hot-melt extrudates were white and sticky formulations and the injection 
moulded tablets could not be removed from the mould, indictating recrystallatization of FBT 
during the formulation process. This observation was confirmed by the difference in 
characterization of these SD by XRD, showing a highly crystalline structure for the PMeOx:FBT SD; 
and by DSC where a crystalline peak (integration shows ± 72 % crystallinity) of FBT is detected at 
± 80 °C (Figure 4). Analysis of the results of the PMeOx:FBT formulations showed poor formulations 
characteristics and no SD properties. Appearance of crystalline FBT may be explained by poor 
interactions between the hydrophilic PMeOx polymer and the more hydrophobic FBT structure. 
25.0 37.5 50.0 62.5 75.0 87.5 100.0
Stability after 20 days of processing
 PEtOx:FBT (80:20) under air
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Hence, since the PMeOx show less interactions with the FBT compared to the formulations with 
PEtOx, we anticipated better results from the formulation of FBT with PnPrOx polymers. The more 
hydrophobic nature of PnPrOx will possibly lead to better interactions with the hydrophobic FBT, 
compared to PEtOx. For the production of the PnPrOx:FBT (80:20) SD by HME/IM, the lower 
processing temperature of ± 90 °C was required, which was expected when taking into account 
a lower Tg of PnPrOx, which is 40 °C compared to 60 °C for PEtOx polymers. The dissolution tests 
from these tablets revealed, however, no improved solubility of FBT compared to the pure FBT. 
An overview of the results is given in Figure 9.  
In conclusion, PEtOx 50,000 g/mol was found to be the preferred excipient for the highly 
crystalline FBT as model API. Related to drug content, PEtOx:FBT (80:20) SD formulations are by 
far the best performing. Preferably, the formulated tablets should be stored under inert 
atmospheric conditions and a moisture free environment due to the hygroscopic nature of the 







Figure 9. Dissolution tests of IM tablets of PnPrOx:FBT (80:20) SD formulations and combined image of the tablets before 
and after dissolution, clearly showing the presence of crystalline FBT. Note that the PnPrOx turns white when in contact 
with water, due to its cloud point temperature which is situated around 30 °C.  
5.3.2  How can we formulate class IV APIs: Flubendazole sol id 
dispersions  
The main difficulties to formulate FLU are its high tendency to crystallize and its poor 
solubility in almost any organic solvent apart from formic acid and dimethyl formamide and 
dimethyl sulfoxide after heat treatment. It is therefore important that the excipients survive the 
chemical conditions for dissolution and formulation of FLU. In this aspect, PAOx polymers could 
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Initial experiments and trials to formulate flubendazole in an amorphous solid dispersion 
with PEtOx polymers as matrix excipient were performed via freeze drying methods. The freeze 
drying method is chosen primarily over solvent casting, since first experiments to perform solvent 
casting by mixing 5 % flubendazole and 95 % Aquazol® in formic acid failed to obtain a 
homogenous amorphous SD, as characterization by DSC revealed various melting peaks most 
likely resulting from FLU crystals (Figure 10, right). This freeze drying procedure included the mixing 
of the FLU and Aquazol® in formic acid, whereby sufficient time (ca. 3 days as optimum 
condition) is needed for homogenous dissolution of both compounds. After dissolution in formic 
acid, the amorphous state of FLU is expected to be kept upon fast freezing. The amorphous 
solution of FLU and Aquazol® is put in a petri dish and the freeze drying process is carried out in 
a desiccator, connected to a liquid nitrogen trap and a membrane vacuum pump (Figure 11). 
After three days of dissolution and consequent freeze drying, the formulation showed 
a thermal transition at 100 °C in DSC, which can most probably be attributed to one of the 
different existing amorphous states or less stable crystals of FLU.20 Because of the presence of 









Figure 10. Structure of flubendazole (left) and DSC chromatograms of pure flubendazole (Tm ± 280 °C), freeze dried 
pure flubendazole, pure Aquazol® 500 polymer (Tg ± 60 °C) and the SD made by solvent casting and freeze drying 
(right). 
In the follow-up experiments, flubendazole containing formulations were made with 
Aquazol®, via solvent electrospinning as advanced technique over spray drying, which is the 
main solvent method currently used for the development of SD of crystalline and poor water-
soluble APIs. The idea behind using electrospinning as SD formulation development process 
raised from the fact that ultra-thin nanofibers can effectively and homogenously mix the FLU and 
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Aquazol® in a SD with efficient loss of the solvent molecules. Through the large surface area which 
is generated when the electrospinning process is applied, the solvent evaporates very fast 





Figure 11. Example of the freeze drying experiments in dessicator, for the production of FLU:PEtOx SD. 
 In the following part a preliminary study is described wherein the formulation of a SD 
with a 10 % FLU content is evaluated. First, the parameters were optimized to electrospin solutions 
of PEtOx polymers up to 30 wt%, from an acetic acid/formic acid (AA/FA) solution with 30/70, 
20/80 and 10/90 AA/FA ratios, of which the SEM data are shown in Figure 12. Here, the 30 wt% 
Aq 200 solutions with 30/70 and 20/80 AA/FA ratios produce the most stable nanofibers.  
 
Figure 12. Scanning electron microscopy images of the different Aquazol® solutions (20 wt% and 30 wt%) electrospun 
from acetic acid/formic acid (AA/FA) mixtures in different ratios respectively, 30/70, 20/80 and 10/90. Yielding stable 
nanofibers for 30 wt% Aquazol® solutions with a 30/70 solvent mixture of AA/FA. 
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Secondly, a solution of 27 wt% PEtOx and 3 wt% FLU in a 30/70 AA/FA solvent mixture is 
chosen to prepare a FLU: Aquazol® (10:90) amorphous SD nanofibrous formulation, as recorded 
by SEM in Figure 13. Further characterization of the FLU SD was performed by DSC (Figure 14), 
showing the absence of crystallization of FLU in the PEtOx nanofibers up to three months (artefact 
at 240 °C also present in second and third heating run). These results have to be emphasized 
since these are based on a single DSC experiment taken after three months. 
 









Figure 14. DSC thermograms (first heating runs) of FLU:PEtOx (10:90) SD nanofibrous formulations, after processing (left) 
and after three months of processing (right).  
 Dissolution tests on FLU:PEtOx (10:90) nanofibers 
A drug dissolution test from the 10 % FLU containing SD formulation nanofibers (± 500 
mg in triplicate), with Aquazol® 200 show ca. 80 % of FLU release after 2 hours of dissolution (Figure 
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15). From the cumulated release diagram, it appears that a supersaturated solution state is 
achieved around 80 % of dissolution. Since the maximum solubility of FLU is approximately 30 
mg/mL and the formulation could release a maximum of 70 mg/mL theoretically. Alternatively, 
it could also be that the rest of the FLU is stuck in the SD. Although it is a preliminary proof-of-
concept study which proofs the ability of PEtOx to maintain FLU in the amorphous form, these 
first test are promising for improving the bioavailability of FLU. Further development and 
optimization of these SD with higher drug content and the use of defined PEtOx polymers will be 
needed to pursue in vivo drug release studies and get further understanding of these 
formulations. The high variability of the results from Figure 15, could be attributed to the fact that 
the electrospun fibers as such were used for the dissolution tests and no further treatment was 
applied to make tablets. This can explain the variability of the dissolution data, because of 
heterogeneity in fibers/fiber mass can give difference in flotation and possible difference in the 
release profile. An additional milling step would homogenize and reduce the particle size with a 











Figure 15. Dissolution test of FLU:Aquazol® 200 (10:90) SD formulations in pH 1 buffer solution (in triplicate); cumulative 































- 166 - 
 
5.4  CONCLUSIONS AND OUTLOOK    
In this chapter amorphous SD formulations with PAOx homopolymers are highlighted. Two 
different approaches are applied to produce such formulations, namely hot-melt extrusion 
coupled to injection moulding and electrospinning of nanofibrous formulations. With both 
techniques we showed the ability of processing PAOx polymers with poorly water-soluble APIs, 
in order to generate amorphous SD formulations with higher bioavailability, compared to the 
pure non-formulated API. More specifically we used FBT in a first case, testing PMeOx, PEtOx and 
PnPrOx with 50,000 g/mol MW for its formulation. Only PEtOx:FBT (80:20 and 60:40) SD showed an 
increased water-solubilization rate, while PMeOx and PnPrOx showed crystallinity of FBT and slow 
release, respectively. Short-term stability essays, 20 days after processing, only revealed good 
stability for the 80:20 PEtOx:FBT formulations, when preserved under inert atmosphere. In a 
second test case, FLU was successfully formulated in a SD with PEtOx in a proof-of-concept study 
using electrospinning to produce nanofibrous amorphous solid dispersions. A first trial with 10 % 
FLU loading and 90 % of PEtOx as excipient, showed an increased water-solubilization rate of ca. 
80 % after 2 hours of dissolution.  
In conclusion, PAOx polymers can be applied to successfully formulate some model APIs 
and improve their aqueous solubility rate of the APIs from these amorphous SD formulations. All 
of these experiments are proof-of-concept minded, showing the great potential of this PAOx 
polymer platform in formulation development of poorly water-soluble APIs. It will be important 
that the next steps in the project involve further optimization allowing the selection of the best 
formulation for in vivo experiments. Such in vivo data will be crucial as it is hard to predict the in 
vivo behavior based on in vitro dissolution tests. Once these in vivo data are gathered and 
proven to be positive, I believe that PAOx are a viable alternative as excipient for poorly water-
soluble (newly developed) APIs to compete with currently marketed solubility enhancing 
polymers. However, it should be noted that the hygroscopic nature of PAOx, could interfere with 
the preparation of some SD and most of all will have an influence on the storage and stability 
conditions of the formulations, implying storage in moisture free conditions. 
In follow-up research on the use of PAOx polymers as SD formulations, a collaboration 
has been started with the laboratory of Prof. Guy Van den Mooter, in order to screen different 
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5.6  ATTACHMENT 
5.6.1   Figure 6: ANOVA resul ts  
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CHAPTER 6 
6 THE USE OF POLY(2-OXAZOLINE)S IN SUSTAINED RELEASE 
FORMULATIONS. 
 
ABSTRACT Formulation development and bioavailability improvement for good water-
soluble crystalline drugs may appear counterintuitive, nevertheless they deserve similar attention 
compared to the aforementioned solid dispersions (SD) as discussed in chapter 5. Different 
strategies have been introduced to reduce burst drug release, i.e. maintain lower drug levels in 
blood plasma over a longer period of time, mostly improving patient compliance in terms of 
adverse effects, multiple dosing, etc. Suppression of burst release can be achieved by e.g. the 
use of biocompatible polymers as excipient in so-called extended or sustained release 
formulations (SRF). In this chapter, an overview of the results regarding the use of defined (high) 
molecular weight (MW) poly(2-alkyl-2-oxazoline)s (PAOx) for SRF are described. SRFs with 
metoprolol tartrate (MPT) as a model active pharmaceutical ingredient (API) with good water 
solubility are described, to evaluate the potential of the PAOx polymer platform for oral drug 
formulation development. For the preparation of the SRF, the focus of this thesis will be on hot-
melt extrusion (HME) coupled to injection molding (IM) to obtain the final oral solid dosage forms. 
Finally, further strategies to improve the implementation of PAOx for formulation in SRF will be 
discussed. 
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6.1  THE IMPORTANCE OF CONTROLLED RELEASE: SUSTAINED RELEASE 
FORMULATIONS  
Controlled drug delivery is omnipresent and important in current medicinal therapies, as 
evidenced by the large number of literature publications on this topic, including recent trends 
such as polymer-drug conjugates,1–4 functionalized nanoparticles5–8 and hydrogels.9–17 Basically, 
the controlled delivery of an active pharmaceutical ingredient (API), independently of the 
administration route, is pursued to reduce side-effects, maintain therapeutic efficacy over a 
longer period of time, reduce loss of valuable API and reduce the number of administrations to 
increase patient compliance.18–23 In this chapter, we will only focus on oral drug formulations, 
where an API and the polymer are mixed in the solid form, to serve as a sustained release 
formulation (SRF) for prolonged therapy. The APIs addressed in SRF mostly belong to class I in the 
biopharmaceutical classification system (BCS) comprising APIs that are highly water-soluble and 
highly permeable through the intestines, as widely discussed in chapter 1. Also class III APIs, which 
have high water-solubility but low permeability through the membranes could benefit from SRF, 
as longer time will be provided for the drug absorption in the gastrointestinal (GI) tract. If one 
considers oral drug administration only, formulations of model APIs such as metoprolol tartrate 
(MPT), 19,24–33 metformin hydrochloride (MTF)12,22 and theophylline (THEO),19, 22, 29,30,34,35 are typically 
studied for SRF based on their good water-solubility and different Tm making them representative 
for a wide range of other APIs (Figure 1). In these oral drug formulations, or so-called SRF, the 
drug is embedded in a preferably amphiphilic to hydrophobic matrix/excipient, while 
maintaining the drug in its crystalline form. In contrast to the solid dispersions (SD), described in 
chapter 5, an amorphous (and higher energy) state of the API, which induces faster release of 
the API has to be avoided at all times for the SRF. The challenges in SRF include a high drug 




Figure 1. Overview of the structures of metoprolol tartrate, metformin and theophylline; including their most important 
properties. 
Recent literature highlighted the importance of biocompatible polymers with regard to SRF 
and other controlled drug formulations, see also chapter 1. One of the finest examples is the use 
of hydroxypropyl (methyl) cellulose (HP(M)C) matrices, which are consistently used in easy and 
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straightforward direct compression methods to formulate different water-soluble APIs in high 
dose (up to ± 50 % API).22, 30, 32,36 Also multiple examples using hot-melt extrusion as continuous 
manufacturing tool for the production of SRF are found, for which some of the currently applied 
polymers are highly challenging due to limited processability of semi-crystalline polymers and 
polymers with a high glass transition temperature (Tg).22,36,3726, 32,38 It has to be noted that the 
processing temperature should stay preferably below the Tm of the API, at all time during the 
preparation of those SRFs. 
MPT is a model API and class I drug in the BCS, i.e. it is being classified as highly water 
soluble with high permeability through the membrane of the stomach and the small intestines. 
The high water-solubility of MPT, compared to the metoprolol succinate (MPS) salt which is often 
used for extended release tablets of metoprolol, probably arises from the fact that 
rearrangement of the tartrate salt of MP is very slow once it is dissolved, inhibiting recrystallization 
and favoring dissolution.39 Pharmaceutically, MPT (and MPS) are part of the cardioselective beta 
blockers which are used for the treatment of hypertension and chest pain related to heart 
diseases such as arrhythmias. Chemically, it is a synthetic analogue of propranolol, the first 
clinically successful beta blocker (Figure 2). Nowadays MPT is commercialized as Lopressor®, 
whereas MPS is commercialized as Tropol XL® for which hydroxypropyl (methyl) cellulose 
(HP(M)C) is mainly used as binder and excipient. Up to date, no commercial formulation is 
available with more than 40 % drug loading.32,40  
 In a recent study by Claes et al., the ability of PAOx to formulate good water soluble 
APIs, particularly MPT, was examined. The results (summarized in Figure 2) are based on Aquazol® 
(Aq), a commercially available ill-defined (Ð~3-4) PEtOx, SRF formulations with 25 % and 50 % 
MPT content produced by HME/IM. As a first conclusion, it was found that formulations could be 
obtained with different molecular weights (MW) of Aquazol®, i.e. Aq 50, Aq 200 and Aq 500. 
Because the HME/IM parameters exceeded the melting temperature (Tm) of the MPT, the MPT 
was mostly present in the amorphous form; nevertheless, recrystallization was not observed via 
DSC and XRD measurements. For the Aq 500:MPT (75:25) SRF, the best results were obtained 
showing complete release of MPT, which was extended up to 3 hours in a pH 1 buffer solution 
(Figure 2, right). Other trends that were found include a faster release for lower MW Aq, 
compared to Aq 500, if the 25 % MPT loading was kept constant in the SRF. Upon increasing the 
MPT loading of the formulations up to 50 %, even faster release was observed compared to the 
25 % MPT formulations.  
 In conclusion, the SRF of MPT including Aq as excipient provided promising results 
towards sustaining MPT up to 3 hours. Unfortunately, for the case of Aq no further fine-tuning of 
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the formulations seems possible since they have reached the limits of this specific matrix, in terms 




Figure 2. Injection moulded tablet after extrusion (Left), structure and properties of metoprolol tartrate (Middle) and 
release profile for the Aquazol SRF containing 25 wt% of MPT, in pH 1 as dissolution medium.  
In this chapter, SRF with defined (dispersity, Ð, below 1.3) high molecular weight (MW) PAOx 
and MPT as model API, will be discussed. As PAOx polymers, a 140,000 g/mol poly(2-ethyl-2-
oxazoline) (PEtOx), the more amphiphilic 50,000 - 80,000 g/mol poly(2-n-propyl-2-oxazoline) 
(PnPrOx) and 50,000 g/mol poly(2-sec-butyl-2-oxazoline) (PsecButOx) polymers, prepared as 
discussed in chapter 4, will be evaluated as excipient for SRF of the highly water-soluble model 
API. Generally, the more hydropobic PAOx polymers are expected to give better results 
regarding their use in SRF. Nevertheless, if too hydrophobic polymers are used, incomplete 
release could be observed. The more hydrophobic PAOx used, i.e. PnPrOx and PsecButOx, 
possess a lower critical solution temperature (LCST) behavior in water meaning that they are 
soluble in water at a given concentration and below a certain temperature, also known as the 
cloud point temperature (Tcp).  
At first, the link between the MPT:Aquazol® SRF (studied by Claeys et al.41) and the use of 
defined PEtOx for its formulation via hot-melt extrusion coupled to injection moulding (HME/IM) 
is studied (section 6.3.1). Typical screening results will be discussed based on differential scanning 
calorimetry (DSC) and powder X-ray diffraction (XRD) to gather information on the crystallinity of 
the API in the formulation. Additionally, dissolution studies are performed to show improved 
release kinetics compared to the bare API in solution. Both pH 1 (simulated stomach conditions) 
and pH 6.8 (simulated intestinal conditions) are used as dissolution medium, to simulate the 
release in the GI tract and to check the influence of pH on the dissolution of the API. 
In this study, first the influence of the use of defined PEtOx polymers was questioned 
compared to the use of ill-defined PEtOx. Secondly, the effect of changing the alkyl side-chain 
of the PAOx polymers towards poly(2-n-propyl-2-oxazoline) leading to a more hydrophobic 
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nature on the ´sustained release´ profile of MPT is investigated, vide section 6.3.1. In section 6.3.2, 
SRF are prepared and investigated, containing a 50,000 g/mol PnPrOx polymer as matrix 
excipient with MPT as model API with a drug load up to 80% API (compared to the 50 % in the 
initial screening study in section 6.3.1). Also, the release from a 80,000 g/mol PnPrOx has been 
investigated. Finally, section 6.3.3 will cover the use of more advanced PsecButOx polymers in 
order to optimize the formulation of MPT, towards longer release times. Hereby, preliminary 
release data reveal further improvements in comparison to the earlier investigated PnPrOx SRF 
with MPT. 
6.2  MATERIALS AND METHODS     
6.2.1  Material s and equipment 
Materials 
EtOx was kindly donated by polymer chemistry innovations (PCI). BaO, HBF4 aqueous 
solution, H2SO4, NaHCO3, MgSO4, MeOH, 2-phenyl-2-oxazoline, butyronitrile, ethanolamine, 
zincacetate and chloromethyl(trimethyl)silane were bought from Sigma Aldrich. 
Chlorobenzene, ethyl acetate (acroseal® grade) were purchased from thermofisher scientific. 
Diethylether, dichloromethane, petroleum ether and acetone were ordered at Merck. MPT was 
purchased from Esteve Quimica (Barcelona, Spain). The polymers were produced as discussed 
in chapter 4, see materials and methods; section 4.2. In section 6.2.2, an overview of the polymer 
characteristics is given in Table 1 and 2. 
Equipment 
Size-exclusion chromatography (SEC) was performed on an Agilent 1260-series HPLC system 
equipped with a 1260 online degasser, a 1260 ISO-pump, a 1260 automatic liquid sampler (ALS), 
a thermostatted column compartment (TCC) at 50 °C equipped with two PLgel 5 µm mixed-D 
columns in series, a 1260 diode array detector (DAD) and a 1260 refractive index detector (RID). 
The used eluent is DMA containing 50mM of lithium chloride at an optimized flow rate of 0.5 
mL/min. The spectra were analyzed using the Agilent ChemStation software with the GPC add 
on. Molar mass and dispersity (Đ) values were calculated against polymethylmethacrylate 
standards from PSS. 
Light scattering (LS) measurements are performed on a 3-angle static light scattering (MALS) 
detector, i.e. miniDAWN TREOS, from Wyatt Technology. The detector is coupled on-line to an 
Agilent 1260 infitiny HPLC system (vide DMA-SEC), and used to determine absolute molar mass 
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of the analyzed polymer samples. The measurements are performed at ambient temperature, 
i.e. no temperature control unit is supplied/installed with the above mentioned LS detector. The 
refractive index (RI) increment (dn/dc) values are either used as reported for the certain polymer 
in DMA or determined via online size-exclusion chromatography (SEC) equipped with an RI 
detector, which measures the RI increase for a 1-10 mg/mL concentration series of the 
mentioned polymers. The LS results are further analyzed with the provided Astra 7 software, also 
designed by Wyatt Technology.  
High resolution powder X-ray diffraction (XRD) was performed on a Thermo Scientific™ 
ARL™ X'TRA Powder Diffractometer from Thermo Fisher Scientific. The power source used is a Kα 
(Cu) 1.54, 40 kV and 30 mA. Furthermore, the scan type includes the 2 theta range, from 5 
degrees to 70 degrees, the step size 0.02 degrees and the scan rate 1,000,000 in continuous 
mode. 
Differential scanning calorimetry (DSC) is performed on a Mettler Toledo DSC1 Star system 
under nitrogen atmosphere with a heating rate of 10 K/min from 20 °C to maximum 300 °C, 
depending on the nature of the model API which is analyzed. Glass transition temperatures (Tg) 
values are reported from the first heating run. 
Hot-melt extrusion coupled to injection moulding is performed on a Haake MiniLab extruder 
coupled to a Haake MiniJet system. 
Freeze drying was performed on a Martin Christ Alpha 2-4 LDPlus with an ice condenser 
temperature of -85 °C and capacity of 4 kg. 
Dissolution testing and drug release from the tablets is determined using the paddle method 
on a VK 7010 dissolution system (VanKel Industries, New Jersey, USA) with a speed of 100 rpm and 
spectrophotometric measurements were performed on a UV-1650PC system from Shimadzu 
Benelux.  
6.2.2  Experimental  methods 
Synthesis of 200 g scale poly(2-oxazoline)s at 60 °C – short description (vide chapter 4) 
 The synthesis of defined high MW PAOx polymers, i.e. 50,000 g/mol and 140,000 g/mol 
PEtOx; 50,000 and 80,000 g/mol PnPrOx and the 50,000 g/mol PsecButOx is performed via the 
sacrificial initiator method (SIM) on large scale. All data regarding the polymerization, such as 
the amounts of initiator, monomer and solvent; and polymerization times are listed in the table 1 
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below. All polymerizations are carried out until 70 % monomer conversion. The SEC 
characterization data are further summarized in table 2. 
Table 1. Overview of all reagents for the polymerization of defined high MW PAOx, on large scale.  
Polymer type MW (theoret.) 











PEtOx_140kDa 1500 / 150 0.094 PhCl/ 140.5 3/ 61.2 29 60 
PnPrOx_50kDa_1-3 443/ 50 1.006 PhCl/ 238.6 4.8/ 312.5 5.5 200 
PsecButOx_50kDa 394/ 50 1.407 PhCl/ 190.0 4.8/ 300 6 200 
 










 kDa kDa  kDa kDa  
PnPrOx_50kDa_1 42.8 53.8 1.14 66.6 80.5 1.11 
PnPrOx_50kDa_2 40.0 44.9 1.13 61.3 80.2 1.18 
PnPrOx_50kDa_3 45.1 56.1 1.16 69.8 83.4 1.12 
PEtOx_140kDa 117.5 141.5 1.35 181.8 206.7 1.32 
PEtOx_Aquazol_200 16.5 170.5 9.00 36.1 174 4.80 
PEtOx_Aquazol_500 53.1 937.3 8.30 120 496 4.10 
PnPrOx_80kDa 40.9 61 1.40 72 99.4 1.30 
PsecButOx_80kDa 27.3 40,0 1.37 40.6 71.3 1.40 
PsecButOx_50kDa 13.2 18.4 1.26 25.6 35.0 1.22 
Preparation MPT:PEtOx, PnPrOx (50:50), MPT:PnPrOx (70:30 or 80:20) and MPT:PsecButOx 
(70:30 or 80:20) tablets via HME/IM 
For the preparation of the MPT SRF, first the pre-weighted mixture of API and polymer 
excipient is cryo-milled to homogenize before HME/IM. Every mixture contained in total a tablet 
weight of around 500 mg per tablet; and three identical tablets were chosen for sequential 
dissolution tests. In Table 3, an overview is given of all the HME/IM (Figure 3) parameters. The 
processing temperature for the extruder varied between 110 – 145 °C, depending on the 
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polymer type used. The mold temperature depicts the IM settings, between 25-30 °C, and the 
pressures applied during the process and after processing are respectively 800 bar for 10 s and 
400 bars for 5 s. Post-pressure is generally applied to prevent the tablets from falling apart, due 






Figure 3. Twin-screw co-rotating hot-melt extruder (Left) and high pressure injection moulder with adjustable 
temperature set(Right) that was used to prepare the SRF. 
 
Table 3. Processing temperatures for HME/IM, for the production of MPT:PAOx SRF.  






MPT:Aq200 50 130 135 
MPT:Aq500 50 145 145 
MPT:PEtOx_140kDa 50 130 135 
MPT:PnPrOx_50kDa 50 110 130 
MPT:PnPrOx_50kDa_1-3  70 - 80 110 130 
MPT:PsecButOx_50kDa  70 - 80 110 110-120 
 All tablets contain in total approximately 500 mg of material, including API and 
excipient, and the drug content is varied between 96.6 and 103 % of the desired value, e.g. in a 
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UV/Vis Calibration curve MPT 
A stock solution is made by dissolving 100.5 mg MPT in 200 mL of PBS (concentration = 502.5 
mg / L). This stock solution is diluted respectively 4, 6, 8, 10, 20 and 40 times. From these six samples 
the absorbance is measured by UV-Vis at a wavelength of 274 nm (Table 5). Each measurement 
is performed three times and the average values are used in the calibration curve (Figure 4). 
Table 5. Absorption curve data for the calibration curve of MPT. 
Sample Concentration 
(mg / L) 
Abs 1 Abs 2 Abs 3 Average abs Standard deviation 
1 12.56 0.062 0.062 0.063 0.062 0.000577 
2 25.13 0.116 0.117 0.116 0.116 0.000577 
3 50.25 0.195 0.195 0.193 0.194 0.001155 
4 62.81 0.250 0.247 0.250 0.249 0.001732 
5 83.75 0.334 0.330 0.330 0.331 0.002309 










Figure 4. Calibration curve of MPT, measured via UV/VIS spectroscopy at a wavelength of 274 nm.  





















Concentration (mg / L)
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Dissolution tests 
Drug release from all the prepared tablets is determined by using the paddle method on a 
VK 7010 dissolution system (VanKel Industries, New Jersey, USA) with a speed of 100 rpm. 
Simulated intestinal fluid (SIF, pH 6.8) and PBS were used as dissolution medium (900 mL) at 37 °C 
± 0.5 °C. Samples were collected at predetermined time points (30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 
h, 16 h, 20 h and 24 h) and spectrophotometrically (UV-1650PC, Shimadzu Benelux, Antwerp, 
Belgium) analyzed using a wavelength of 274 nm for MPT. No filtration step was included before 
the analysis of the UV/vis samples. For each SRF type formulation three tablets were dissolved 
and analyzed, in three separate dissolution baths, the error bars in the release profiles are 
provided. 
Statistical evaluation of the dissolution tests 
Statistical evaluation was performed with Origin Pro 8.5 Statistics, using a one-way ANOVA, with 
Tukey’s post-hoc test to assess the differences between the means of the cumulative release 
profiles of figures 7, 9, 10 and 12. Significance level was chosen at a probability of p < 0.05, in 
order to assess the significance difference between the different profiles to be random or not. In 
the attachments (vide 6.6), a complete overview of the output data from ANOVA sorted per 
figure. 
Disintegration tests 
Disintegration tests were performed as per Pharmacopoeia standards.42 The disintegration time 
was tested on three different tablets from the same formulation batch using Pharma test 
disintegration tester (Dist-3, Germany) with discs. PBS was used as disintegration medium and the 
temperature was set at 37 °C. The time was recorded until no material from any of the tablets 
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6.3  RESULTS AND DISCUSSI ON    
6.3.1  Ini tial  tests wi th Aquazol ®  and defined high molecular weight 
poly(2-oxazol ine)s for sustained release formulations 
 In this study, we first questioned if the use of defined high MW PEtOx, with a MW of 
140,000 g/mol, would be feasible in SRF with MPT and if it would further sustain the release 
(compared to the results with Aq in Figure 2). Secondly, additional assets to change the side-
chain structure of the PAOx polymers towards a more hydrophobic moiety, e.g. towards PnPrOx 
50,000 g/mol, are proposed for the preparation of extended SRF in combination with MPT. An 
overview of the size-exclusion chromatography (SEC) results for these polymers used as matrix 








Figure 5, Size-exclusion chromatograms (SEC) of the Aquazol, defined PEtOx and PnPrOx polymers used for the 
preparation of SRF containing 50 wt% MPT. SEC is measured in N,N-dimethylacetamide with LiCl, while MW results are 
calculated against PEtOx standards. 
 Tablets produced by HME/IM revealed a stringent difference between the PEtOx and 
PnPrOx matrices for SRF. For the 140,000 g/mol PEtOx:MPT (50:50) SRF the tablets were found to 
be glassy and transparent immediately after processing. Since the processing temperature of 
130 °C resembles the Tm of MPT, MPT is present mostly in the amorphous form, explaining the 
appearance of the tablets after preparation. However, for SRF it is better to keep the API in the 
crystalline form to assure extended release. Efforts to lower the processing temperature of the 
extrusion process for this PEtOx matrix towards 100 °C failed and resulted in a too high torque. 
The production of ill-defined, Aq:MPT (50:50) SRF, was also repeated as previously reported by 
Claeys et al.;41 and used as a reference for the characterization and dissolution experiments. 
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 In contrast to PEtOx, the production of the 50,000 g/mol PnPrOx:MPT (50:50) SRF resulted 
in white and rather sticky tablets. The white color indicates that the MPT is present in its crystalline 
form, which will be confirmed in further characterization experiments, as discussed later in this 
section. The stickiness of the tablets, on the other hand, originates from the characteristics of the 
PnPrOx polymer used, i.e. a low glass transition temperature of approximately 40 °C. The process 
temperature for these SRF could be set at a lower value of 110 °C compared to PEtOx SRF 
keeping the MPT crystalline.  
 Characterization of the PEtOx:MPT and PnPrOx:MPT (50:50) by XRD and DSC (Figure 6) 
confirmed the visual observation after production of both types of tablets. The PEtOx:MPT tablets 
show no crystallinity, for the Aquazol polymers, and minor crystallinity (± 15 %), for the formulation 
with the 140,000 g/mol PEtOx polymer, respectively. Whereas the PnPrOx SRF with MPT revealed 
a crystalline structure in XRD and the melting transition in DSC confirms the obtained white tablets 










Figure 6. XRD (Left) and DSC (Right) characterization data for the PEtOx:MPT and PnPrOx SRF with 50 wt% of MPT. As a 
reference the DSC of pure MPT is presented. 
 Dissolution tests are performed for the PEtOx:MPT and PnPrOx:MPT (50:50) SRF in a PBS 
(pH 6.8) buffer solution and release of the MPT concentration was measured via UV-Vis 
spectrometry at an absorption wavelength of 274 nm. Prior to the dissolution tests, a MPT 
calibration curve was established, which can be found in section 6.2.2. The dissolution medium 
for all the tablets is identical and tests were performed in triplicate, for accurate analysis. For the 
PEtOx:MPT tablets, an experiment timeframe of 6 hours was chosen, since the release is 
expected to be analogous to the Aquazol:MPT tablets measured in the previous study by Claeys 
et al.41 For the PnPrOx:MPT tablets a timeframe of 24 hours was chosen as no release studies were 
ever carried out for this excipient. The results of the dissolution tests can be found in Figure 7.  
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 Similarly to the earlier release studies by Claeys et al. (Figure 2),41 complete release from 
the Aquazol® matrices is observed after only two hours, with Aq 500 showing a slower sustained 
release profile compared to the Aq 200 matrix. For the 140,000 g/mol PEtOx:MPT SRF very similar 
release is observed as with Aq 200 indicating that further increasing the MW of the PEtOx 
polymer, will most likely not result in the desired difference in the sustained release capacity of 
the PEtOx matrix, i.e. preferably over 24 hours. A one-way ANOVA statistical analysis revealed 
that the variations in data for the Aq 500, Aq 200 and PEtOx 140kDa formulations are rather 












Figure 7. Dissolution testing for the SRF of Aquazol, 140,000 g/mol PEtOx and 50,000 g/mol PnPrOx containing 50 wt% of 
MPT; in PBS (pH 6.8). ANOVA statistics test gives a significant difference (p = 0.05) for the means, MPT:PnPrOx is 
significantly different from the other data sets (detailed description vide 6.6.1). 
For the 50,000 g/mol PnPrOx:MPT (50:50) SRF, the sustained release profile changed 
drastically, with only 60 % cumulated release of the MPT after 24 hours. Despite the fact that we 
expected the release to be more sustained by changing the side-chain from ethyl towards 
propyl, such a large increase in release time was rather surprising and shows a huge potential in 
the development of SRF with MPT and other APIs. Statistical analysis via one-way ANOVA 
confirmed that the data for PnPrOx 50 kDa are significantly different from the release profiles 
with Aq and PEtOx polymers. 
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6.3.2  Sustained release formulations wi th poly(2-n-propyl -2-
oxazol ine) polymers  and metoprolol  tartrate 
As a follow up on the promising and preliminary results concerning the PnPrOx 50,000 
g/mol polymer as matrix excipient in SRF containing 50 wt% of MPT (section 6.3.1), the questions 
arose whether drug loading could further be increased and whether the polymer molecular 
weight influences the release profile, if other APIs could form SRF with PnPrOx and which 
methodologies could be applied for the formulation process and consequent tableting method. 
In this section, the increased drug loading and the influence of molecular weight on the drug 
release will be discussed with regard to HME/IM of MPT:PnPrOx SRF, while the other questions are 
being addressed by Aseel Samaro in the framework of her PhD at the Faculty of Pharmacy 
(Ghent University). 
To push the limits of the SRF and to challenge the formulation to its maximum drug 
capacity in terms of release profile, formulation of MPT with PnPrOx 50,000 g/mol was performed 
with a drug loading that was increased up to 70 % and 80 % of MPT (Figure 8). Since, MPT is 
regarded as one of the most hydrophilic and low melting model API, these target drug loads are 
quite challenging as will be demonstrated by the dissolution profiles. 
 
Figure 8. Overview of the structures of MPT; including its most important properties, i.e. water solubility and melting 
temperature Tm, in combination with the structure of poly(2-n-propyl-2-oxazoline) 50,000 and 80,000 g/mol. 
MPT:PnPrOx (70:30)and (80:20) sustained release formulations 
The dissolution profile of the prepared MPT:PnPrOx (70:30) SRF prepared via HME/IM can 
be found in Figure 9. Complete release is achieved after 6 hours, in contrast to the incomplete 
release profile found up to 24 hours for 50 % of MPT with PnPrOx as matrix excipient. Not only MPT 
dissolution was tested, but also the mechanical strength of the tablets was evaluated with a 
disintegration test. During the disintegration test, the tablet is moved up and down in the 
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dissolution medium, to simulate the peristaltic movements of the GI tract via an in vitro test. 
Disintegration was found to be faster, i.e. less than an hour, than the provided release profile in 
Figure 9 posing a potential problem for further use. A reason for this behavior is most probably 
attributed to the fact that only 80 % of crystalline MPT is found in the IM tablets, which are 
processed (Tprocess = 130 °C) around the Tm of MPT (123 °C) inducing partial melting of the MPT. 
Furthermore, the PnPrOx matrix possesses a low glass transition temperature, around 40 °C, which 
makes the tablets prone to easy deformation.  
Increasing the drug load up to 80 % MPT (Figure 9) accelerates the release even more up to 4 
hours. As an intermediate conclusion for MPT SRF with PnPrOx as matrix excipient, incomplete 
release was found with IM tablets containing 50 % of MPT compared to full release after 4 hours 
with 80 % of MPT loaded into the tablets. Even though a more ideal sustained release may be 
anticipated at 60 % of MPT, all IM tablets showed poor disintegration stability, making the PnPrOx 












Figure 9. Release profile for the MPT:PnPrOx (50:50, 70:30 and 80:20) SRF in simulated intestinal fluid (SIF, pH 6.7) up to 24 
hours. ANOVA statistics test gives a significant difference (p = 0.05) for the means, MPT:PnPrOx (50:50) is significantly 
different from the other data sets with MPT:PnPrOx 70:30 and 80:20 (detailed description vide 6.6.2). 
  Statistical analysis of Figure 9, via one-way ANOVA, shows that the 50 % MPT 
formulations with PnPrOx are significantly different from the 70 and 80 % formulations. The data 
for the MPT:PnPrOx (70:30) and MPT:PnPrOx (80:20) are not significantly different.  
Based on these results two strategies are proposed to provide more mechanical 
stability to the tablets. First in this section, the influence of molecular weight of the PnPrOx matrix 
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on the release profile and disintegration stability will be investigated. The second strategy holds 
changing the polymer structure towards a hydrophobic polymer with a higher Tg, which will be 
further elaborated in section 6.3.3. 
 In an attempt to overcome the low disintegration stability, PnPrOx with a MW of 80,000 
g/mol was investigated for SRF with 70 % MPT. In the comparison of the SRF based on the 80,000 
g/mol PnPrOx polymer, with the 50,000 g/mol PnPrOx the release was found, to be slower (but 
not significant according to ANOVA) with the larger polymer i.e. 8 hours versus 6 hours (Figure 
10). Even though the release form the higher MW PnPrOx was slightly longer sustained, no 
significant improvement was found in the disintegration test. Therefore, it can be concluded that 
the search for another more, hydrophobic PAOx polymer (see section 6.3.3) is the preferred way 









Figure 10. Release profile for the MPT:PnPrOx (70:30) SRF in simulated intestinal fluid (SIF, pH 6.7) up to 8 hours, with 
different MW, i.e. 50,000 g/mol vs 80,000 g/mol, PnPrOx polymers as excipient. ANOVA statistics test gives not a 
significant difference (p = 0.05) for the means (detailed description vide 6.6.3). 
 
6.3.3  Sustained release formulations with poly(2-sec-butyl -2-
oxazol ine) polymers and metoprolol  tartrate  
An important parameter for the mechanical stability of the tablets, at a certain 
temperature, is the Tg. Since the Tg of PnPrOx is quite close to room temperature, i.e. 
approximately 40 °C, the PnPrOx behaves as a fragile matrix with regard to tablet disintegration 
studies at room temperature, vide supra. The proposition for another, higher Tg polymer with 
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preferably the same or stronger hydrophobic properties than PnPrOx pointed us in the direction 
to synthesize a 50,000 g/mol PsecButOx polymer (Figure 11). 
The Tg of PsecButOx is situated around 55 °C, which should give enough mechanical 
strength at room temperature in its usage as a matrix excipient, to prevent fast disintegration of 
tablets made thereof. Therefore, SRF of MPT were studied using a 50,000 g/mol PsecButOx 
polymer as sustained release matrix. For a good comparison, the release profile of the API:PnPrOx 














Figure 11. Overview of the structures of the most hydrophilic model APIs, including MPT and MTF; including their most 
important properties, i.e. water solubility and melting temperature Tm, in combination with the structure of poly(2-n-
propyl-2-oxazoline) and poly(2-sec-butyl-2-oxazoline) both with a MW of 50,000 g/mol.  
MPT:PsecButOx (70:30)and (80:20) sustained release formulations 
The results for the MPT:PsecButOx SRF are shown in Figure 12. The slower release of PsecButOx SRF 
compared to the PnPrOx matrix formulations immediately stands out. While the PnPrOx matrix 
led to complete MPT release after 6 hours, only 60 % of MPT release is achieved after 24 hours 
with the PsecButOx matrix. Importantly, the processing temperature for IM could be kept at 110 
°C for PsecButOx, which induced no loss of crystallinity of MPT in the SRF. The latter could be an 
explanation why the release is so different compared to the previous observed release profiles 
for PnPrOx. Furthermore, PsecButOx is more hydrophobic and possesses a higher Tg, in 
comparison to the PnPrOx matrix, which can also contribute to longer retention of MPT.  The 
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disintegration tests show overall better performance for the PsecButOx polymers compared to 










Figure 12. Release profile for the MPT:PsecButOx (80:20 and 70:30) SRF in simulated intestinal fluid (SIF, pH 6.7) up to 24 
hours, with comparison of PsecButOx and PnPrOx (MPT:PnPrOx; 80:20 and 70:30) polymers as excipient. ANOVA statistics 
test gives a significant difference (p = 0.05) for the means, MPT:PsecButOx (80:20) is significantly different from the other 
data sets (detailed description vide 6.6.4). 
 The SRF of PsecButOx with a drug load of 80 % of MPT showed complete release after 
approximately 9 hours compared to only 4 hours for PnPrOx as matrix for SRF. Altogether, it can 
be concluded that a tremendous improvement of the tablet properties with PsecButOx as matrix 
for the formulation of MPT is achieved as no disintegration was found for this 80 % MPT SRF either, 
which is highly promising towards future in vivo experiments. In the statistical analysis, via ANOVA, 
it is found that only the MPT:PsecButOx (80:20) is significantly different from the other data sets. 
Although statistical analysis is provided, we have to be careful with the drawn conclusions. For 
example if we include the disintegration data, MPT:PsecButOx (70:30) is also significantly different 
from the PnPrOx formulations, since the disintegration time is found to be 40 min for MPT:PnPrOx 
(70:30) and for MPT:PsecButOx (70:30) 12 hours. 
6.4  CONCLUSIONS AND OUTLOOK    
In this final chapter, the formulation of MPT with the use of PAOx polymers, more 
specifically PEtOx, PnPrOx and PsecButOx, as matrix excipient for SRF, is discussed.  
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Firstly, the formulation of a 50 wt% containing MPT SRF with Aquazol, 140,000 g/mol PEtOx 
and 50,000 g/mol PnPrOx was formulated via HME coupled to IM, as a proof-of-concept study. 
Complete characterization, by DSC and XRD, revealed the presence of only a minor crystalline 
fraction of MPT in the PEtOx matrices, whereas high crystallinity of MPT was found in the PnPrOx. 
The latter observation was verified by performance of dissolution tests on all the prepared 
tablets, revealing fast release from the PEtOx matrices compared to sustained release of only 60 
% after a period of 24 hours for the PnPrOx matrix. Despite the fact that we expected a change 
in dissolution profile of the MPT when going from a hydrophilic matrix, PEtOx, towards a thermo-
responsive and more hydrophobic matrix, PnPrOx, it is undoubtedly a drastic change in release 
profile.  
As a second part of this chapter, further investigations were performed to evaluate 
PnPrOx as matrix for formulating higher drug loads of MPT, combined with analysis of the MPT SRF 
with PnPrOx of varying molecular weight and tablet stability. For the MPT:PnPrOx SRF a drug load 
between 50 and 80 % revealed sustained release within 24 hours down to 4 hours, respectively. 
However, the shear-stress stability, i.e. the ability to disintegrate, of the PnPrOx containing SRF 
with MPT was insufficient as the tablets did not pass the disintegration test within the time period 
where they provide release of the specific API. In other words, the tablets would not survive 
appropriate in vivo shear-stress conditions and consequently may induce faster release 
compared to what is shown in the in vitro dissolution tests, also when a higher MW PnPrOx of 
80,000 g/mol was used.  
In a final part, PsecButOx was proposed as an alternative for the PnPrOx matrix, to 
formulate MPT. The PsecButOx is slightly more hydrophobic and possesses a higher Tg, resulting in 
higher tablet stability compared to the use of the PnPrOx matrix. The release pattern for MPT 
changed to 60 % release after 24 hours for a drug load of 70 % of MPT and complete release 
after 9 hours when a drug load of 80 % was used. These preliminary results in combination with 
the higher shear-stress stability indicate that these PsecButOx tablets have great potential for SRF 
and studies will be extended to in vivo in the near future.  
As a conclusion, this chapter provides a case study for the use of thermo-responsive and 
hydrophobic PAOx polymers as matrix excipient for the formulation of SRF with an extremely 
water-soluble model API, i.e. MPT. It will be important on short-term, to evaluate all the data 
which are gathered via in vitro dissolution tests and to select the most promising SRF for further 
analysis in in vivo tests.  
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CHAPTER 7 
7 OVERALL CONCLUSIONS AND OUTLOOK 
 
7.1  ENGLISH SUMMARY PHD THESIS  
In this PhD thesis, two main parts were addressed along the path towards the use of poly(2-
oxazoline)s (PAOx) as matrix excipient in oral drug formulations, being a polymer synthesis part 
and a drug formulation part. In the first the three chapters (chapter 2-4), the polymer syntheses 
are described and solutions to their main challenges provided. After this, two final chapters 
(chapter 5-6) on drug formulation with high molar mass PAOx polymers are included and 
described. 
For the polymer synthesis, chapter 2-4, it was the goal to try and find the appropriate 
conditions for the cationic ring-opening polymerization of 2-methyl-2-oxazoline (MeOx), 2-ethyl-
2-oxazoline (EtOx) and 2-n-propyl-2-oxazoline (nPrOx), in order to obtain the reproducible 
synthesis of their corresponding high molar mass PMeOx, PEtOx and PnPrOx polymers on large 
200 g scale. The development of a reproducible process, on large scale, for the synthesis of PAOx 
polymers for biomedical applications needs careful attention when PAOx as basis for future 
approval of PAOx by the regulatory agencies, i.e. European Medicines Agency (EMA, EU) and 
Food and Drug Administration (FDA, US). 
First, in chapter 2, the journey towards the preparation of defined PMeOx has been 
described. The CROP of MeOx is found to be challenging due to the large solubility difference 
between the MeOx monomer and PMeOx polymer. PMeOx is even to be found insoluble in its 
own monomer. Attempts to find a suitable solvent to keep PMeOx in solution during its 
polymerization identified (via solvent screening) both N,N-dimethyl acetamide (DMA) and 
sulfolane as potential polymerization solvents. Because of the remarkable acceleration up to 
three-fold (compared to the polymerization in acetonitrile) for the CROP of MeOx in sulfolane at 
140 °C, we investigated the kinetics of this polymerization reaction in more detail. A kinetic study 
at five different temperatures (ranging from 60 °C to 140 °C) revealed interesting accelerations 
from 1.7 fold at 60 °C to 3 fold at 140 °C for the CROP of MeOx in sulfolane compared to the 
CROP in acetonitrile. In addition, the polymerization of EtOx and 2-phenyl-2-oxazoline (PhOx) in 
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sulfolane were successfully performed and investigated to question the use of sulfolane as 
common polymerization solvent for the synthesis of PAOx polymers. Thirdly, the ability of block 
copolymer synthesis by sequential monomer addition in sulfolane is demonstrated, as a proof of 
the livingness of the CROP of 2-oxazolines in sulfolane, as well as to show the compatibility of 
both alkyl and aryl containing monomers with sulfolane as polymerization solvent. Finally, 
preliminary data proved the ability to synthesize a higher molar mass PMeOx polymer in 
sulfolane. Nonetheless, this last synthesis procedure needs further optimization as it was found to 
be difficult to handle the high boiling point of sulfolane, with regard to the acquired reaction 
conditions for preparing defined high molar mass PAOx polymers. In addition, the quest towards 
finding another extremely polar solvent, such as e.g. hexamethylphosphoramide (HMPT), for the 
CROP of MeOx can continue. 
In the next chapter, (chapter 3) the solvent optimization for the CROP of EtOx was 
addressed. For this, the synthesis of PEtOx polymers has been chosen because it is the most 
widely studied monomer in literature (with the intention to obtain kinetic insights) for the CROP 
of 2-oxazolines. Also, it is remarkable that a broad solvent screening was never performed for the 
kinetics of the CROP of EtOx, most likely because the state-of-the-art polymerization conditions, 
in solvents like acetonitrile and chlorobenzene, serves the need of people working with PAOx 
polymers. We challenged whether the existing polymerization conditions are indeed the best 
there are, or whether there are improvements and other options available, regarding 
polymerization solvents. From the whole series of solvents (anisole, chlorobenzene, ethyl acetate, 
acetonitrile, 1,3-dimethyltetrahydropyrimidin-2(1H)-one (DMPU), nitrobenzene and sulfolane) 
that were selected for studying the kinetics of the polymerization reaction, a selection of two 
solvents (apart from acetonitrile and chlorobenzene) deserve special attention, being sulfolane 
(explanation vide supra or chapter 2) and ethyl acetate. The polymerization in ethyl acetate is 
selected because of its relevance towards using a green solvent for the synthesis of PAOx. Apart 
from the results for the CROP of EtOx in sulfolane and ethyl acetate, it was hard to generalize 
other trends which were observed with the other solvents, although the boiling points of the 
solvents appeared to correlate with the observed trends for the kp´s. 
Next, chapter 4 focused on the large scale synthesis of defined high molar mass PAOx for 
biomedical applications, and more specifically for oral drug formulation (vide infra). While the 
previous two chapters dealt with mostly the optimization of the synthesis of low molar mass (< 
20,000 g/mol) PAOx polymers, this chapter discussed the upscaling of the synthesis method, i.e. 
sacrificial initiator method (SIM), for the preparation of defined high molar mass PAOx polymers. 
This SIM, as invented by Monnery and Hoogenboom (WO2016008817 A1, 2016), was originally 
designed to synthesize high molar mass PAOx polymers, in a defined manner, at 1 g scale. 
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Nevertheless, to be able to perform the synthesis on 200 g scale, challenges such as upscaling 
of initiator synthesis, non-commercial monomer synthesis, purification methods and the SIM need 
to be addressed. The polymers that were synthesized on large scale include 25,000 g/mol, 50,000 
g/mol and 100,000 g/mol PEtOx polymers and 50,000 g/mol PnPrOx polymers. Every synthesis of 
the aforementioned polymers was performed in triplicate at 60 °C on 200 g scale revealing good 
reproducibility. General observations include 10 % higher Ð values, with respect to the 1 g scale 
synthesis, but with reproducible errors and target molar masses. Also, the synthesis of a series of 
PEtOx (high) molar mass standards, within a molar mass range of 10,000 g/mol to 200,000 g/mol, 
was achieved on larger scale (50 g) at lower temperatures (42 °C). However, if they were 
compared to the PEtOx standards synthesized on 1 g scale, they failed to provide the same 
results as molar mass calibration. The latter arose the question of inefficient stirring on large scale 
polymerizations compared to small scale. In a final experiment, we therefore sampled on three 
different places in a large scale polymerization mixture, in order to verify the occurrence of a 
broader Ð in the PEtOx standards as a result of inefficient stirring of large scale reactions. As a 
conclusion, further upscaling could involve the use of e.g. larger reactors, mechanical stirring, 
etc. to ensure homogenous mixing and lower Ð values. Nonetheless, we were able to synthesize 
reproducible large scale batches of a series of PAOx polymers.  
 In the second part of this thesis, the polymers synthesized in chapter 2-4 are utilized for 
the preparation of oral drug formulations. From chapter 1 it is clear that the use of polymers in 
drug formulations belongs to an emerging technology in drug delivery. Here, we proposed and 
challenged the use of PAOx polymers as excipient for the delivery of active pharmaceutical 
ingredients (APIs). The influence of PAOx polymers on the drug delivery manner, i.e. immediate 
versus extended release, can be divided into two types of formulations, being solid dispersions 
(SD, chapter 5) and sustained release formulations (SRF, chapter 6).  
First, in chapter 5, the influence of PAOx on the release and improved bioavailability of poorly 
water-soluble APIs has been addressed. This research originated from preliminary results by 
Claeys et al. (Macromol. Rapid Commun., 33, 1701-1707, 2012) on the use of Aquazol® (ill-defined 
PEtOx) for the solubility improvement of fenofibrate (FBT). In this project, first the use of defined 
PEtOx for FBT SD formulations was compared to the use of Aquazol®. The tablets, prepared via 
hot-melt extrusion coupled to injection molding (HME/IM), were characterized by differential 
scanning calorimetry (DSC) and x-ray diffraction (XRD) and showed the absence of crystallinity 
of FBT. The dissolution tests performed on the FBT:PEtOx (20:80 and 40:60) SD showed similar 
release profiles as found for FBT:Aq200 SD (with similar drug loadings). It has to be noted that the 
FBT:PEtOx (40:60) SD showed the appearance of some crystallinity right after processing, which 
could be attributed to supersaturation of the PEtOx matrix. Furthermore, both PMeOx and PnPrOx 
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polymers with a molar mass of 50,000 g/mol, were tested for formulation with FBT. Unfortunately, 
the formulations containing these polymers showed high crystallinity of FBT. In correlation to the 
increased crystallinity found for the FBT:PMeOx (20:80) and FBT:PnPrOx (20:80) formulations, 
slower release was found compared to the FBT:PEtOx SD. Lastly, different attempts to formulate 
flubendazole (FLU) in a SD with PEtOx polymers were taken. Apart from solvent casting and freeze 
drying techniques, which were not able to formulate a SD with FLU and PEtOx, the 
electrospinning technique was explored, in order to get faster solvent evaporation which should 
lead to trapping the amorphous API in the polymer matrix. In a preliminary test, we were able to 
form a FLU:PEtOx (10:90) SD formulation, electrospun from a formic acid/acetic acid mixture. 
Characterization of the FLU:PETOx SD revealed the absence of crystallinity up to 3 months after 
processing. Furthermore, in the dissolution tests it is shown that 80 % FLU is released from the PEtOx 
matrix within the first two hours. This promising result indicates that PEtOx can serve as an 
immediate release matrix for SD with FLU, which should be further investigated in terms of drug 
loading as a function of electrospinning process.  
Secondly, in chapter 6, the influence of PEtOx in combination with a series of more 
hydrophobic PAOx polymers is investigated for sustained release of extremely water soluble APIs. 
Throughout this study, metoprolol tartrate (MPT) is addressed as a good water-soluble model API 
with a relatively low melting point (± 130 °C) for the formulation in sustained release formulations 
(SRF). This research is also based on a preliminary study with Aquazol and 50 % of MPT loading, 
which showed moderately sustained release of MPT over 90 min. Again, the tablets for SRF were 
prepared via HME/IM. Within the research of this thesis, the possibility to further extend the release 
of MPT over a period of 24 hours, when combined with a PAOx polymer matrix, is questioned. 
Furthermore, the increase of the drug loading up to 80 % of MPT and the ability to slow down the 
release of MPT with a defined 140,000 g/mol PEtOx polymer were explored. It was shown that 
the MPT:PEtOx (50:50) SRF did not have any influence on slowing down the release and showed 
an even faster release (100 % release MPT in 1 hour), compared to the previously tested Aquazol 
500 matrix. In an attempt to use the more hydrophobic PnPrOx matrix (with a molar mass of 
50,000 g/mol) for the 50 % MPT SRF, we discovered incomplete release of only 60 % of MPT over 
24 hours. Following this interesting observation, the drug loading was increased and MPT:PnPrOx 
(70:30 and 80:20) SRF were prepared and tested in dissolution tests. The release of MPT from the 
PnPrOx was found to range from being incomplete within 24 hours down to complete release 
within 4 hours for drug loads ranging from 50 to 80 % of MPT, respectively. Unfortunately when 
the MPT:PnPrOx SRF were tested against shear-stress stability, they showed much faster 
disintegration compared to the release time they provide. In other words, the tablets would not 
survive the in vivo shear-stress conditions and consequently induce faster release compared to 
what is shown in the in vitro dissolution tests, also when a higher MW PnPrOx of 80,000 g/mol used. 
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Therefore, in a final part, poly(2-sec-butyl-2-oxazoline) (PsecButOx, 50,000 g/mol) polymer was 
proposed as an alternative for the PnPrOx matrix to formulate MPT. The PsecButOx is slightly more 
hydrophobic and possesses a higher Tg, resulting in higher tablet stability compared to the use 
of the PnPrOx matrix. In conclusion, it was found that the release pattern for MPT changed to 60 
% release after 24 hours for a drug load of 70 % MPT. For a MPT:PsecButOx (80:20) formulations 
complete release was observed after 9 hours. No disintegration of the corresponding tablets was 
observed within the provided sustained release period, for any of the PsecButOx SRFs. These 
preliminary results have great potential and will be extended to in vivo studies in the near future. 
As a conclusion, this chapter provides a case study for the use of thermo-responsive and 
hydrophobic PAOx polymers as matrix excipient for the formulation of SRF with an extremely 
water-soluble model API, i.e. MPT. 
Overall, this PhD thesis combined the successful optimization of the synthesis of a series of 
(high molar mass) poly(2-alkyl-2-oxazoline)s and the investigation on their ability to formulate 
(poorly) water soluble APIs in SD and SRF formulations. The synthesized PAOx polymers are varying 
in hydrophilicity from PMeOx to PsecButOx (hydrophilic to hydrophobic) polymers, with a molar 
mass varying between 10,000 g/mol and 200,000 g/mol. It is important to note that the first steps 
were made in the direction of upscaling towards ± 1 kg scale, with the focus on improving 
reproducibility of the PAOx production process. In the end, this will be extremely important for 
the approval (by regulatory agencies) of PAOx polymers in biomedical applications, in 
combination with all the other tests needed, including toxicity studies, clinical trials, etc. 
Furthermore, with regard to the drug formulation part of the thesis, it is clear that PAOx polymers 
show potential in both immediate release (from SD) and sustained release (from SRF) 
formulations of a series of model APIs. This is proven on the grounds of in vitro dissolution tests and 
characterization data, such as DSC and XRD. On the other hand, the advantage of PAOx 
polymers in terms of tunability (structure, Tg, molar mass) has come forward in the results for SRF. 
Yet, up till now only model APIs were tested and formulated with (a few) PAOx polymers. 
Therefore, in the near future it will be crucial to perform in vivo dissolution tests with a selection of 
the best performing PAOx:API formulations based on the in vitro dissolution testing.  
Future perspectives  
As for future perspectives, tremendous efforts are shown in this thesis for the improvement 
and scale up of the CROP of 2-oxazolines and the application of PAOx polymers in SD and SRF 
oral dosage formulations. Still, there are some important challenges remaining for the near 
future. These challenges include for example a reduction in the overall reaction times for the 
preparation of high molar mass POAx, since 18 days’ polymerization time for a PEtOx 140 kDa is 
Chapter 7 
- 208 - 
 
rather long, but not impossible, for industrial synthesis.  A further scale increase from 200 g up to 
2 kg scale towards 20 kg scale, is desirable and should be investigated further for which further 
challenges have to be addressed to maintain efficient heat and mass transfer. Especially the 
latter is expected to become more and more difficult at larger scale as the viscosity of the 
polymerization mixtures rises significantly during the polymerization, which should be addressed 
by moving to mechanical stirrers. Next, in this thesis mostly PEtOx and PnPrOx were produced on 
a 200 g scale, but there is still a range of other PAOx (co)polymers available which remained 
uncovered within the scope and time frame of this PhD thesis. In terms of reaction insights and 
the influence of different polymerization solvents for the CROP of EtOx, some trends were 
discovered, but further examination of possible trends has to be performed. Here, a good 
selection of additional solvents need to be investigated to cover the preliminary conclusions. To 
dissect the identified correlation with boiling point, it is recommended to directly compare a 
series of solvents with different polarities, but rather similar boiling points. 
The pharmaceutical part of this work also offers further perspectives for the future. The first 
examples reported in this thesis show the applicability of different well-defined PAOx for the 
formulation of class I and class II APIs, with different water-solubility, in SRF and SD formulations, 
respectively. Nevertheless, in the future even more examples should be investigated, 
broadening the range of (model) APIs, formulation techniques (such as spray drying) and 
assessing also PAOx copolymers as excipient, in order to be able to make some valid structure-
property relationships between the APIs and the PAOx (co)polymers used. Furthermore, the use 
of PAOx blends to tune the release rate of the API appears to be a highly promising research 
direction (preliminary experiments already performed for SRF). Desptie this high potential of PAOx 
for oral drug formations, the long-term challenge will remain to get approval for the PAOx 
(co)polymers for application in (oral) drug formulations. As this requires major investments to pass 
the regulatory trajectory, one should focus on developing formulations with PAOx that reveal 
unique properties that cannot be achieved with any of the approved excipients to date, such 
as high drug loading in SD, enhanced solubility of an API that could not yet be formulated or 
ultra-high drug loading SRF. If successful, this will provide thorough arguments to invest in their 
further use as matrix excipient for SRF and SD; and broader within the pharmaceutical and 
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7.2  NEDERLANDSE SAMENVATTING (DUTCH SUMMARY PHD THESIS) 
 Dit doctoraatsproefschrift beschrijft de onderzoeksstappen en experimenten richting 
het gebruik van poly(2-oxazoline)s (PAOx) als hulpstof voor medicijn formulaties. Het kan verder 
onderverdeeld worden in twee grote delen, meer bepaald het gedeelte waarin de polymeer 
synthese wordt beschreven en het gedeelte rond medicijn formulaties. In beide delen van het 
werk zijn verscheidende uitdagingen aan bod gekomen en werd een mogelijke oplossing voor 
de verschillende problemen gevonden. Verder zullen in het eerste luik van deze samenvatting 
de drie hoofdstukken (Hoofdstuk 2 t.e.m. 4) rond de PAOx polymeersynthese beschreven 
worden. Daarna wordt een kort overzicht gegeven van de resultaten met oog op medicijn 
formulaties en daarbij het gebruik van hoog molecuulgewicht PAOx polymeren, welke 
beschreven worden in hoofdstuk 5 en 6 van het doctoraat. 
 In het gedeelte van de polymeersynthese (Hoofdstuk 2-4), was het hoofdzakelijk de 
bedoeling om geschikte condities te vinden voor de kationische ring-opening polymerisatie 
(KROP) van 2-methyl-2-oxazoline (MeOx), 2-ethyl-2-oxazoline (EtOx) en 2-n-propyl-2-oxazoline 
(nPrOx), als basis voor de synthese van de corresponderende gedefinieerde hoog 
molecuulgewicht polymeren, PMeOx, PEtOx en PnPrOx. Hierin was het belangrijk om ook de 
eerste stappen te nemen richting opschaling van dit polymerisatieproces, vooral met de nadruk 
op reproduceerbaarheid van de resultaten. Dit is ook van uiterst belang met betrekking tot het 
goedkeuren (door de regulerende instanties, Food and Drug Administration, FDA en European 
Medicine Agency, EMA) van het gebruik van PAOx polymeren voor biomedische toepassingen, 
naar de toekomst toe. 
 Allereerst, in hoofdstuk 2, wordt beschreven hoe gedefinieerde PMeOx polymeren 
gesynthetiseerd kunnen worden. De uitdaging voor de KROP van MeOx, en het bekomen van 
gedefinieerde PMeOx polymeren, bestaat erin zowel het monomeer als het polymeer in 
oplossing te houden gedurende de polymerisatie. Dit is niet vanzelfsprekend, aangezien PMeOx 
niet oplosbaar is in zijn eigen monomeeroplossing wat een bulkpolymerisatie uitsluit. Via de 
screening van verschillende solventen werden polaire solventen zoals N,N-dimethylacetamide 
(DMA) en sulfolaan geïdentificeerd als mogelijke oplossing. Tijdens deze screening kwam 
sulfolaan naar voren als uitverkoren solvent voor de KROP van MeOx dankzij het versnellend 
effect (drievoudige versnelling t.o.v. polymerisatie in acetonitril) van sulfolaan op de 
propagatiestap (snelheidsbepalende stap van de KROP) voor de KROP van MeOx. Dit 
opmerkelijke resultaat heeft ons aangezet om kinetische studies uit te voeren bij vijf verschillende 
temperaturen (tussen 60 °C en 140 °C) voor de KROP van MeOx in sulfolaan. Zelfs bij 60 °C 
versneld sulfolaan de polymerisatie tot 1,7 keer t.o.v. de polymerisatie van MeOx in acetonitril. 
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Verder in dit hoofdstuk werden ook de KROP van EtOx en 2-phenyl-2-oxazoline (PhOx) 
uitgevoerd in sulfolaan, samen met hun kinetische studies bij dezelfde temperaturen die 
geselecteerd werden voor de KROP van MeOx. In het algemeen vonden we voor alle drie de 
monomeren een versnelde polymerisatiekinetiek. We kunnen dus stellen dat sulfolaan als 
universeel polymerisatie solvent voor de KROP van 2-oxazolines kan worden aangewend. In een 
volgende stap werd ook de synthese van een PMeOx-PhOx blok copolymeer succesvol 
uitgevoerd. Dit was belangrijk om te kunnen concluderen dat de CROP in sulfolaan als solvent, 
het levend karakter van de KROP behoud. In een laatste gedeelte werd er ook een eerste 
poging ondernomen voor de synthese van een hoog molecuulgewicht polymeer, meer 
bepaald een 50 000 g/mol PMeOx polymeer, in sulfolaan. Dit laatste is belangrijk omdat dit het 
eerste solvent is waarin de synthese van PMeOx met een hoog molecuulgewicht succesvol 
wordt beschreven. Uiteraard is hier in de toekomst nog verdere optimalisatie nodig. Verder is het 
belangrijk om de zoektocht naar alternatieve polaire, bv. hexamethylfosfortriamide (HMPT), 
solventen, voor de KROP van MeOx, voort te zetten. Dit omdat het hoge kookpunt van sulfolaan 
nadelig is voor de huidige hoog molecuulgewicht synthese, via statische destillatie, voor PAOx 
polymeren.  
 Als tweede luik in het polymeer synthese gedeelte, wordt in hoofdstuk 3 de solvent 
optimalisatie voor de KROP van EtOx beschreven. De keuze voor het EtOx monomeer vloeit voort 
uit het feit dat dit het meest besproken monomeer is met betrekking tot het onderzoeken van 
reactie kinetiek. Verder is er nog nooit een brede screening van solventen voor deze reactie 
kinetisch gebeurd, waarschijnlijk omdat de goed werkende polymerisatie in acetonitril en 
chlorobenzeen de nood aan andere polymerisatie solventen doet verminderen. Wij stelden 
echter de vraag of deze condities het beste resultaat geven m.b.t. de karakteristieken van PEtOx 
polymeren. Twee solventen, uit een serie van apolaire tot extreem polaire solventen (anisol, 
chlorobenzeen, ethyl acetaat, acetonitril, DMPU, nitrobenzeen en sulfolaan), springen er 
bovenuit, namelijk sulfolaan (al besproken hierboven) en ethyl acetaat. De polymerisatie in ethyl 
acetaat is uitermate interessant voor het ontwikkelen van een ´groene´ synthese methode voor 
PEtOx polymeren. Uit de resultaten van de andere solventen bleek het moeilijk om een 
algemene trend te vinden voor de kinetiek van de polymerisatie van EtOx, hoewel het lijkt alsof 
er een correlatie is met de kookpunten van de solventen en de geobserveerde trends voor de 
propagatieconstanten. 
 In het laatste hoofdstuk rond polymeersynthese (Hoofdstuk 4), wordt de opschaling van 
gedefinieerde hoog molecuulgewicht PAOx polymeren beschreven. Dit is in contrast met de 
vorige hoofdstukken die meer de optimalisatie van PAOx polymeren beschreven met een 
molecuul gewicht lager dan 20 000 g/mol. Daarom staat in dit hoofdstuk de sacrificiële initiator 
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methode (SIM) centraal. Deze SIM werd uitgevonden door Monnery en Hoogenboom, en 
beschrijft de hoog molecuulgewicht synthese van PAOx polymeren, d.m.v. een zuiveringsstap 
over levend polymeer voorafgaande aan de polymerisatie. Deze reacties werden initieel 
uitgevoerd op kleine schaal (1 g). Om het verder mogelijk te maken de reacties uit te voeren 
op grotere schaal (200 g tot 1 kg schaal) was het nodig om rekening te houden met 
verschillende uitdagingen. Deze omvatten onder meer het opschalen van de initiator synthese, 
de synthese van niet-commerciële monomeren, de zuiveringsmethodes van monomeer en 
solvent, en het opschalen van de SIM. Uiteindelijk slaagden we er in om een reeks PAOx 
polymeren, met name 25 000 g/mol, 50 000 g/mol en 100 000 g/mol PEtOx polymeren en 50 000 
g/mol PnPrOx polymeren, te synthetiseren op grote schaal. Tijdens deze synthese werd 
geopteerd om te kijken naar de reproduceerbaarheid en werd daarbij elke reactie in drievoud 
uitgevoerd. In het algemeen kwamen we tot de conclusie dat de dispersiteiten 10 % hoger 
lagen t.o.v. de synthese van de PAOx polymeren op kleine schaal. Hoewel deze ietwat 
polymeren minder gedefinieerd bleken te zijn, waren de standaard afwijkingen op het 
theoretische molecuulgewicht miniem. Bovendien zijn deze polymeren uiterst geschikt voor 
medicijn formulaties, aangezien ze kunnen gemaakt worden op reproduceerbare wijze. Een 
hogere dispersiteit is hier van ondergeschikt belang aan de reproduceerbaarheid van het 
proces. In een laatste aspect werd er gekeken of er ook PEtOx polymeerstandaarden met 
extreem lage dispersiteit (< 1,05) konden worden gesynthetiseerd op 50 g schaal. Deze PEtOx 
standaarden werden gemaakt met een variatie in molecuulgewicht tussen de 10 000 g/mol en 
200 000 g/mol. Echter, wanneer de vergelijking werd gemaakt met de standaarden gemaakt 
op 1 g schaal, werd er geconstateerd dat de standaarden op 50 g schaal niet voldeden aan 
de strikte eisen om te dienen als massa standaarden. In de zoektocht naar een mogelijke 
verklaring hiervoor, werd er gedacht aan de mogelijkheid van inefficiënte homogenisatie van 
het reactiemengsel tijdens de polymerisatie. Om dit idee te bekrachtigen werd er een 
experiment opgesteld waarin op drie verschillende plaatsen in het mengsel (op grote schaal) 
een staal werd genomen. Hierbij werd bevonden dat vanaf 50 % conversie er wel degelijk een 
inefficiënte homogenisatie van het mengsel optreedt. Daarbij kan dit dus dienen als een 
mogelijke verklaring voor het falen van het maken van nauwer gedefinieerde polymerisatie 
standaarden. Een mogelijke oplossing voor verdere opschaling zou bv. kunnen zijn door te 
werken met grotere reactoren, mechanische roerders, etc. 
 In het tweede gedeelte van de thesis werden de gesynthetiseerde polymeren uit 
Hoofdstuk 2 t.e.m. 4 gebruikt voor de bereiding voor orale medicijn formulaties. Uit de introductie 
(Hoofdstuk 1) is het duidelijk dat het gebruik van polymeren voor deze formulaties aan potentieel 
aan het winnen is. In dit deel, bestuderen we het gebruik van PAOx polymeren voor de bereiding 
van formulaties met actieve farmaceutische ingrediënten (APIs). Afhankelijk van de invloed van 
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de PAOx polymeren op de afgifte van het medicijn, meer bepaald onmiddellijke versus 
vertraagde afgifte, spreken we over respectievelijk vaste dispersies (SD, Hoofdstuk 5) of 
gecontroleerde afgifte systemen (SRF, Hoofdstuk 6).  
 Eerst en vooral werd in Hoofdstuk 5 de invloed van PAOx polymeren op de afgifte en 
biologische beschikbaarheid van slecht wateroplosbare APIs onderzocht. Voorgaand 
onderzoek, uitgevoerd door Claes et al. (Macromol. Rapid Commun., 33, 1701-1707, 2012), wees 
al uit dat Aquazol (ongedefinieerde PEtOx polymeren) de oplosbaarheidssnelheid verbeterde 
van fenofibraat (FBT) als model medicijn voor slecht wateroplosbare APIs. In dit project werd er 
daarom eerst voortgegaan op het gebruik van gedefinieerde PEtOx polymeren, met een 
molecuulgewicht van 50 000 g/mol, voor de formulatie van FBT in SD ter vergelijking van de 
bekomen resultaten voor Aquazol. De FBT:PEtOx tabletten met 20 en 40 % FBT werden, zoals in 
het artikel van Claeys et al., gemaakt via smelt extrusie gekoppeld aan spuitgieten  (HME/IM). 
Na het bereidingsproces werden de tabletten gekarakteriseerd op afwezigheid van FBT 
kristallen, via X-straal diffractie (XRD) en dynamische differentiecalorimetrie (DSC). Dit is 
belangrijk omdat amorfisatie van FBT een eerste aanwijzing is voor het sneller afgeven van het 
medicijn in een SD formulatie. Vervolgens wezen oplosbaarheidstesten uit dat de FBT:PEtOx SD 
met 20 en 40 % FBT inderdaad een snellere afgifte induceren van FBT, t.o.v. ongeformuleerd FBT. 
Als we verder de vergelijking maken met de eerder bestudeerde FBT:Aquazol SD (20:80 en 40:60), 
werd een gelijkaardig afgifte profiel voor FBT geobserveerd (80 % afgifte van FBT binnen het uur). 
Het is belangrijk om te vermelden dat de formulaties met 40 % FBT een kleine fractie API in 
kristallijne vorm bevatten, dat ontstaat net na de bereiding via HME/IM. Dit kan wijzen op een 
mogelijke verzadiging van de PEtOx matrix bij een medicijn belading boven de 20 % FBT. 
Vervolgens werden ook PMeOx en PnPrOx (beiden met een molecuulgewicht van 50 000 g/mol) 
polymeren getest m.b.t. formulatie van FBT in SD. Dit leverde echter niet de gewenste resultaten 
waarbij zelfs met een medicijn belading van 20 % FBT kristallisatie optrad. Er werden bijgevolg 
voor deze 2 andere polymeren ook geen (betere) afgifte profielen verkregen, m.b.t. de 
oplosbaarheidstesten. Voortgaande op de bekomen resultaten voor de PEtOx polymeren met 
FBT, besloten we ook flubendazol (FLU) te gaan proberen formuleren in een SD. Aangezien FLU 
een zeer hoge smelttemperatuur heeft (Tsmelt > 240 °C), werd hier geopteerd om een solvent 
methode te kiezen voor het maken van FLU SD. In de eerste pogingen werden zowel solvent 
casten als vriesdrogen aangewend als technieken voor het bekomen van de formulaties met 
FLU:PEtOx. Via deze technieken was het echter niet mogelijk om een goede amorfe dispersie 
van FLU te bekomen. Mogelijks had dit te maken met het inefficiënt verwijderen van het 
oplosmiddel na formulatie. Daarom werd er in laatste instantie gekozen voor het elektrospin 
proces, waarbij dankzij de verhoogde oppervlak-volume verhouding zou moeten leiden tot een 
snellere verdamping van het oplosmiddel. Uiteindelijk werd er via dit proces een eerste 
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succesvolle amorfe formulatie met 10 % FLU en PEtOx bekomen wat bevestigd werd via 
karakterisatie met DSC. De dissolutie test (80 % afgifte van FLU binnen de 2 uur) wees uit op het 
bekomen van efficiënte FLU:PEtOx (10:90) SD formulaties. In de toekomst zal moeten uitwijzen of 
deze formulatie met FLU en PEtOx als hulpstof kan leiden tot een efficiënte formulatie met hogere 
medicijn belading. 
 Een tweede en laatste farmaceutische toepassing werd beschreven in Hoofdstuk 6. 
Hierbij werd de invloed van een serie van PAOx polymeren, met verschillende hydrofiliciteit, 
onderzocht als gecontroleerde afgifte matrix voor goed wateroplosbare medicijnen. In deze 
studie werd metoprolol tartraat (MPT) aangewend als model voor een goed wateroplosbaar 
medicijn met relatief laag smeltpunt (± 130 °C). Ook hier werd onderzoek naar verricht, door 
Claeys et al., met het gebruik van Aquazol voor de formulatie van SRFs met 50 % belading. Deze 
MPT:Aquazol SRF, bereid via HME/IM, gaven volledige afgifte binnen 90 min. We vroegen ons 
hier af of we een (andere) hoog molecuulgewicht PAOx matrix konden gebruiken, om de afgifte 
te verlengen over een periode van 24 h. Hierbij werd ook de vraag gesteld naar de maximale 
mogelijke medicijn belading in deze SRF (tot maximaal 80 % MPT). In eerste instantie werd 50 % 
MPT geformuleerd met een 140 000 g/mol PEtOx polymeer. Deze MPT:PEtOx (50:50) SRF gaf 
echter een snellere afgifte (binnen het uur) t.o.v. de Aquazol polymeren als matrix. Vervolgens 
werd een 50 000 g/mol PnPrOx (meer hydrofoob t.o.v. PEtOx) polymeer gekozen voor het 
formuleren van dezelfde hoeveelheid MPT. In de bekomen resultaten voor de MPT:PnPrOx 
(50:50) SRF werd een uitzonderlijk lange termijn van afgifte ontdekt, met onvolledige afgifte van 
MPT (60 %) binnen 24 h tot gevolg. Gebaseerd op dit resultaat, gingen we verder kijken naar 
een MPT belading tot 80 %. Voor deze laatste formulatie werd volledige afgifte van MPT 
gerealiseerd na 4 h. Desondanks deze goede resultaten, bleken de PnPrOx polymeren 
uiteindelijk niet bestand tegen uitwendige stress (testen uitgevoerd ter simulatie van de 
peristaltische bewegingen in de maag). Om dit probleem te omzeilen, is de keuze gemaakt om 
een nog hydrofober polymeer aan te wenden voor gebruik van MPT in SRF, zijnde poly(2-sec-
butyl-2-oxazoline) (PsecButOx, met een molecuulgewicht van 50,000 g/mol) polymeren. Dankzij 
de iets hogere glastransitie temperatuur van PsecButOx (± 55 °C t.o.v. 30 °C voor PnPrOx) werd 
er verwacht dat deze ook een gecontroleerde afgifte van MPT zouden kunnen realiseren, met 
een verhoogde resistentie voor uitwendige stress. De bekomen MPT:PsecButOx (70:30 en 80:20) 
SRF, toonden zeer gunstig en gecontroleerde afgifte profielen van respectievelijk 60 % MPT 
afgifte na 24 h en volledige afgifte na 9 h. Verder werd er geen degradatie waargenomen 
tijdens de uitvoering van de stabiliteitstesten van de SRFs. Deze laatst bekomen resultaten voor 
PsecButOx polymeren en SRF met MPT vertonen een enorm potentieel om in vivo testen uit te 
voeren in de nabije toekomst.  
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 Samengevat kunnen we stellen dat deze doctoraatsthesis de combinatie vertoont van 
polymeerchemie met farmaceutische toepassingen, en meer specifiek het maken van medicijn 
formulaties voor orale medicijn afgifte. Voor het polymeer gedeelte werd een serie van PAOx 
polymeren, met verschillende hydrofiliciteit (PMeOx – PsecButOx) en molecuulgewichten, 
gesynthetiseerd. Hier is het belangrijk te vermelden dat de focus werd gelegd op het verkrijgen 
van een reproduceerbaar proces voor de synthese van deze PAOx polymeren op 1 kg schaal. 
Verder betekent dit een belangrijke stap in de richting van medische goedkeuring voor PAOx 
polymeren. Ook werd er bewezen dat PAOx polymeren effectief kunnen ingezet worden voor 
het formuleren van zowel SD als SRF. Echter, is het belangrijk in te zien dat dit onderzoek enkel 
werd verricht m.b.t. het formuleren van een aantal model medicijnen (voor zowel slecht als 
goed wateroplosbare medicijnen) en dat hierbij ook alleen de oplossingsprofielen in waterige 
buffers (in vitro, pH 6.8) opgesteld werden, die de toestand in het lichaam simuleren. Het zal dus 
nodig zijn om in de toekomst oplossingsprofielen te bepalen in bv. model dieren, om de 
relevantie van dit onderzoek te benadrukken en verhogen. Hierbij zal dan een selectie van de 
beste - in dit onderzoek vernoemde formulaties - kunnen dienen voor verdere tests.  
  Toekomstige perspectieven 
Belangrijke stappen werden genomen inzake het verbeteren en opschalen van de KROP van 2-
oxazolines en omtrent het toepassen van PAOx polymeren met betrekking tot SD en SRF orale 
medicijn formulaties. Ondanks het werk in deze thesis, blijven er nog een aantal uitdagingen 
voor de nabije toekomst. Deze uitdagingen omvatten onder meer een vermindering in de 
algemene reactietijd voor de productie van hoog molecuulgewicht PAOx polymeren. Dit 
omdat een reactietijd van 18 dagen voor een PEtOx poylmeer met een molecuulgewicht van 
140 kDa wat nog steeds tamelijk lang (daarom niet onmogelijk) is, zeker in het licht van het 
streven naar een industrieel opschaalbare reactie. Ook zal verdere opschaling van 200 g naar 
2 kg tot zelfs 20 kg een prioriteit moeten worden voor verder onderzoek, met de nadruk op hoe 
efficiënte massa en warmte transfer kan gebeuren op een nog grotere schaal. Vooral de 
warmte transfer zal moeilijker controleerbaar zijn op grote schaal omdat de viscositeit enorm 
toeneemt tijdens de polymerisatie, wat zal kunnen beïnvloed worden door over te schakelen op 
mechanisch roeren van het reactiemengsel. Verder, is er in deze thesis enkel de nadruk gelegd 
op het produceren van PEtOx en PnPrOx polymeren op 200 g schaal. Het is natuurlijk zo dat er 
nog een grote variëteit aan andere (functionele) PAOx (co)polymeren kan gesynthetiseerd 
worden, hoewel deze niet werden gemaakt of behandeld binnen het tijdsbestek van deze 
thesis. In termen van verdere reactie inzichten, werd er al heel wat verwezenlijk met betrekking 
tot het effect van het polymerisatiesolvent op de reactie. Hoewel sommige trends werden 
geobserveerd, is het nog steeds moeilijk om algemene conclusies te vormen inzake de invloed 
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dat deze solventen hebben gecorreleerd aan hun fysicochemische eigenschappen. Hiervoor 
zullen een reeks extra solventen verder onderzocht moeten worden om de eerste conclusies, 
die gemaakt werden in deze thesis, verder te staven. Om de invloed van het kookpunt van het 
solvent verder onder de loep te nemen, zou het aan te raden zijn om een reeks solventen met 
vergelijkende kookpunten, maar verschillende polariteit, te onderzoeken voor de KROP van 
EtOx.  
 Het farmaceutische luik van deze thesis opent ook perspectieven naar de toekomst. Eerst 
en vooral tonen we de mogelijkheid van het gebruik van goed-gedefinieerde PAOx polymeren 
voor de formulatie van klasse I en II APIs, met een verschillende water-oplosbaarheid, in 
respectievelijk SRF en SD formulaties. Dit neemt niet weg dat er in de toekomst meer onderzoek 
moet gedaan worden op bv. een uitbreiding van het aantal APIs, verschillende formulatie 
technieken (bv. ook kijken naar sproeidrogen) en het onderzoeken naar het effect van PAOx 
copolymeren op de formulatie van APIs. Dit laatste, zou er dan ook voor kunnen zorgen dat we 
meer structuur-eigenschapsrelaties kunnen maken tussen de geformuleerde APIs en daarbij 
gebruikte PAOx copolymeren. Het nader onderzoeken van formulaties met PAOx polymeer 
blends kan dan op zich weer een andere manier zijn om afgifte van het API als dusdanig te 
finetunen. Hier zijn ook al preliminaire testen aan het onderzocht worden voor SRF. Desondanks 
het hoge potentieel van het gebruik van PAOx polymeren voor orale afgifte systemen zal de 
goedkeuring/regularisatie van hun gebruik als excipient een belangrijke uitdaging worden op 
lange termijn. Deze goedkeuring vraagt een grote investering om het regularisatieproces te 
doorkruisen enerzijds, daar anderzijds we moeten focussen op het onderzoeken van formulaties 
met PAOx polymeren die unieke kwaliteiten naar voren brengen. Deze kwaliteiten en unieke 
eigenschappen hebben dan vooral te maken met betrekking tot hoge medicijn-belading in SD, 
verbeterde oplosbaarheid van een API dat met de huidige markt excipienten niet 
formuleerbaar blijkt of het kunnen formuleren van zeer hoog API beladen SRF. Indien deze 
kwaliteiten en eigenschappen succesvol kunnen worden aangetoond, zal dit zich ook vertalen 
naar voldoende argumenten om te investeren in PAOx polymeren als excipient van de toekomst 
voor SD en SRF. Uiteindelijk kan het goedkeuren van één PAOx formulatie in de clinical trials 
ervoor zorgen dat er een breder gebruik komt van PAOx polymeren in farmaceutische en 
biomedische toepassingen, op langere termijn.  
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